PHYSIOLOGICAL REVIEWS Vol. 81, No. 3, July 2001 Printed in U.S.A.

Physiological and Molecular Basis of Thyroid Hormone Action PAUL M. YEN Molecular Regulation and Neuroendocrinology Section, Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

I. II. III. IV.

Introduction Background: Thyroid Hormone Synthesis Multiple Thyroid Hormone Receptor Isoforms Thyroid Hormone Receptor Functional Domains A. DNA-binding domain B. Ligand-binding domain C. Hinge region D. Amino-terminal (A/B) domain V. Thyroid Hormone Response Elements VI. Thyroid Hormone Receptor Complexes VII. Phosphorylation of Thyroid Hormone Receptors VIII. Molecular Mechanisms of Thyroid Hormone Receptor Action A. Corepressors/basal repression B. Coactivators/transcriptional activation C. Cross-talk with other nuclear hormone receptors D. Nongenomic effects of TH IX. Thyroid Hormone Effects on Target Tissues A. Bone B. Heart C. Fat D. Liver E. Pituitary F. Brain X. Resistance to Thyroid Hormone XI. Genetically Engineered Mouse Models of Thyroid Hormone Action XII. Conclusion

1097 1098 1099 1102 1102 1102 1104 1104 1105 1106 1107 1108 1108 1111 1114 1115 1116 1116 1117 1118 1119 1120 1120 1121 1124 1126

Yen, Paul M. Physiological and Molecular Basis of Thyroid Hormone Action. Physiol Rev 81: 1097–1142, 2001.— Thyroid hormones (THs) play critical roles in the differentiation, growth, metabolism, and physiological function of virtually all tissues. TH binds to receptors that are ligand-regulatable transcription factors belonging to the nuclear hormone receptor superfamily. Tremendous progress has been made recently in our understanding of the molecular mechanisms that underlie TH action. In this review, we present the major advances in our knowledge of the molecular mechanisms of TH action and their implications for TH action in specific tissues, resistance to thyroid hormone syndrome, and genetically engineered mouse models.

I. INTRODUCTION Thyroid hormones (THs) play critical roles in differentiation, growth, and metabolism. Indeed, TH is required for the normal function of nearly all tissues, with major effects on oxygen consumption and metabolic rate (375). Disorders of the thyroid gland are among the most common endocrine maladies. Furthermore, endemic cretinhttp://physrev.physiology.org

ism due to iodine deficiency remains a public health problem in developing countries at the advent of the third millennium. Thus the study of TH action has important biological and medical implications. The story of TH action is interwoven with many of the major advances in biomedical science during the past century. Contributions from clinical medicine, physiology, biochemistry, and molecular genetics have had major

0031-9333/01 $15.00 Copyright © 2001 the American Physiological Society

1097

1098

PAUL M. YEN

impacts on our understanding of TH action (376, 551). The following outline sketches only some of the many early contributions to our knowledge. In 1888, the Clinical Society of London published the definitive report that first linked cretinism and adult hypothyroidism to the destruction of the thyroid gland (97a). Soon afterward, thyroid extracts from sheep were used for the treatment of hypothyroidism. Around this time, Emil Kocher performed some of his pioneering studies on the pathology and surgery of the thyroid gland for which he was awarded the Nobel prize in medicine in 1909. In 1914, Kendall (241) isolated 3,5,3⬘,5⬘-tetraiodo-Lthyronine (T4) from thyroid extracts, and almost 40 years later, Gross and Pitt-Rivers (178) synthesized 3,5,3⬘-triiodo-L-thyronine (T3) and demonstrated its presence in human plasma and its ability to prevent goiter in thiouracil-treated rats. Over the ensuing years, the metabolic and oxygen consumption effects of THs as well as its effects on development, particularly in amphibians, were appreciated (59, 79, 463). In the 1960s, Tata and co-workers (509, 510) first suggested that THs might be involved in the transcriptional regulation of target genes. These investigators observed that T3 treatment of hypothyroid rats induced a rapid increase in RNA synthesis in the liver which preceded new protein formation and mitochondrial oxidation (509, 510). The groups of Oppenheimer (372) and Samuels (441) then used radiolabeled TH to demonstrate specific nuclear binding sites in different T3-sensitive tissues, and thus provided the first evidence for TH receptors (TRs). Moreover, T3 binding was observed in almost all tissues (377). Attempts to purify these receptors biochemically were only partially successful; however, photoaffinity labeling of nuclear extracts demonstrated different-sized receptors and raised the possibility of multiple TR isoforms (123, 384). Studies on T3 induction of the rat growth hormone (GH) gene transcription suggested that TRs recognized enhancer sequences or TH response elements (TREs), similar to steroid hormone receptors (101, 281, 282, 440). Thus TRs behaved similar to steroid hormone receptors with respect to nuclear site of action, recognition of specific DNA sequences, and ligand-dependent regulation of transcription. In 1985, the glucocorticoid receptor was cloned and, surprisingly, had homology with a known viral oncogene product, v-erbA, that in conjunction with v-erbB, can cause erythroblastosis in chicks (209). Subsequent cloning of the estrogen receptor suggested that there was a family of nuclear hormone receptors (174). A year later, the laboratories of Evans (545) and Vennstrom (444) ushered in the molecular era of TH action when they cloned two different TR isoforms and showed they were the cellular homologs of v-erbA. Since the molecular cloning of TRs 15 years ago, there has been an explosion of information on the molec-

Volume 81

ular mechanisms of TR action. The power of molecular genetics has greatly aided our understanding of the roles of unliganded and liganded TRs in regulating target genes. We have learned that there are multiple TR isoforms that bind to TREs with variable orientation, spacing, and sequences for TRE half-sites. TRs also interact with other nuclear proteins such as corepressors or coactivators to form complexes that regulate local histone acetylation and interact with the basal transcriptional machinery. Additionally, the solution of the crystal structures of the TR ligand-binding domain (LBD) and other nuclear hormone receptors have provided insight into some of these complex interactions at the molecular level. The development of transgenic and knockout mouse models have shed light on the roles of TRs in the regulation of specific target genes and development. These findings have greatly aided our understanding of the molecular mechanisms of TH action in normal and disease states. In particular, much has been learned about the pathogenesis of the human genetic disorder of resistance to thyroid hormone (RTH). We review some of the major advances in these areas by initially focusing on what is known about the molecular mechanisms of TH action and then discuss their implications for TH action in specific tissues, RTH, and genetically engineered mouse models. II. BACKGROUND: THYROID HORMONE SYNTHESIS TH synthesis and secretion is exquisitely regulated by a negative-feedback system that involves the hypothalamus, pituitary, and thyroid gland [hypothalamic/pituitary/thyroid (HPT) axis] (467). Thyrotropin releasing hormone (TRH) is a tripeptide (PyroGlu-His-Pro) synthesized in the paraventricular nucleus of the hypothalamus. It is transported via axons to the median eminence and then to the anterior pituitary via the portal capillary plexus. TRH binds to TRH receptors in pituitary thyrotropes, a subpopulation of pituitary cells that secrete thyroid stimulating hormone (TSH). TRH receptors are members of the seven-transmembrane spanning receptor family and are coupled to Gq11. TRH stimulation leads to release and synthesis of new TSH in thyrotropes. TSH is a 28-kDa glycoprotein composed of ␣- and ␤-subunits designated as glycoprotein hormone ␣- and TSH ␤-subunits. The ␣-subunit also is shared with other hormones such as luteinizing hormone, follicle stimulating hormone, and chorionic gonadotropin. Both TRH and TSH secretion are negatively regulated by TH. An important mechanism for the negative regulation of TSH may be the intrapituitary conversion of circulating T4 to T3 by type II deiodinase. Additionally, somatostatin and dopamine from the hypothalamus can negatively regulate TSH secretion. TSH is the primary regulator of TH release and se-

July 2001

1099

THYROID HORMONE ACTION

cretion. It also has a critical role in thyroid growth and development. TSH binds to the TSH receptor (TSHr), which also is a seven-transmembrane spanning receptor coupled to Gs (255, 382). Activation of TSHr by TSH or autoantibodies in Graves’ disease leads to an increase in intracellular cAMP and stimulation of protein kinase Amediated pathways. A number of thyroid genes, including Na⫹/I⫺ symporter (NIS), thyroglobulin (Tg), and thyroid peroxidase (TPO), are stimulated by TSH and promote the synthesis of TH. Of note, activating mutations in TSHr and Gs have been described in autonomously functioning thyroid nodules and familial congenital hyperthyroidism (381, 383). The THs, T4 and the more potent T3, are synthesized in the thyroid gland (Fig. 1). Iodide is actively transported and concentrated into the thyroid by NIS (102, 475). The trapped iodide is oxidized by TPO in the presence of hydrogen peroxide and incorporated into the tyrosine residues of a 660-kDa glycoprotein, Tg. This iodination of specific tyrosines located on Tg yields monoiodinated and diiodinated residues (MIT, monoiodo-tyrosines; DIT, diiodo-tyrosines) that are enzymatically coupled to form T4 and T3. The iodinated Tg containing MIT, DIT, T4, and T3, then is stored as an extracellular storage polypeptide in the colloid within the lumen of thyroid follicular cells. Genetic defects along the synthetic pathway of THs have been described in humans and are major causes of congenital hypothyroidism in iodine-replete environments (117, 261). The secretion of THs requires endocytosis of the stored iodinated Tg from the apical surface of the thyroid follicular cell (511). The internalized Tg is incorporated in phagolysosomes and undergoes proteolytic digestion, recapture of MIT and DIT, and release of T4 and T3 into the circulation via the basal surface. The majority of released TH is in the form of T4, as total serum T4 is 40-fold higher than serum T3 (90 vs. 2 nM). Only 0.03% of the total serum T4 is free (unbound), with the remainder bound to carrier proteins such as thyroxine binding globulin (TBG), albumin, and thyroid binding prealbumin. Approximately 0.3% of the total serum T3 is free, with the remainder bound to TBG and albumin. It is the free TH that enters target cells and generates a biological response. The major pathway for the production of T3 is via 5⬘-deiodination of the outer ring of T4 by deiodinases and accounts for the majority of the circulating T3 (50, 256).

Type I deioidinase is found in peripheral tissues such as liver and kidney and is responsible for the conversion of the majority of T4 to T3 in circulation. Type II deiodinase is found in brain, pituitary, and brown adipose tissue and primarily converts T4 to T3 for intracellular use. These deiodinases recently have been cloned and demonstrated to be selenoproteins (280). 5⬘-Deiodination by type I deiodinase and type III deioidinase, which is found primarily in placenta, brain, and skin, leads to the generation of rT3, the key step in the inactivation of TH. rT3 and T3 can be further deiodinated in the liver and are sulfo- and glucuronide-conjugated before excretion in the bile (124). There also is an enterohepatic circulation of TH as intestinal flora deconjugates some of these compounds and promotes the reuptake of TH. Although THs may exert their effects on a number of intracellular loci, their primary effect is on the transcriptional regulation of target genes. Early studies showed that the effects of THs at the genomic level are mediated by nuclear TRs, which are intimately associated with chromatin and bind TH with high affinity and specificity (375, 440). Similar to steroid hormones that also bind to nuclear receptors, TH enters the cell and proceeds to the nucleus (Fig. 2). It then binds to TRs, which may already be prebound to TREs located in promoter regions of target genes. The formation of ligand-bound TR complexes that are also bound to TREs is the critical first step in the positive or negative regulation of target genes and the subsequent regulation of protein synthesis. Given their abilities to bind both ligand and DNA as well as their ability to regulate transcription, TRs can be regarded as ligand-regulatable transcription factors. III. MULTIPLE THYROID HORMONE RECEPTOR ISOFORMS In 1986, the laboratories of Vennstrom (444) and Evans (545) independently cloned cDNAs encoding two different TRs from embryonal chicken and human placental cDNA libraries. Several unexpected findings stemmed from their landmark work. First, they demonstrated by amino acid sequence comparison that TRs are the cellular homologs of the viral oncogene product v-erbA. Second, TRs were shown to have amino sequence homology with steroid hormone receptors. This was initially surprising

FIG.

mones.

1. Structure of thyroid hor-

1100

PAUL M. YEN

Volume 81

FIG. 2. General model for thyroid hormone action in the nucleus. TR, thyroid hormone receptor; RXR, retinoid X receptors.

since T3 and cholesterol-derived steroids are structurally different ligands. However, in the ensuing years, TRs have been shown to belong to a large superfamily of nuclear hormone receptors that include the steroid, vitamin D, and retinoic acid receptors as well as “orphan” receptors for which there are no known ligand or function (35, 285). TRs share a similar domain organization with other family members as they have a central DNA-binding domain containing two “zinc fingers” and a carboxy-terminal LBD. These initial studies also suggested that there were multiple TR isoforms. Subsequent work by many groups has confirmed that there are two major TR isoforms encoded on separate genes, designated as TR␣ and TR␤, encoded on human chromosomes 17 and 3, respectively (284). Moreover, these multiple isoforms exist in different spe-

cies such as amphibians, chick, mouse, rat, and human (284). Both TR isoforms bind T3 (reported dissociation constant values between 10⫺9 and 10⫺10 M) and mediate TH-regulated gene expression (148, 340, 449). In mammalian species, TR␣-1 and TR␤-1s range from 400 to slightly over 500 amino acids in size (284, 289) and contain highly homologous DNA-binding domains and LBD (Fig. 3). In addition to two separate genes that encode TRs, there is additional heterogeneity of TRs due to alternative splicing (220, 292, 330, 349). Alternative splicing of the initial RNA transcript of the TR␣ gene generates two mature mRNAs that each encode two proteins: TR␣-1 and c-erbA␣-2. In the rat, these proteins are identical from amino acid residues 1–370, but their respective sequences diverge markedly thereafter (Fig. 3). Consequently,

FIG. 3. Comparison of amino acid homologies and their functional properties among TR isoforms. The length of receptors is indicated just above the receptor diagrams, and the percent amino acid homology with TR␤-2 is included in the receptor diagrams.

July 2001

THYROID HORMONE ACTION

c-erbA␣-2 cannot bind T3 because it contains a 122-amino acid carboxy terminus that replaces a region in TR␣-1 that is critical for TH binding. Additionally, c-erbA␣-2 binds TREs weakly but cannot transactivate TH-responsive genes. Thus TR␣-1, but not c-erbA␣-2, is an authentic TR. Indeed, c-erbA␣-2 may act as an inhibitor of TH action possibly by competing for binding to TREs (253, 291). The TR␣-1 and c-erbA␣-2 system, then, represents one of the first examples in which multiple mRNAs generated by alternative splicing encode proteins that may be antagonistic to each other. Mitsuhashi et al. (330) also have described a second TR␣ variant, c-erbA␣-2V, in which the first 39 amino acids of the divergent sequence are missing (330). Its function currently is unknown. Yet another interesting feature of the TR␣ gene is the employment of the opposite strand to encode a gene product, rev-erbA. ReverbA mRNA contains a 269-nucleotide stretch which is complementary to the c-erbA␣-2 mRNA due to its transcription from the DNA strand opposite of that used to generate TR␣-1 and c-erbA␣-2 (293, 331). This protein also is a member of the nuclear hormone receptor superfamily. It is expressed in adipocytes and muscle cells, and can bind to TREs and retinoic acid response elements (RAREs) and repress gene transcription (190, 477, 597). However, rev-erbA should be considered an orphan receptor since its cognate ligand and function are not known. One potential role for rev-erbA may be to regulate the splicing that generates c-erbA␣-2 as increased levels of rev-erbA mRNA correlate with increased TR␣-1 mRNA relative to c-erbA␣-2 (80, 224, 290). There also are two TRs derived from the TR␤ gene (205, 284). This gene contains two promoter regions each of which is vital for the transcription of an mRNA coding for a distinctive protein. By the use of alternate promoter choice, one or both of the coding mRNAs are generated (566). The resultant TR␤ isoforms are designated as TR␤-1 and TR␤-2. The amino acid sequences of the DNA binding, hinge region, and LBDs of these two TR␤s are identical, but the amino-terminal regions bear no homology (Fig. 3). Both are authentic receptors as they bind TREs and TH with high affinity and specificity and can mediate TH-dependent transcription. The expression of the two TR␤ isoforms may be regulated by pituitaryspecific transcription factors such as Pit-1 (566). Both TR␣-1 and TR␤-1 mRNAs and proteins are ubiquitously expressed in rat tissues (204). However, TR␣-1 mRNA has highest expression in skeletal muscle and brown fat, whereas TR␤-1 mRNA has highest expression in brain, liver, and kidney. In contrast to the other TR isoforms, TR␤-2 mRNA and protein have tissue-specific expression in the anterior pituitary gland and specific areas of the hypothalamus as well as the developing brain and inner ear (47, 48, 98, 204, 590). In the chick, TR␤-2 mRNA also is expressed in the developing retina (473).

1101

Careful low-stringency hybridization studies so far have not yielded any additional TR isoforms. Double TR␣ and TR␤ knockout mice are viable, and these mice did not have detectable [125I]T3 binding in nuclear extracts of several tissues (171, 316a). However, a number of short forms of TR␣ and TR␤ generated by alternative splicing of mRNA or by use of internal translational start sites have been found in embryonic stem cells and in fetal bone cells and may have biological significance (41, 75, 553, 567). The identification of a novel estrogen receptor isoform (ER␤) 10 years after the discovery of ER␣ serves as a cautionary warning to remain open to the possibility of novel TR isoforms, particularly in restricted tissues or during transient periods in fetal development (265). The regulation of the TR mRNAs is isoform and cell type dependent. In the intact rat pituitary, T3 decreases TR␤-2 mRNA, modestly decreases TR␣-1 mRNA, and slightly increases rat TR␤-1 mRNA (204). Despite these opposing effects, the total T3 binding decreases by 30% in the T3-treated rat pituitary. Similar findings also were observed in GH3 cells, a somatolactotropic rat cell line (205). In other tissues, T3 slightly decreases TR␣-1 and c-erbA␣-2 mRNA except in the brain where c-erbA␣-2 levels are unaffected. TR␤-1 mRNA is minimally affected in nonpituitary tissues. Additionally, the hypothalamic tripeptide TRH decreases TR␤-2 mRNA, slightly decreases TR␣-1 mRNA, and minimally affects TR␤-1 mRNA in GH3 cells (230). Retinoic acid blunts the negative regulation by T3 in these cells (114, 231). Additionally, in patients with nonthyroidal illness in which their circulating free T3 and T4 levels were decreased, TR␣ and TR␤ mRNAs were increased in peripheral mononuclear cells and liver biopsy specimens (556). Thus induction of TR expression may compensate for decreased circulating TH levels in these patients. Each of the TR isoforms found in human, rat, and mouse are highly homologous with respect to their amino acid sequences (284). This conservation among species suggests that there may be important specialized functions for each isoform (109). However, the evidence for isoform-specific functions has been scant since most cotransfection experiments have failed to show important functional differences. Nonetheless, recent studies have suggested that TR␤-1 may exhibit isoform-specific regulation of the TRH and myelin basic protein genes, and TR␤-2 may play an important role in the regulation of the GH and TSH␤ gene expression in the pituitary (4, 129, 208, 283, 305). Future studies with TR knockout mice, antisense oligonucleotides in tissue culture, and isoform-specific ligands, perhaps in conjunction with cDNA microarrays, should shed more light on the respective roles of TR isoforms in regulating specific target genes (24, 86, 136, 151).

1102

PAUL M. YEN

Volume 81

FIG. 4. General organization of major TR domains and functional subregions.

IV. THYROID HORMONE RECEPTOR FUNCTIONAL DOMAINS Mutational analyses of TRs and comparisons with other members of the nuclear hormone receptor superfamily have yielded much information on the structural features of TRs (284, 583). All TRs have a similar domain organization as that found in all nuclear hormone receptors: an amino-terminal A/B domain, a central DNA-binding domain containing two “zinc fingers” (DBD), a hinge region containing the nuclear localization signal, and a carboxy-terminal LBD (Fig. 4). It should be noted that each of these domains and regions may subserve multiple functions, and thus their names may only reflect the first function ascribed to them. A. DNA-Binding Domain The DBD is located in the central portion of TR and has two zinc fingers, each composed of four cysteines coordinated with a zinc ion (Fig. 5). The integrity of each zinc finger is critical, as deletion of zinc fingers or amino acid substitution of these cysteine residues abrogates DNA-binding and transcriptional activity of steroid hormone receptors and TRs (173, 345, 460, 592). Within the first zinc finger, there is a “P box,” comprised of amino acids located between and just distal to the third and fourth cysteines, which is similar to that of estrogen recetors (ERs), retinoic acid receptors (RARs), retinoid X receptors (RXRs), and vitamin D recep-

tors (VDRs) (106, 317, 531). This critical region has been shown to be important in sequence-specific recognition of hormone response elements by different members of the nuclear hormone superfamily and contacts nucleic acids and phosphate groups within the major groove of the TRE (353, 413). Additionally, there are other important contact points within the minor groove of the TRE just downstream from the second zinc finger (A-box region). Also, as discussed below, TRs can heterodimerize with RXRs and can bind to TREs that are arranged as direct repeats separated by a four nucleotide gap. These TR/RXR heterodimers bind to TREs with a 5⬘ to 3⬘ polarity with TR in the downstream position (268, 391, 586). The ability to heterodimerize with RXR is critical for TR binding to the asymmetric TRE, as dimerization contacts stabilize the DNA binding and determine the spacing between half-sites. Within the DBD, there are dimerization interfaces in the TR just upstream of the first zinc finger, within the first zinc finger, and in a subregion distal to the second zinc finger (T box). The RXR dimerization surfaces are located in the second zinc finger including an arginine located in the D box, a region which previously has been shown to be important for distinguishing spacing between half-sites of hormone response elements (315, 531). B. Ligand-Binding Domain The LBD not only is necessary for TH binding but also plays critical roles for dimerization, transactivation,

FIG. 5. DNA-binding domains of human TR␤. Schematic drawing of the two zinc fingers of human TR␤ and the various subregions within the DNA-binding domains. Squares, TR/RXR heterodimerization contacts; ovals, direct base contacts; solid circles, direct phosphate contacts. [From Rastinejad et al. (413). Reprinted by permission from Nature, copyright 1995 Macmillan Magazines Ltd.]

July 2001

THYROID HORMONE ACTION

and basal repression by unliganded TR. The recent solutions of the crystal structures of the liganded TR␣-1, unliganded RXRa, and RAR␥ LBDs have greatly aided our understanding of its role on these functions and the attendant conformational changes that occur when T3 binds to the receptor (Fig. 6) (46, 417, 544). Ligand is buried deep within a hydrophobic pocket in the LBD formed by discontinuous stretches that span almost the entire LBD. In particular, the most carboxy-terminal region (Helix 12) contributes its hydrophobic surface as part of the ligandbinding cavity. The hydrophobic residues face inward, whereas the conserved glutamate faces outward. The cavity also is bounded by hydrophobic surfaces from helices 3, 4, and 5. Although the crystal structure of unliganded TR has yet to be solved, the crystal structure of unliganded RXR␣ shows that helix 12 projects into the solvent. Thus it is likely that helix 12 undergoes major conformational changes upon ligand binding, from a more open conformation to a closed one, which has been likened to a “mouse trap” mechanism. In an analogous manner, estrogen-bound LBD shows a similar structure as ligandedTR LBD with helix 12 facing inward (61). However, helix 12 of raloxifene-bound ER LBD is in a different position,

FIG. 6. TR␣-1 ligand-binding domain crystal structure. Dark mass represents ligand. ␣-Helices are indicated. [From Wagner et al. (544). Reprinted by permission from Nature, copyright 1995 Macmillan Magazines Ltd.]

1103

lying in a groove between helices 3 and 5. Thus the relative positions of helix 12 and the boundary helices may determine whether coactivators can interact with TR. Indeed, studies using TR-LBD mutants based on the TR-LBD crystal structure have confirmed these regions for interacting with the coactivator GRIP-1 (107, 134). TR␣ and TR␤-1 isoforms can bind T3 and various TH analogs with subtle differences in affinity. TR␣ binds T3 with slightly higher affinity than TR␤-1 (449). Triac (3,5,3⬘triiodothyroacetic acid) binds TR␣-1 with similar affinity as T3 and binds TR␤-1 with two- to threefold higher affinity than T3. Several novel thyromimetics have been designed which bind TR␤-1 (GC-1 and CGS 23425) with 10- to 50-fold higher affinity (86, 512). The transcriptional activities of these isoform-specific compounds parallel their binding affinities and may offer novel therapeutic treatments of diseases such as hypercholesterolemia while sparing the heart (which contains mostly TR␣) from side effects. The crystal structures of hTR␣ and hTR␤ LBDs have been solved and may provide important information for designing even more selective thyromimetics in the future (419). The LBD also is involved in several other important receptor functions. Scattered throughout the LBD are discontinuous heptad repeats that have been proposed to form hydrophobic interfaces for TR homo- and heterodimerization (145). Mutations in the ninth heptad repeat region have selectively decreased TR homo- and heterodimer formation, suggesting that there may be different subregions of the LBD that are important for TR dimerization (21, 140, 344, 592). Indeed, the TR␣-1 LBD crystal structure demonstrates that there is a hydrophobic surface in the ninth heptad repeat region that could serve as a potential dimerization interface (544). A natural TR␤ mutation from a patient with resistance to TH at amino acid 316 also displayed decreased homodimer formation, suggesting that additional regions of the LBD may be important for dimerization (189, 360, 592). The relative contributions to dimerization by the LBD and DBD interfaces may depend on the receptor. A recent study suggests that a region that contains the ninth heptad region called the “I box” may be important for RAR heterodimerization with RXR in solution and for binding to direct repeats of variable spacing (392). On the other hand, the DBD dimerization interface may be important for dictating binding to direct repeats of a specific spacing (in this case, a 5-nucleotide gap). Recent studies suggest that the ninth heptad region may be more important for heterodimerization of TR␣-1, whereas the DBD may play the dominant role for c-erbA␣-2 because it lacks a complete ninth heptad region due to alternative splicing (416, 568). Baniahmad et al. (27) used a GAL4-fusion system to identify at least three transcriptional activation regions in the LBD and designated them as ␶2, ␶3, and ␶4 (27). Uppalari and Towle (534) also have used a yeast trans-

1104

PAUL M. YEN

fection system to describe several activation regions in TR␤-1 LBD as well as in the hinge region (534). In particular, ␶4 located near the carboxy terminus has high homology with LBD sequences found in other nuclear hormone receptors previously designated as the activation function-2 (AF-2) domain (Fig. 7). This sequence located within helix 12 has been shown to be important for liganddependent transcriptional activation by other nuclear hormone receptors (31, 105, 278). Recently, Chatterjee and co-workers (521) have made point mutations in this region and have observed normal T3 binding and DNA binding, but no transcriptional activation, using a GAL4/TR␤ LBD fusion protein system (521). As discussed earlier, helix 12 likely undergoes major conformational changes upon ligand binding (419). Studies with steroid hormone receptors and TRs have demonstrated that the AF-2 domain is important for interactions with coactivators such as SRC-1 and related family members (419). Interestingly, mutations in the AF-2 region of the TR LBD had modest effects on T3-dependent interaction of the coactivator TRAM-1 (SRC-3), whereas a mutation in helix 3 of the TR LBD severely impaired T3-dependent interaction with TRAM-1 but had little effect on interaction with SRC-1 (503). Ligand-dependent GRIP-1 (SRC-2) interactions with TR involve helices 3, 5, 6, and 12 (134). These findings suggest that different subregions of TR may differentially contribute to interaction with specific coactivators. Additionally, several groups reported that corepressors may interact with sequences on helices 3, 5, and 6 that overlap sequences involved in interacting with coactivators (214, 348, 390). Several mutations from patients with resistance to TH and artificial mutations in helices 3 and 5 do not interact with coactivators or corepressors (97, 348, 390). C. Hinge Region The hinge region between the DBD and T3-binding domain likely contains an amino acid sequence that is

FIG. 7. Comparison of AF-2 regions of nuclear hormone receptors. Conserved ␾␾xE␾␾ sequences are underlined.

Volume 81

associated with nuclear localization (126). This lysine-rich sequence is highly conserved among nuclear hormone receptors and bears homology with the simian virus 40 T antigen nuclear localization sequence. TRs are likely imported into the nucleus shortly after synthesis as they are predominantly found in the nucleus and can bind DNA, even in the absence of hormone. Furthermore, unlike some steroid hormone receptors, TRs do not associate with cytoplasmic heat shock proteins (103). Recent studies using green fluorescent fusion proteins of wild-type TR␤ and TR␤ hinge region mutants demonstrated this region may be important for T3-mediated translocation of TR into the nucleus (605). The hinge region also has additional properties. The laboratories of Evans (83) and Rosenfeld and co-workers (211) identified corepressor proteins that can interact with unliganded TRs, RARs, and v-erbA and mediate repression of basal transcription by these receptors and v-erbA (see sect. VIII). Mutations in the TR␤-1 hinge region abrogate the basal repression by corepressor. Additionally, a v-erbA mutation in the hinge region that abrogates its oncogenic potential also failed to interact with a corepressor, silencing mediator for RAR and TR (SMRT) (83). These findings suggest that the hinge region of unliganded TRs located on helix 1 may serve as a contact surface with corepressors or have allosteric effects on their interaction. Recent work by several groups also suggest that sequences within helices 3, 5, and 6 of the LBD contribute to corepressor binding (214, 348, 390). D. Amino-Terminal (A/B) Domain The amino-terminal regions have variable lengths and divergent sequences among the TR isoforms. Even among different species, this region is less well conserved for a given TR isoform, because the rat and human TRs are 97 and 99% identical in their DBDs and LBDs, respectively, but only 85% identical in their amino-terminal domains (254). The role(s) of the amino-terminal domain is poorly understood. Studies of the glucocorticoid receptor have suggested that there is a major activation function domain, ␶1, which has structural similarities with viral acidic activator proteins such as VP16 (209). Previous work by Tora and co-workers (524, 525) with progesterone and truncated estrogen receptors also have suggested that the amino-terminal domain may modulate cell-specific and promoter-specific transcription. Cotransfection studies generally have demonstrated only a few examples of isoform-specific transcriptional activation by TRs. Farsetti et al. (129) have shown that TR␤-1 has higher transcriptional activity than TR␣-1 via a myelin basic protein TRE reporter in the context of the native promoter, but not with the viral thymidine kinase promoter (129). Jeannin et al. (224) observed similar TR␤-1-specific effects on

July 2001

THYROID HORMONE ACTION

myelin basic protein, but not on malic enzyme, gene expression suggesting that isoform-specific gene regulation may occur in a subset of target genes (224). Similar TR␤1-specific effects on the regulation of the TRH promoter also have been observed (181, 305). TR␤-2 may have a more potent role in the negative regulation of glycoprotein ␣-subunit and TSH␤ than other TR isoforms (208, 275). In particular, TR␤-2 mediates strong ligand-independent activation of negatively regulated target genes such as glycoprotein hormone ␣-subunit and TSH␤ (275). Indeed, recent studies of TR knockout mice have implicated TR␤-2 as the major TR isoform in negative regulation of TSH (3). The role of the amino-terminal domain in transcriptional activation is still controversial. Some studies have shown that deletion of the amino-terminal domain of TR␤-1 had no effect on T3-dependent transcriptional activation by TR␤-1 (516, 592), suggesting that it does not contain a major activation function domain like the glucocorticoid receptor. On the other hand, studies of TR␣-1 and TR␤-1 from several species have shown that the amino-terminal domain may be important for transcriptional activation and interactions with the general transcription factor TFIIB (25, 183, 520). Additionally, it has been shown that the chick TR␤-2 amino-terminal region may have two activation domains (472). A minimal subregion of amino acids 21–50 allows human TR␤-2 to interact with coactivators in the absence of ligand and may account for the ligand-independent activation of some positively regulated target genes (358). However, one study of the amino-terminal region suggested that rat TR␤-2 does not appear to have a strong activation domain in the amino-terminal region (520), whereas other studies have shown that TR␤-2 transactivates similar to TR␤-1 (205, 478). It is possible that differences in species, cell types, TREs, and minimal promoters may account for these different observations (129, 491, 580). The aminoterminal domain also may modulate ligand-independent repression via positively regulated TREs because one study showed that TR␣-1 is more potent than TR␤-1 or TR␤-2 in mediating basal repression in the absence of T3

1105

(208). Recent studies showed that the amino terminus of TR␤-2 may interact with the silencing domain of the corepressor, SMRT, and thereby block the recruitment of other components of the corepressor complex (575). Finally, the amino-terminal domain of TR also may influence the conformation of the DBD and the repertoire of TREs to which it can bind (184, 232). V. THYROID HORMONE RESPONSE ELEMENTS Steroid hormone receptors bind as homodimers to conserved palindromic hormone response elements that mediate hormone regulation of target genes (160). In contrast, TRs can bind to TREs as monomers, homodimers, and heterodimers in vitro. In general, most of these TREs are located upstream from the minimal promoter, but in certain cases, also can be located in 3⬘flanking sequences downstream from the coding region (40, 600). Mutational analyses of the rat growth hormone gene TRE, and sequence comparison among known TREs from other T3-responsive genes, have suggested a putative consensus hexamer half-site sequence of (G/A)GGT(C/ G)A (84, 555). However, there can be considerable variation found in primary nucleotide sequences of TREs as well as the number, spacing, and orientation of their half-sites (555). In particular, TRs can bind to TREs in which half-sites are arranged as palindromes (TREpal), direct repeats (DRs), and inverted palindromes (IPs). The optimal spacing for these half-site arrangements are zero, four, and six nucleotides, respectively (TREpal0, DR4, and IP6) (Fig. 8). Almost all positively regulated target genes contain two or more half-sites; however, TRs can activate transcription via an artificial single octamer half-site, perhaps even as monomers (240). Approximately 30 natural TREs have been described so far with DRs, followed by IPs, as the most common motifs (555). Several groups also have observed that TR homo- and heterodimers bind to TREs arranged as IPs and DRs better than palindromes (17, 268, 333, 588). In the case of DRs, it has been shown that VDRs preferentially

FIG. 8. Half-site orientation and optimal nucleotide spacing between half-sites. N refers to nucleotides, and arrows show direction of half-sites on the sense strand. TRE, thyroid hormone response element.

1106

PAUL M. YEN

transactivate via reporter vectors containing DRs with a three-nucleotide gap (DR3), TRs via a four-nucleotide gap (DR4), and RARs via a gap of five nucleotides (DR5), according to a “3– 4 –5” rule (160, 532). Heterodimerization with RXR and specific DNA contact points in the DBD may play important roles in determining heterodimer spacing on direct repeats (153, 160, 413). However, the DNA binding and transcriptional activation via these elements do not appear to be absolutely receptor specific because TRs can bind and transactivate weakly on DR5 and DR6, and RARs can bind and transactivate on DR4 (557, 588). VDRs can bind to DR4 and DR5 (587) but cannot transactivate via these HREs. However, VDR has dominant negative activity on T3 and RA-mediated transcription via these elements. Additionally, the primary sequence of the half-site may be important in maintaining receptor-specific binding to DRs as mutation of the third nucleotide of the half-site hexamer from a G to a T enabled VDR binding and ligand-mediated transactivation via a DR4 (418). It also has been shown that flanking and spacing sequences in TREs can affect DNA-binding and transcriptional activation, either by making contacts with TR or local DNA bending (216, 240, 242, 244). TRs can form heterodimers with RXRs, which also are members of the nuclear hormone receptor superfamily (see below). This enables TR complexes to bind to TREs in a specific orientation relative to the minimal promoter. Palindromic and inverted palindromic TRE half-site sequences are symmetric and thus do not dictate a particular heterodimer orientation on the TRE. On the other hand, TRE half-sites in DR4 have a 5⬘ to 3⬘ polarity so the direct repeat motif could specify the heterodimer orientation on the TRE. Several approaches have been used to study this issue. Mutant TRs or RXRs containing amino acid substitutions in the P box of the first zinc finger of the DNA-binding domain that allow preferential binding to a glucocorticoid hormone response element (GRE) half-site have been used to study TR/RXR heterodimer binding to hybrid response elements containing TRE and GRE half-sites (268, 391, 586). These results showed that TR binds to the downstream half-site and RXR to the upstream half-site when TR/RXR heterodimer binds to DR4. Methylation interference studies also showed that TR␣-1 and TR␣-1/RXR preferentially bound to the downstream half-sites of DR4 and the IP F2 (216). The apparent polarity of TR/RXR complexes on F2 may be due to degeneracy of one of the half-site sequences or possibly contributions by the flanking and spacing sequences. Cotransfection studies in which the orientation of these TREs were reversed also decreased T3-mediated transcriptional activity (216). Taken together, these findings suggest that TR/RXR heterodimers bind with a specific polarity which, in turn, can modulate transcriptional activity. This “shape” of the TR complex may be important in protein-protein interactions with coactivators and

Volume 81

corepressors that link the liganded TR/RXR heterodimer with the transcriptional machinery. In this connection, Kurokawa et al. (267) demonstrated that RAR/RXR heterodimers bound to DR1 and DR5 with different polarities. In the former case, they remained bound to a corepressor and mediated constitutive basal repression, and in the latter case, they dissociated from corepressor in the presence of all-trans-retinoic acid and mediated transcriptional activation. Similarly, it has been shown that the TRE sequence can affect corepressor release from TR in the presence of ligand (368). VI. THYROID HORMONE RECEPTOR COMPLEXES Early studies of TR binding to specific DNA sequences utilized methods such as the avidin-biotin complex/DNA (ABCD) assay that did not allow direct visualization of TR complexes bound to DNA (63, 161, 585). However, successful employment of electrophoretic mobility shift assays (EMSAs) demonstrated that TRs could bind to synthetic and natural TREs as monomers, homodimers, and heterodimers in vitro (144, 288, 557, 584). TR␤-1 may have a greater tendency than TR␣-1 to form homodimers on several different TREs, suggesting that these two TR isoforms may have different dimerization potentials (109, 607). Domain swap experiments have suggested that the amino-terminal region of TR␣-1 may inhibit homodimer formation via an allosteric mechanism (208). Initially, TRs were thought to mediate their effects on transcription as homodimers, similar to steroid hormone receptors. However, two groups observed that TRs surprisingly heterodimerized with proteins from pituitary and liver nuclear extracts (63, 341). These proteins were called TR auxiliary proteins (TRAPs) and enhanced TR binding to TREs (63, 341). Because these proteins were expressed in nuclear extracts from many different tissues and species (63, 287, 341, 494), TR/TRAP heterodimers potentially could be formed in all cells that contain TRs. Because these heterodimers appeared to bind better to TREs than TR homodimers, it was speculated that they played a role in T3-regulated transcription. Several groups showed that TRs heterodimerize with RXRs, members of the nuclear hormone receptor superfamily which have high homology with RARs (250, 300, 321, 589, 594, 602). RXRs bind their cognate ligand, 9-cisretinoic acid, with high affinity (202, 304). They can form homodimers as well as heterodimers with RARs, VDRs, and peroxisome proliferator activated receptors (PPARs) (160). Several lines of evidence suggest that RXRs are the major TRAPs and thus play a critical role in T3-mediated transcription. First, they were observed to enhance TR binding to TREs. Second, studies using anti-RXR antibod-

July 2001

THYROID HORMONE ACTION

ies showed that the major endogenous TRAPs are RXRs or related proteins (287, 420, 494). Third, TR/TRAP and TR/RXR heterodimer complexes both remained bound to TREs in the presence of T3 (17, 333, 422, 584, 589) (see below). Fourth, heterodimer-selective, but not homodimer-selective, mutants were able to mediate transcriptional activation of TRE-containing reporters (21, 140, 344, 592). Mutant TRs containing deletions or amino acid substitutions of amino acids at positions 290 –310 or in the ninth heptad region of the LBD concomitantly decreased heterodimerization and transactivation (21, 140, 344, 360, 592). Fifth, RXR enhanced T3-mediated transcription in yeast cells that do not contain endogenous TRAPs (65, 187). And last, RXR enhanced T3-mediated transcription in a reconstitutable in vitro transcription system (294). TR/RXR heterodimer formation increases the repertoire of target genes that can be regulated by T3 as heterodimers bind to TREs with variable sequence and orientation of half-sites (160). Moreover, there are at least three members of the RXR subfamily, so it is possible that different RXR isoforms may form TR/RXR heterodimers that have different TRE-binding specificities and/or abilities to transactivate target genes. Additionally, it is possible that an endogenous ligand like 9-cis-retinoic acid can bind and activate the heterodimer partner of the TR complex. Of note, addition of both 9-cis-retinoic acid and T3 synergistically activated transcription on two different TRE-containing reporters (227, 429). However, in other cases, TR can block 9-cis-binding to RXR and thereby abrogate retinoid stimulation of target genes (91, 147, 266). Finally, TRs can heterodimerize with other members of the nuclear receptor family including RAR, PPAR, chicken ovalbumin upstream promoter transcription factor (COUP-TF), and VDRs (45, 99, 314, 448, 519, 589). The functional significance of these heterodimers, most of which have been demonstrated in vitro by EMSA, is not known. However, they do not appear to be major endogenous TRAPs and may have restricted roles in particular target genes or tissues (287, 494). If they do have physiological roles, though, these heterodimers increase further the diversity of TR complexes and the potential of receptor cross-talk on target genes. Although TRs can form monomers, homodimers, and heterodimers on TREs in EMSA (284, 583), the role(s) of TR monomers and homodimers on transcription is not well understood. In contrast to steroid hormone receptors in which ligand enhances receptor binding to HREs, T3 decreases TR␣-1 and TR␤-1 homodimer as well as TR␣1/TR␤-1 dimer binding to several TREs arranged as DRs and IPs (17, 333, 422, 584). Unliganded TR homodimers also interact better with corepressors than unliganded TR/RXR heterodimers in vitro (207, 311). Thus it is possible that unliganded homodimers may form a complex with corepressors that are involved in basal repression of

1107

target genes in the absence of T3, which then dissociates from the TRE in the presence of T3. Cross-linking and coimmunoprecipitation studies suggest that TR monomers and TR/RXR heterodimers exist in solution, whereas TR homodimers form weakly in solution (268, 288, 581). T3 and 9-cis-retinoic acid promote dimerization in solution, and thus may preform a transcriptionally active complex before DNA binding (95, 234). It appears that dimerization promotes DNA binding (392), and DNA binding enhances dimerization (56, 366, 581). VII. PHOSPHORYLATION OF THYROID HORMONE RECEPTORS Recently several groups also have observed that increasing the phosphorylation state of cells can enhance T3-mediated transcriptional activation of target genes (229, 308, 496). The mechanisms for this enhanced transcriptional activation are not known but may involve phosphorylation of TR, RXR, or coactivators. In support of the potential role of TR phosphorylation in transcriptional activation, it recently has been demonstrated that TR can be phosphorylated in vitro and in vivo (165, 167, 308, 492). Chick TR␣-1 has at least two serine phosphorylation sites in the amino-terminal A/B domain, but the functional role(s) is not known (167). Additionally, these sites do not appear to be conserved across species. The human TR␤-1 can be phosphorylated in vivo and in vitro (308), although the phosphorylation sites have not been determined. Two groups have used HeLa cytosol extract to in vitro phosphorylate Escherichia coli-expressed TR␤-1 (39, 492). Sugawara et al. (492) examined the binding of phosphorylated TR␤-1 to several TREs and found that phosphorylation selectively enhanced TR homodimer, but not TR/RXR heterodimer, binding to several different TREs. Bhat et al. (39) showed that phosphorylation enhanced DNA binding by both TR complexes. Interestingly, phosphorylation by protein kinase A can decrease v-erbA and chick TR␣-1 monomer binding to TREs (530). These results suggest that phosphorylation may be another mechanism, in addition to T3 binding, that can modulate TR complex binding to TREs. Additionally, T3 itself can modulate the phosphorylation state of TR (518). Recently, Davis et al. (113) have shown that TR␤-1 associates with mitogen-activated protein (MAP) kinase in coimmunoprecipitation studies and that ligand binding may stimulate TR phosphorylation by MAP kinase. Interestingly, previous studies have shown that MAP kinase can modulate transcriptional activity of ER and PPAR␥ by phosphorylation of the receptor (238, 406). Moreover, MAP kinase phosphorylation of the steroidogenic factor-1 (SF-1) and ER AF-1 regions leads to enhanced coactivator

1108

PAUL M. YEN

recruitment and transcriptional activation (188, 528). Stimulation of the protein kinase A pathway also potentiated T3-mediated transcription in a cell-specific manner (301), suggesting multiple kinase pathways may modulate transcriptional activity of TR. Power et al. (405) have demonstrated that some nuclear hormone receptors can be activated by dopamine stimulation in the absence of ligand, mostly likely via receptor phosphorylation. It is possible that some ligand-independent effects by TR may be due to receptor phosphorylation by cell-specific kinases or phosphatases, or due to cell-specific expression of certain membrane-signaling receptors that can activate transcription by unliganded TR. In this connection, celltype specific phosphorylation may stabilize TR␤-1 protein (517). Additionally, it has been shown that DNA binding by the alternative splice variant of TR␣-1, c-erbA␣-2, is regulated by casein kinase II phoshorylation of serines in its carboxy terminus (239). This phosphorylation is critical for determining the dominant negative activity (ability to block wild-type TR action) by c-erbA␣-2. These findings suggest that phosphorylation potentially may regulate diverse and important TR functions, although the precise location of phosphorylation sites, their regulation, and their functional roles remain to be elucidated. VIII. MOLECULAR MECHANISMS OF THYROID HORMONE RECEPTOR ACTION A. Corepressors/Basal Repression In contrast to steroid hormone receptors that are transcriptionally inactive in the absence of ligand, unli-

Volume 81

ganded TRs bind to TREs and may modulate transcription of target genes (Fig. 9). Several laboratories showed that unliganded TRs can repress basal transcription of positively regulated TREs in cotransfection studies (26, 53, 603). It was not known initially whether these observations were physiologically relevant or peculiar to cotransfection systems. Early observations showing that T3 decreased TR homodimer binding to TREs led to the hypothesis that unliganded TR homo- and/or heterodimers might mediate basal repression (584). This notion was further supported by the demonstration that TR binding to TREs was important for mediating basal repression, as mutations in TR␤-1 DBD or the TRE primary sequence abrogated basal repression (26, 592). Unliganded TRs have been shown to interact directly with TFIIB, a key component of the basal transcription machinery (25, 183, 394, 520, 523), and potentially can interfere with the assembly of a functional preinitiation complex at the promoter. Studies of TR action in in vitro transcription systems (142) suggested that direct interaction between TRs and the basal transcriptional machinery could help mediate ligand-dependent basal repression. On the other hand, several studies also suggested that soluble corepressors may be critical for mediating basal repression (407, 522). The cloning and functional characterization of several corepressors have greatly enhanced our understanding of basal repression and shed light on these previous issues (Fig. 10). Several laboratories used the yeast twohybrid system or biochemical purification to clone proteins that exhibited decreased interaction with TR and RAR in the presence of their cognate ligands (83, 211, 295, 442). One of them was a 270-kDa protein called nuclear

FIG. 9. Model for repression, derepression, and transcriptional activation by TR in the absence or presence of T3.

July 2001

THYROID HORMONE ACTION

1109

FIG. 10. Comparison of the organization and structure of putative nuclear hormone receptor corepressors. NCoR, nuclear receptor corepressor.

receptor corepressor (NCoR), which also was isolated as an RXR-interacting protein, RIP 13 (211, 459). It contains three transferable repression domains and two carboxyterminal ␣-helical interaction domains. NCoR was able to mediate basal repression by TR and RAR, as well as orphan members of the nuclear hormone receptor family such as rev-erbA␣ and COUP-TF. It had little or no interaction with steroid hormone receptors and did not mediate basal repression by these receptors. NCoR also has been shown to interact with TFIIB, TAFII32, and TAFII70, so part of its ability to repress transcription may be due to its ability to interact with the basal transcripitonal machinery. Recently, a truncated version of NCoR, NCoRi, which is missing the repressor region, has been identified, which may represent an alternative-splice variant of NCoR (207). This protein blocks basal repression by NCoR and potentially may serve as a natural antagonist for NCoR if it is expressed in signficant amounts in tissues. Another corepressor, SMRT, has been identified and has homology with NCoR (83, 295, 442). The original sequence for SMRT was derived from a partial clone, but it is now appreciated that full-length SMRT is similar in size and has similar repression and nuclear receptor interaction domains as NCoR. SMRT also is able to mediate basal repression of TR and RAR in cotransfection studies. Another protein, small ubiquitious nuclear corepressor (SUN-CoR), was isolated and enhanced basal repression by TR and rev-erbA (596). This 16-kDa protein may form part of a corepressor complex as it interacts with NCoR. Studies of TR and v-erbA have defined the importance of the hinge region for interactions with NCoR and SMRT, because mutations in this region abrogate basal repression without affecting transcriptional activation (83, 211, 324). Interestingly, rev-erbA␣ contains two amino-terminal regions which interact with NCoR and are required for basal repression, suggesting that nuclear hormone receptors may have different interaction sites with corepressors (597). Within the interaction domains of NCoR and SMRT are consensus LXXI/HIXXXI/L sequences that resemble the LXXLL sequences that enable coactivators to interact with nuclear hormone receptors (214, 348, 390). Interestingly, these motifs allow both corepressors and coactivators to interact with similar amino acid residues on helices 3, 5, and 6, which are part

of the ligand pocket of TR. Differences in the length and specific sequences of the corepressor and coactivator interaction sites coupled with the conformational changes in the AF-2 region upon ligand binding may determine whether corepressor or coactivator binds to TR (390). Additionally, corepressors can bind to the TR heterodimer partner RXR. It appears that helix 12 of RXR masks a corepressor binding site in RXR, which is unmasked upon heterodimerization with TR (599). Recently, several groups have shown that corepressors can complex with other repressors, Sin 3 and histone deacetylase 1 (HDAC1), that are mammalian homologs of well-characterized yeast transcriptional repressors RPD1 and RPD3 (13, 200, 271, 347, 352). Thus local histone deacetylation may play a critical role in basal repression by nuclear hormone receptors. Moreover, this mechanism of basal repression may be employed by other transcription factors such as Mad/Max and Myc/Mxi heterodimers (13, 200, 271). Anti-NCoR antibodies have been shown to coimmunoprecipitate HDAC activity (200). Additionally, microinjection of specific antibodies generated against mSin3 and RPD3 were able to block basal repression by NCoR (200). Recent studies by Lazar (286) and Wong (J. M. Wong, personal communication) suggest that HDAC4 may interact directly with NCoR at a different repressor site than Sin3 and HDAC1. Recent coimmunoprecipitation studies also suggest that HDAC3 may be the major HDAC associated with SMRT (286). Another component of the corepressor may be the protooncogene c-Ski which has been shown to be involved in transcriptional represson by Mad and TR (354). It is likely that histone deacetylation by unliganded TR/corepressor complex may help maintain local chromatin structure in a state that shuts down basal transcription. In this connection, studies examining TR␤A promoter in a Xenopus oocyte system showed that simultaneous chromatin assembly and TR/RXR binding were required for basal repression of transcription (562, 563). This repression was relieved by addition of T3 and was accompanied by chromatin remodeling. These data demonstrate that histone acetylation and deacetylation, and the consequent changes in chromatin stucture and nucleosome positioning, may be important determinants of gene transcription (Fig. 11). Additionally, DNA methylation may play a role

1110

PAUL M. YEN

Volume 81

FIG. 11. Molecular model for basal repression in the absence of T3 and transcriptional activation in the presence of T3. X refers to potential unidentified cofactors. See text for details.

in basal repression as methyl-CpG-binding proteins can associate with a corepressor complex containing Sin3 and HDACs (351, 543). This repression was relieved by the deacetylase inhibitor trichostatin A. These findings suggest that two repression processes, DNA methylation and histone deacetylation, may be linked via methyl-CpGbinding proteins. TR also can activate transcription in the absence of ligand. Samuels and co-workers (201) showed that unliganded TR surprisingly could transactivate via rGH and PRL TREs in pituitary cell lines (89). Additionally, several groups have reported ligand-independent gene transcription in neuroblastoma and Xenopus cells (346, 385). It is not known whether cell-specific activators or inhibitors or other mechanisms account for these observations. Last, TRs can activate transcription of negatively regulated genes such as RSV LTR, glycoprotein hormone ␣-subunit, TSH␤, and TRH in the absence of ligand (88, 206, 305, 342, 433). Brent et al. (57) showed that a negative TRE (nTRE) from the glycoprotein hormone ␣-subnunit gene could be placed in different positions relative to the

rat growth hormone minimal promoter (even downstream), and still mediate negative regulation. They showed that the nTRE sequence may play a more important role than its position relative to the minimal promoter. Additionally, several groups have found nTREs located in the 3⬘-untranslated region of target genes (40, 600). Recent studies have suggested that ligand-independent activation may be mediated by TR recruitment of corepressors, and this may be mediated by protein-protein interactions of DNA (500, 501). Interestingly, these effects could be blocked by pharmacological inhibition of HDAC activity. These findings suggest that histone deacetylation may promote ligand-independent activation of a negatively regulated target gene. Another study showed that T3-mediated negative regulation may also require HDAC activity (445). On the other hand, NCoRi (which does not contain the repression domains) enhances ligand-independent regulation in a reporter containing the TRH promoter (207). NCoRi activation function is stronger than NCoR, so the ligand-independent activation function may map to the carboxy terminus of

July 2001

THYROID HORMONE ACTION

NCoR (93). These studies suggest a role for corepressors in ligand-independent activation of some negatively regulated target genes, but the precise mechanism needs to be further defined. The physiological role of corepressors is only partially understood. Corepressors have been implicated in leukemias that have RAR fusions and acute myolegenous leukemia/eight-twenty-one (ETO) fusions from chromosomal translocations (158, 176). Additionally, the TR␣/ TR␤ double-knockout mice have a milder phenotype than congenitally hypothyroid mice, suggesting that basal repression by unliganded receptor may have more deleterious effects on transcription in target tissues. Lazar (286) recently found that transducin B-like protein coimmunoprecipitated with SMRT. This histone-binding protein was deleted in patients with congenital sensory-neural deafness (33). Interestingly, TR␤ knockout mice and affected patients from a family with resistance to TH due to absence of TR␤ also have sensory neural deafness (149, 414). It is interesting to speculate that absence of TR␤ or an associated repressor complex protein can cause a similar phenotype. Last, Feng et al. (135) have targeted a dominant negative NCoRi to the liver in transgenic mice. They observed that basal transcription of spot 14 and Bcl3 (a target gene identified by cDNA microarray) was higher in hypothyroid transgenic mice than in littermate controls. When mice were treated with T3, both genes were induced to similar levels. These findings suggest that NCoR-mediated basal repression in vivo could be reversed by overexpression of NCoRi without effects on transcriptional activation. Interestingly, transcription of several other target genes was unchanged in hypothyroid transgenic mice, suggesting that there may be gene-specific repression by different corepressors. B. Coactivators/Transcriptional Activation Recent studies using Far-Western and coimmunoprecipitation approaches showed that liganded TR may interact with multiple nuclear proteins that potentially can form a transcriptionally active complex (141, 394). Work by several groups previously showed that TRs can interact with general transcription factors (25, 142, 183, 520). Moreover, these interactions seemed to be ligand dependent, suggesting that direct contact between TR and general transcription factors could play a role in derepression and transcriptional activation (27, 142). In support of this possiblity, ER was shown to interact with TBP, TAFII 30, and TFIIB (217, 221, 434), and PR could interact with TAFII 110. Petty et al. (396) also showed that liganded TR␤ interacts with several Drosophila TAFs, particularly TAFII 60 and TAFII 110, and the latter could augment T3-dependent transcription (396). Previous studies using cotransfection and in vitro

1111

transcription systems highlighted the importance of minimal promoters in mediating T3-regulated transcription (129, 491, 580). These studies raised the possibility that adapter proteins, or coactivators, might bridge the liganded TR complex with components of the basal transcriptional machinery. Previously, several viral transcription factors were shown to interact with coactivators to enhance transcription (62, 170, 310). Similarly, several potential coactivators for hormone-regulated transcription were reported, including CREB binding protein (CBP) which interacts with CREB (269). Also, several groups identified proteins that interacted with ER in a liganddependent manner and thus could potentially participate in estrogen-dependent transcriptional activation (72, 186, 221). These putative coactivators interacted with the AF-2 region located in helix 12 of the LBD. This region has high homology among many members of the nuclear hormone receptor family and was shown to be important for liganddependent transcription for several receptors (27, 31, 105, 278, 601) (Fig. 6). This region contains a critical ␾␾XE␾␾ sequence in which ␾ represents a hydrophobic amino acid and X represents any amino acid. Recently, O’Malley and co-workers (369) used a yeast two-hybrid system to clone a putative factor that enhanced transcriptional activation for steroid hormone receptors, which they called steroid receptor coactivator-1 (SRC-1) (Fig. 12). This protein also associates with several other members of the nuclear hormone receptor superfamily, including TRs, and enhances their liganddependent transcription. Subsequent work has shown that the original cDNA clone was only partial, and the full-length clone encoded a 160-kDa protein (235, 369, 507). Additionally, there may be alternative splicing of SRC-1 mRNA, leading to multiple SRC-1 isoforms. The functional significance of the SRC-1 isoforms currently is not known; however, one splice variant, SRC-1E, which lacked 56 amino acids of SRC-1 and had unique 14 amino acids at the carboxy terminus, enhanced T3-mediated transcriptional activation better than SRC-1 (194, 235). Another 160-kDa protein, TIFII/GRIP-1/SRC-2, has been identified that interacts with liganded nuclear hormone receptors, including TRs, and has partial sequence homology with SRC-1. These findings suggest there may be a family of coactivators related to SRC-1 (210, 541). Indeed, another family member, AIB1/pCIP/ACTR/TRAM1/RAC3/ SRC-3, has been identified that augments transcription by nuclear hormone receptors (19, 82, 306, 503, 526). As seen in Figure 12, there are several common features among these putative coactivators. First, there are multiple putative nuclear hormone receptor interaction sites that seem to bear a signature LXXLL sequence motif in which X represents any amino acid. This sequence has been shown to be important for coactivator binding to nuclear hormone receptors (199, 325). These coactivators also have a polyglutamine region, similar to androgen recep-

1112

PAUL M. YEN

FIG.

Volume 81

12. Comparison of the organization and structure of p160 nuclear hormone receptor coactivators.

tors. There is polymorphism observed in the length of these trinucleotide repeats of SRC-3, but the functional signficance, if any, is not known (198). Additionally, in the amino-terminal region, there is a basic helix-loop-helix (bHLH) motif, suggesting that these coactivators may bind to DNA. Also located in this region is the so-called Per-Arnt-Sim (PAS) domain, which interestingly, also is seen in several transcription factors that regulate the circadian rhythm and in the heterodimer partner of the dioxin receptor (387, 402). Thus the PAS region may serve as a dimerization interface and potentially allow crosstalk among other coactivators or transcription factors. SRC-1 can be phosphorylated by MAP kinase, and its activity may be regulated by membrane-bound receptors such as epidermal growth factor (431). There also are multiple nuclear receptor interaction domains in the SRCs that may confer receptor specificity (122, 316, 505, 540). Among the SRC family members, there may be a certain degree of functional redundancy, as SRC-1 knockout mice were viable and fertile and had only a modest decrease in growth and development in reproductive tissues and a mild disurbance of the hypothlamic/pituitary/ thyroid (HPT) axis (550, 570). Interestingly, there was a concomitant increase in TIF2/SRC-2 mRNA in these mice, suggesting that upregulation of TIF2 may compensate for some of the loss of SRC-1 function. Interestingly, the SRC-3 knockout mouse has a much more severe phenotype with decreased growth, delayed puberty, and decreased litter size (569). The effects on the HPT axis and potential contribution to the phenotype are not known at the present time. Recently, several groups have shown that SRC-1 can interact with the CBP, the putative coactivator for cAMPstimulated transcription as well as the related protein, p300, which interacts with the viral coactivator E1A (73, 235, 476, 577). CBP/p300 can serve as a coactivator for CREB, p53, AP-1, and NFkB. It is possible that CBP/p300

may serve as an integrator molecule for different signaling inputs (262) (Fig. 10). The biological importance of CBP in humans is exemplified by patients with RubensteinTaybi syndrome who have mental retardation, short stature, and craniofacial and other anomalies, as well as mutations in CBP (393). p300 knockout mice die in utero and display defects in cell proliferation as well as neural and heart development (578). CBP knockout mice also die in utero with defects in hematopoesis and angiogenesis (363). These findings suggest that although CBP and p300 behave similarly in enhancing nuclear hormone receptor action in cotransfection studies, they are not functionally equivalent in vivo. Recent studies also have shown that CBP/p300 can interact with PCAF (p300/CBP-associated factor), the mammalian homolog of a yeast transcriptional activator, general control nonrepressed protein 5, GCN5 (42, 574). Like GCN5, PCAF has intrinisic histone acetyltransferase (HAT) activity. The HAT activity of PCAF is directed primarily toward H3 and H4 histones. PCAF itself is part of a preformed complex that contains TBP associated factors (TAFs) which have been shown to interact with SRC-1 and SRC-3 (82, 361, 479). CBP also has been shown to be part of a stable complex with RNA polymerase (pol) II (350). Thus PCAF and CBP can serve as adaptors of nuclear receptors to the basal transcriptional machinery and have an enzymatic function (HAT activity). These dual roles likely contribute to nuclear receptor transcriptional activity (Fig. 12). Subsequent studies showed that CBP/p300, as well as SRC-1 and SRC-3, have HAT activity, although their specificity for histone substrates differed (82, 262, 362, 479). Recruitment of different coactivators with different HAT activities may be a mechanism for promoter- or cell-specific regulation of target genes. Recently, Lanz et al. (277) reported that an RNA transcript, steroid receptor RNA activator (SRA), could enhance AF-1-mediated transcription of the progesterone

July 2001

THYROID HORMONE ACTION

receptor and was part of the SRC-1 complex (277). It is possible that SRA may be part of a ribonucleoprotein scaffold that many help recruit SRC-1 to nuclear hormone receptors. Additionally, Stallcup recently showed that a methyltransferase, CARM-1, can be associated with GRIP-1 and methylate the histone H3 (81). These findings suggest that histone methylation as well as acetylation may be employed to alter local chromatin stucture. In vivo foot-printing studies also have suggested conformational changes in the chromatin structure near TREs and retinoic acid response elements after ligand addition (118, 143, 243, 562). Additionally, liganded receptor binding to the hormone response element allowed other enhancer elements in the promoter to be footprinted (118). In studies on TR␤A promoter in Xenopus oocytes, Wolffe et al. (561, 562) have shown that chromatin assembly is critical for basal repression by unliganded TR/RXR heterodimers. Moreover, trichostatin A, a HDAC inhibitor, relieves this basal repression but does not disrupt chromatin structure. In contrast, liganded TR/RXR disrupts chromatin structure, releases the corepressor complex, and recruits coactivators such as CBP and PCAF with HAT activity. Recent studies with green fluorescent proteins have shown that TRs are predominantly in the nucleus and that T3 can mediate intranuclear reorganization in the presence of ligand (34). Moreover, this change does not require DNA binding. This reorganization may be due to association with chromatin, active transcriptional complexes, and/or nuclear matrix components (34, 213, 482). Recently, the groups of Freedman (411, 412) and Roeder (595) have isolated a complex of proteins (DRIPS, vitamin D receptor interacting proteins; TRAPs, TR-associated proteins) ranging from 70 to 230 kDa that interacted with liganded VDRs and TRs in GST-pulldown studies. These proteins had similar sizes as a previously reported complex of proteins originally isolated by coimmunoprecipation with an antibody against epitope-tagged TR␣. A critical coactivator in this complex is DRIP205/ TRAP220, which contains a LXXLL motif similar to SRC family members and appears to anchor ⬃15 other proteins. Interestingly, none of these proteins is a member of the SRC family and their associated proteins. Instead, several DRIP/TRAP components are mammalian homologs of the yeast Mediator complex, which associates with RNA Pol II (179, 219). DRIP/TRAP complex is virtually identical to a previously described SRB-MED-containing cofactor complex (SMCC) that can interact with p53 and VP16 to enhance transcription (219). These findings suggest that TR may recruit DRIP/TRAP complex which, in turn, may recruit or stabilize RNA Pol II holoenzyme by virtue of shared subunits. Additionally, DRIP/TRAP complex does not appear to have intrinisic HAT activity (411). Taken together, these findings suggest a model in which there may be at least two distinct coactivator complexes

1113

for nuclear hormone receptors; however, the precise functional roles of the two different coactivator complexes are not known. It is possible that the p160/SRC complex may initiate transcriptional activity by recruiting cofactors with HAT activity to ligand-bound nuclear hormone receptors, and DRIP/TRAP complex may then bind to nuclear receptors that can then recruit RNA Pol II holoenzyme to promote transcription of target genes (Fig. 11). Recently, it has been shown that CBP can acetylate ACTR (SRC-3) and promote its dissociation from nuclear hormone receptors, so acetylation of components of the p160/SRC complex from HAT activity may facilitate the exchange of complexes (82). Balasubramanian and Moore (22) recently showed that mammalian homologs of Sw-1/ Snf, BRG-1 and BRM-1, can associate with TR in vitro and activate transcription. These chromatin remodeling proteins have ATPase activity and previously were shown to enhance GR-mediated transcriptional activity in yeast (67). Recently, the sequential recruitment of coactivator complexes and correlation with transcription has been demonstrated for ER and TR (461a, 461b). Understanding the interplay of these coactivator complexes and the mechanisms by which they activate transcription will certainly be the subjects of intense study in the future. In addition to the p160/SRC and DRIP/TRAP complexes, a number of coacativators have been identified, but their relationship to these complexes, if any, is not known. Moore and co-workers (295, 296) have identified several other proteins that interact with TR␤-1 LBD. These proteins, called TRIPs (TR-interacting proteins), are diverse; one of them is the human homolog of a yeast transcription factor, another a new member of a class of nonhistone chromosomal proteins, and yet another contains a conserved domain asssociated with ubiquitination of specific target proteins. Monden et al. (334) have identified a putative coactivator, p120, that does not bear homology with SRC-1 but interacts with liganded TR and contains an LXXLL motif (334). Another protein called TRIP230 (TR and Rb interacting protein of 230 kDa) was intially cloned on the basis of its ability to interact with the retinoblastoma protein (74). This protein binds to liganded TR and augments T3-mediated transcriptional activation. Interestingly, cotransfection of Rb blocks the TRIP230 enhancement of transcription, suggesting crosstalk between TR- and Rb-mediated pathways. Another coactivator, TR-binding protein (TRBP; ASC-2; RAP250), interacts with TR via a LXXLL motif and stimulates transcription of several nuclear hormone receptors, AP-1, CREB, and NF␬B (66, 252, 298). It also interacts with DRIP 130 and CBP/p300. Yet another protein, TR uncoupling protein (TRUP), binds to TR/RXR heterodimers and prevents their binding to TREs (64). In contrast to coactivators, it blocks T3-mediated transcription, presumably by the foregoing mechanism. Additionally, there are a number of other nuclear proteins that have been identi-

1114

PAUL M. YEN

fied by two-hybrid screening that interact with steroid hormone receptors and also may interact with TRs (212, 326). These findings suggest that there may be different classes of coactivators in addition to the SRC and DRIP/ TRAP complexes. However, the functional significance of these coactivators on TR-mediated transcription remains to be further defined. C. Cross-talk With Other Nuclear Hormone Receptors TRs and other nuclear hormone receptors can modulate transcriptional activities of each other. This crosstalk can occur via several mechanisms: promiscuous binding to HREs, formation of heterodimers, and competition for cofactors (450, 582). The first two mechanisms seem to be the most prevalent among nuclear hormone receptors and can result in either enhanced or decreased transcriptional activity. As mentioned earlier, TR/RXR heterodimers may mediate dual-ligand regulation of transcription in some instances and block ligand-dependent transcription via RXR in others (162, 297, 314, 429, 493). Similar mechanisms also may occur for TR blockade of RAR-mediated transcription (29, 297, 589). Carlberg and co-workers (448) demonstrated that VDR and TR formed heterodimers on the mouse and rat calbindin HREs which are arranged as DR3 and DR4, respectively, and both vitamin D and T3 could coregulate transcription via these elements. VDR/RXR, but not VDR/ TR, bound to several TREs, and VDR exhibited dominant negative activity as it blocked T3-mediated transcriptional activity on DR4 and the chick lysozyme TRE, F2 (587). Aranda and co-workers (156) also have found that VDR blocked TR-mediated transcription in the rGH TRE. Interestingly, cotransfection of SRC-1 or SRC-3 could augment VDR-mediated transcription on TRE- and RARE-containing reporters (DR4 and DR5) (504). TRs and ERs also exhibit cross-talk. TRs and ERs have identical “P box” sequences and recognize the same consensus half-site sequence, AGGTCA (160). However, ERs bind as homodimers to EREs arranged as palindromes separated by three nucleotides. Although TRs can bind to estrogen response elements (EREs), they are unable to transactivate via these elements (420, 456). Nonetheless, TRs can block estrogen stimulation of vitellogenin gene expression possibly by forming transcriptionally inactive complexes (e.g., TR/RXR heterodimers) on the ERE (161, 456, 609). Zhu and co-workers (397, 608) have shown that TR can bind to the EREs of pro-enkephalin and progesterone receptor promoters in rat hypothalamic cells and decrease estrogen-mediated proenkephalin mRNA synthesis. Because these two estrogenregulated target genes are important in the hypothalamic regulation of sexual behavior in rats, coexpression of TR

Volume 81

with ER may be an important modulator of estrogen response in this neuroendocrine tissue. ERs also can block T3-regulated transcription by TR (579, 591). The mechanism for transcriptional blockade may depend on the TREs of particular target genes. In one example, ER␣ blocked the T3-mediated negative regulation of the glycoprotein hormone ␣-subunit gene (579). ER bound to a hormone response element containing an imperfect palindrome sequence. TR monomer also bound to this composite response element and negatively regulated transcription. Thus ER competition with TR for DNA binding to the response element may block T3-mediated negative regulation of this target gene. Additionally, ER blocked T3-mediated transcriptional activation via DR4 and F2 (591). In contrast to the glycoprotein hormone ␣-subunit gene, this blockade did not require DNA binding since the transcriptional blockade was observed with ER mutants that did not bind to TREs or EREs. Similar results also were observed using GR and GR truncation mutants. Interestingly, neither ER or GR had any effect on repression of basal transcription by unliganded TR, suggesting that this blockade by the steroid hormone receptors had a selective effect on these two TR functions. It is likely that overexpression of ER and GR titrated limiting amounts of a cofactor(s) critical for transcriptional activation by liganded TR, but not basal repression, by unliganded TR. Similar results were observed for PR- and TR-mediated transcription in an in vitro transcription system (601). There also are several other examples of cross-talk between other nuclear hormone receptors and TRs. PPARs can decrease T3-mediated transcription, possibly via competition for binding to HREs and/or titration of RXRs or coactivators (45, 233, 332). COUP-TF also can interfere with TR-mediated as well as RAR- and VDR-mediated transcriptional activity (99). Nuclear hormone receptors have been shown to have cross-talk with c-jun and c-fos protooncogene (AP-1) proteins (450). On the proliferin promoter, positive or negative glucocorticoid regulation was regulated by c-jun or c-fos and binding to a composite element containing overlapping an AP-1 binding site and glucocorticoid response element (119). In other cases, c-jun and GR have reciprocal antagonism mediated via protein-protein interactions (451, 576). Similarly, several groups have shown a ligand-dependent repression of AP-1 activity by TRs (312, 388, 604). Interestingly, Lopez et al. (312) also have shown that unliganded TR can positively regulate AP-1 activity on some elements (312). Additionally, c-jun can antagonize T3-mediated transcription via positively and negatively regulated TREs (312, 388, 560, 604). The mechanism for these reciprocal effects seems to be protein-protein interactions between TR and c-jun because several groups have observed formation of TR/c-jun complexes in solution (312, 560, 604). Furthermore, TR and AP-1 com-

July 2001

THYROID HORMONE ACTION

plexes can both interact with CBP, providing another potential point for cross-talk. Recently, Yamamoto and co-workers (426) examined TR- and GR-mediated repression of collagenase gene transcription by jun. Interestingly, two jun mutants disrupted TR-mediated repression but not GR-mediated repression. Also, the repression by TR, but not GR, could be blocked by the histone deacetylase inhibitor trichostatin A. These findings suggest that TR- and GR-mediated repression on this gene occur via distinct mechanisms. D. Nongenomic Effects of TH There is general agreement that most of the effects of T3 are mediated by TR regulation of target gene transcription in the nucleus. However, there are a number of reports on nongenomic effects by T3 and T4 (116). Evidence for these nongenomic effects include the lack of dependence on nuclear TRs and structure-function relationships of TH analogs that are different from their affinities for TRs. There also can be rapid onset of action (typically seconds to minutes), and utilization of membrane-signaling pathways, typically involving kinases or calmodulin, that have not been implicated in direct TR function. The putative nongenomic effects by TH are diverse. However, the biological significance is not well understood in many cases. Transport of T3 across plasma and nuclear membranes have been subjects of interest over the years. T3 is lipophilic and generally thought to diffuse passively across the plasma and nuclear membranes. However, there is some evidence for facilitated transport across plasma membranes and high-affinity TH binding sites in the plasma membranes of different cells (274, 335, 378, 421, 439). In one study of human erythrocytes, T3 is concentrated 55-fold inside cells. There also is evidence for a stereo-specific transporter of T3 into the nucleus as there was a 58-fold higher concentration of L-T3 and 4-fold higher concentration of D-T3 in the nucleus than in the cytoplasm using isotope dilution methods, although different affinities for TR may also contribute to this difference (378). However, the identification of the specific proteins that might be involved in T3 transport has remained elusive. One potential transporter may be the multidrug resistance P-glycoprotein that can modulate TH concentration when overexpressed in cells (421). Another family of transporters may be the organic anion transporter proteins that have been shown to import TH into hepatocytes (1, 154). In addition to transporters, some other potential targets of T3 in the plasma membrane include Ca2⫹-ATPase, adenylate cyclase, and glucose transporters (112, 115, 274, 335, 378, 439, 454, 455). In the last case, it has been long appreciated that T3 can enhance uptake of sugars in

1115

a variety of tissues via a mechanism that does not require new protein synthesis, suggesting a direct effect on the plasma membrane transport system (453– 455). Additionally, T3 has been shown to bind to an endoplasmic reticulum-associated protein, prolyl hydroxylase, and also to a subunit of pyruvate kinase when the enzyme is monomeric but not tetrameric (20, 85, 237). It is not known whether T3 modulates the activities of these enzymes or whether these enzymes may subserve other functions related to T3 action such as transport or storage. In this connection, it is of interest that thyroxine, T4, can inhibit deiodinase type II activity by an allosteric mechanism and may promote targeting of a substrate-binding subunit to endosomes (132). Recently, Stensapir et al. (481) also have shown that deiodinase type II can be proteosomally degraded in the presence of T4 and/or T3. Sterling and colleagues (483– 485) reported the presence of specific mitochondrial receptors over 20 years ago and thus provided an attractive unifying model for T3 effects on mitochondrial activity and cellular energy state. There is some evidence that the site of TH action in mitochondria is the adenine nucleotide translocase of the inner mitochondrial membrane (428, 483). However, this work has been difficult to confirm as there are conflicting reports in the literature on the site of TH action in mitochondria (116, 185, 276). Recently, a 43-kDa protein related to TR␣-1 LBD has been described in mitochondria that also could bind to TREs and mitochondrial DNA sequences (70, 567). Moreover, transfection of TR␣-1 in CV-1 cells resulted in mitochondrial localization and stimulation of mitochondrial activity. These results suggest that there indeed may be specific mitochondrial receptors for T3 which also may serve as transcription factors in mitochondria. There also are reports of nongenomic effects on cell structure proteins by THs. Actin depolymerization blocks type II deiodinase inactivation by T4 in cAMP-stimulated glial cells, suggesting that an intact actin cytoskeleton is important for this downregulation of deiodinase activity (131, 132). Interestingly, T4, but not T3, can promote actin polymerization in astrocytes (468) and thus may influence the downregulation of type II deiodinase activity by a secondary mechanism, perhaps by targeting to lysosomes (131, 132). Moreover, the regulation of actin polymerization also could contribute to the effects of TH on arborization, axonal transport, and cell-cell contacts during brain development. In this connection, Farwell et al. (133) have shown that T4 was required for integrin clustering and attachment to laminin by integrin in astrocytes. Finally, Davis and co-workers (307) have observed that the antiviral effects of interferon-␥ can be potentiated by T4 and T3. These effects were rapid and did not require protein synthesis because they were not blocked by cycloheximide treatment and required protein kinase C and protein kinase A activation. These data suggest that cir-

1116

PAUL M. YEN

culating levels of T4 may play an important role in modulating cytokine effects in early host defense. IX. THYROID HORMONE EFFECTS ON TARGET ISSUES TRs are expressed in virtually all tissues, although the relative expression of TR isoforms may vary among tissues (128, 204, 487). As mentioned previously, TR␤-1 mRNA is highly expressed in liver but also expressed in almost all other tissues, whereas TR␤-2 mRNA is most highly expressed in the anterior pituitary. TR␣-1 is expressed in almost all tissues. In addition to this variable expression of TR isoforms in different tissues, the role of TH can vary in different tissues. Indeed, the myriad effects by a single hormone on so many different tissues is surprising and underscores TH’s vital role in cellular function. Thus, in addition to its role on the metabolism of macronutrients and overall energy and oxygen consumption, TH also regulates important functions in specific tissues. Recently, the transcriptional regulation of target genes in some of these tissues has been studied. We highlight some of the effects of TH in its major target tissues, and if known, describe their effects on the transcription of target genes in those tissues. A. Bone TH is critical for normal bone growth and development. In children, hypothyroidism can cause short stature and delayed closure of the epiphyses. Biochemical studies have shown that TH can affect the expression of various bone markers in serum, reflecting changes in both bone formation and resorption (10, 337, 430). TH increases alkaline phosphatase and osteocalcin in osteoblasts. Additionally, osteoclast markers such as urinary hydroxyproline, urinary pyridinium, and deoxypyridinium cross-links are increased in hyperthyroid patients. These observations suggest that both osteoblast and osteoclast activities are stimulated by TH. Indeed, there is enhanced calcification and bone formation coupled to increased bone resorption in hyperthyroid patients (328, 337). Additionally, the time interval between formation and subsequent mineralization of osteoid is shortened. The net effect on these bone cells is bone resorption and loss of trabecular bone thickness in hyperthyroidism. There also is marked increase in porosity and decreased cortical thickness in cortical bone in hyperthyroid patients (30, 175, 328, 430). These effects can lead to osteoporosis and increased fractures. TH may act on bone via TH stimulation of growth hormone and insulin-like growth factor I (IGF-I) or by direct effects on target genes. Mundy et al. (339) demonstrated that T3 had a direct effect on bone resorption in

Volume 81

organ culture, suggesting the latter mechanism could occur. Recent studies have shown that T3 also can directly stimulate IGF-I production in osteoblasts and enhance T3 stimulation of [3H]proline incorporation, alkaline phosphatase, and osteocalcin (215). TRs recently have been demonstrated in osteoblast cell lines, osteoclasts derived from an ostoclastoma, as well as in rat and human bone samples (5, 6, 12, 329, 554). Both TR␣-1 and TR␤-1 as well as c-erbA␣-2 are expressed in most osteoblast cell lines, although there is a predominance of TR␣-1 in some cell lines (e.g., ROS25/1 and UMR 106) (554). Williams et al. (554) have speculated that osteoblast phenotype expression may correlate with specific TR isoform expression as the more undifferentiated cell lines expressed predominantly TR␣-1. TR␤-1 and c-erbA␣-2 are highly expressed in chondrocytes (5). Moreover, TH inhibits growth and stimulates differentiation of chondrocytes in culture (218). Recent studies have shown that TR␤2 mRNA was unexpectedly expressed in human chondrocytes and osteoclasts in situ (6). Little is known about direct TH effects on osteoclasts because of the difficulty in obtaining primary cultures or cell lines. Recently, TR protein was detected in a human osteoclastoma and in human bone samples by immunostaining (5, 12), suggesting that TH might have direct effects on osteoclasts. However, two groups have used a bone slice resorption assay to show that functionally isolated osteoclasts were unable to respond directly to T3 by increasing bone resorption, and could only do so if other bone cells were present (9, 58). These results would suggest that TH may not have a direct effect on bone resorption but may mediate its effects via paracrine factors secreted by osteoblast cells. Indeed, TH stimulated prostaglandins and IGF-I in organ culture studies (247). Additionally, there have been reports of interferon-␥ and cyclosporin A inhibiting bone resorption by TH, suggesting cytokines may also serve as mediators of TH effects on osteoclasts (247, 273). Additionally, a clinical study suggests that interleukin-6 may be involved in mediating bone loss in hyperthyroidism (272). Although TH increases the activities of osteoblasts and osteoclasts in vivo and in culture, little is known about its effects on the transcription of target genes in these cells. There are a number of osteoblast proteins that are stimulated by TH. These include proteins involved in matrix formation such as alkaline phosphatase, osteocalcin, and collagen (10, 247). Additionally, IGF-I and IGFbinding protein-2 mRNA are stimulated by T3 in rat primary cultures and osteoblastic cell lines (247). However, it is not known whether TH directly regulates transcription of these target genes. Varga and co-workers (163) have used subtractive hybridization of TH-treated mouse osteoblastic cells to isolate a cDNA that corresponded to the insulin growth factor binding protein-4 (IGFBP-4) (163). IGFBP-4 mRNA was stimulated by T3 and retinoic

July 2001

THYROID HORMONE ACTION

acid in mouse osteoblastic cells after 48 h of treatment and remained elevated after 14 days of treatment. The T3 stimulation of IGF and IGFBPs suggests that TH may participate in osteoblast differentiation and proliferation by regulating growth factor synthesis and action. As mentioned earlier, little is known about the direct role of T3 on osteoclasts. Thus far, no T3-regulated target genes have been described in osteoclasts. B. Heart TH lowers systemic vascular resistance, increases blood volume, and has inotropic and chronotropic effects on cardiac function (248). The combination of these effects on both the circulation and the heart itself results in increased cardiac output. Hyperthyroid patients have a high output circulation state, whereas hypothyroid patients have low cardiac output, decreased stroke volume, decreased vascular volume, and increased systemic vascular resistance (248). These changes in cardiac function by TH ultimately depend on the regulation of target genes within the heart and indirect effects due to hemodynamic changes by TH. TH enhances overall total protein synthesis in the heart (120, 121). Additionally, it regulates the transcription of several specific proteins that are critical for cardiac function such as myosin heavy chain (MHC) genes (120). The myosin holoenzyme has a molecular mass of 500,000 kDa and is composed of two MHCs and four light chains. There are two heavy myosin genes (␣ and ␤) whose products dimerize to form three different myosin chain isoenzymes: myosin V1 (␣/␣), myosin V2 (␣/␤), and myosin V3 (␤/␤). The relative expression of the MHC genes in ventricles is species dependent, since ␣-MHC gene is highly expressed in rodents and rabbits, whereas ␤-MHC gene is predominantly expressed in humans. Myosin V1 has higher ATPase activity and increased velocity of fiber shortening than myosin V3, so the relative expression of isoenzymes in the heart can determine cardiac contractility. In hypothyroid rats, myosin V3 predominates so the less active myosin subtype participates in the contractile process resulting in decreased velocity of fiber shortening. In contrast, T3 treatment stimulates ␣-MHC gene expression and decreases ␤-MHC gene expression, leading to increased myosin V1, and enhanced cardiac contractility. These opposing effects on MHC gene expression have been demonstrated in whole animals as well as neonatal rat myocytes in culture (23, 120, 336). TH also regulates myosin isoenzyme expression during development (336). In the rat fetus, ␣-MHC mRNA expression is high in the atria, whereas ␤-MHC mRNA expression is high in the ventricles. ␣-MHC mRNA then increases shortly after birth in the ventricles and almost completely replaces ␤-MHC mRNA 7 days after birth.

1117

There is no change in ␣-MHC mRNA level in the atria. This developmental switch in the rat ventricles likely is triggered by the surge in circulating TH levels that occurs just after birth. It should be noted that in humans and higher mammals, there is a different developmental pattern as myosin V3 (␤/␤) is predominantly expressed in the ventricles from fetal development to adulthood, whereas V1 (␣/␣) is expressed in the atria. Additionally, the effects of T3 on induction of ␣-MHC mRNA and protein have been small in higher mammals, suggesting that other factors in addition to a switch in MHC isoforms may be playing a role in the inotropic action of TH in these species compared with rodents and rabbits. However, in one clinical study, a man with profound hypothyroidism and severe cardiomyopathy underwent serial ventricular biopsies before and after T4 replacement (270). The patient’s ventricular sample showed a low ␣-MHC mRNA level before treatment that increased 11-fold after T4 treatment. The patient had significant improvement in several indices of cardiac function, suggesting that induction of ␣-MHC by TH likely contributed to his clinical outcome. The promoter and upstream regions of ␣- and ␤-MHC genes have been analyzed, and putative TREs for both these genes have been reported (336). In the ␣-MHC promoter there are two TREs that are imperfect direct repeats separated by four nucleotides located between ⫺100 and ⫺150. In vitro binding studies and cotransfection studies suggested that the upstream TRE may be more important for T3-mediated transcription. However, transgenic studies in which the transgene contained the ␣-MHC promoter linked to the chloramphenicol acetyltransferase (CAT) cDNA showed that mutation of the downstream, rather than the upstream TRE, reduced CAT activity in the atria and ventricles of euthyroid mice (490). ␤-MHC is negatively regulated by T3 (364). A putative TRE containing a single half-site that is located adjacent to the TATA box may play a role in this negative regulation (138). The rate of diastolic relaxation of the heart is related to intracellular Ca2⫹ concentration and sarcoplasmic reticulum Ca2⫹-ATPase (SERCA2) activity. The ATPase is an ion pump that removes calcium from the cytosol and stores it in the sarcoplasmic reticulum during diastole. This decrease in the intracellular Ca2⫹ generated during systole then leads to muscle relaxation. Hypothyroid rats had decreased levels of SERCA2 mRNA that could be markedly stimulated by T3 administration (427). Similar findings also were observed in fetal chicken cardiac myocytes (598). These findings suggest that induction of this ATPase may account for TH enhancement of cardiac output by relaxing the heart with greater speed (lusitropic effect). Three different TREs that are arranged as DRs and IPs in the promoter region of the SERCA2 gene that confer T3 responsiveness (191, 471). T3 also has been shown to regulate expression of several ion channels in

1118

PAUL M. YEN

the heart such as the voltage-gated potassium channel Kv1.5, Na⫹-K⫹-ATPase, and the hyperpolarizaton activated cyclic nucleotide-gated channel (365, 379, 572). Additonally, TH can regulate ␤-adrenergic receptor number in the heart and may thereby enhance sensitivity to catecholamines (558). Recently, a dominant negative mutant TR␤ was targeted to the heart in transgenic mice. ␣-MHC and SERCA2 mRNA were decreased, but ␤-MHC mRNA was increased, in the hearts of the transgenic mice (166). Cardiac muscle contraction was prolonged, and the QRS interval was prolonged on electrocardiogram (EKG). TR␣ ⫺/⫺ knockout mice showed decreased heart rate and QRS interval prolongation on EKG, whereas TR␤ ⫺/⫺ knockout mice had elevated heart rate that was unresponsive to TH administration (228, 552). These findings suggest that TR␣-1 may have a major role in maintaining baseline heart rate, whereas TR␤ may mediate TH stimulation of heart rate. Finally, a novel and potentially exciting therapeutic use of T3 as an inotropic agent has been in cardiac surgery. Novitsky (356) showed improved cardiac function and hemodynamics when brain-dead organ donors were pretreated with T3 and cardiac transplant recipients were treated with T3 postoperatively. A small group of patients that underwent cardiac bypass surgery and were treated postoperatively with T3 also showed some benefit (357). However, a large randomized study showed that although T3 increased cardiac output and decreased systemic vascular resistance in patients who underwent coronaryartery bypass surgery, there was no improvement in outcome or changes in postoperative therapy (249). C. Fat TH plays important roles in the development and function of brown and white adipose tissue (8). TH can induce white adipose tissue (WAT) differentiation from preadipocytes in young rats as well as in preadipocyte cell lines such as Ob17 and NIH3T3-F442A cells (139, 177, 303, 514). In these studies, T3 not only induced intracellular lipid accumulation and various adipocyte-specific markers such as malic enzyme and glycerophosphate dehydrogenase, but also stimulated adipocyte cell proliferation and fat cell cluster formation (139, 177). The mechanism(s) by which T3 induces WAT differentation currently is not known but likely involves transcriptional regulation of important target genes by TRs. Both TR␣-1 and TR␤-1 are expressed in Ob17 cells, with the TR␣-1 as the predominantly expressed TR isoform. Rev-erbA␣ also is induced during the differentiation of NIH3T3-L1 fibroblasts into adipocytes (80). This induction of rev-erbA␣ was related to an increase in TR␣-1/cerbA␣-2 levels. Additionally, enzymes of the lipogenic

Volume 81

pathway, ATP-citrate lyase, malic enzyme, and fatty acid synthase, are induced by T3 in differentiating adipocytes (43, 159, 245, 389), suggesting T3 promotes the acquisition of differentiated functions in white adipocyte tissue. Studies in the adult rat have shown that T3 plays important roles in regulating basal oxygen consumption, fat stores, lipogenesis, and lipolysis (374, 375). In WAT, T3 induces key lipogenic enzymes such as acetyl CoA carboxylase, malic enzyme, glucose-6-phosphate dehydrogenase, fatty acid synthase, and spot 14 (43, 159, 245, 338, 389). The expression of these genes is also modulated by other factors such as high-carbohydrate diet, insulin, and cAMP (374, 375). Additionally, T3 also regulates lipolysis in a coordinate manner with lipogenesis (374, 404). Recently, a member of the nuclear hormone receptor family, PPAR␥, has been shown to stimulate differentiation of adipocytes (527). Although prostaglandin J2 and thiazolidinediones are the major ligands for PPAR␥, fatty acids have been shown to stimulate transcriptional activity of PPARs, either by metabolites or by induction of genes that may promote formation of endogenous ligands within the cell (146, 251, 527). Thus TH stimulation of lipolysis may activate other nuclear hormone receptor systems, and thereby promote differentiation. Recent studies also have shown that both TR␣ and TR␤-1 are differentially expressed during the development of brown adipose tissue (BAT) (529), a major contributor to facultative thermogenesis in rodents. Facultative thermogenesis occurs in response to cold exposure or overeating and depends on T3 and adrenergic stimulation of mitochondrial uncoupling protein (UCP) synthesis (164, 203, 375, 432). There are three UCP isoforms, UCP1, UCP2, and UCP3, that are stimulated by T3 in rat BAT (49, 279, 359, 408). UCP3 mRNA is stimulated by T3 in mouse BAT and skeletal muscle (168, 226). It is not known whether these effects are directly mediated by T3 or via downstream signals such as free fatty acids generated by lipolysis. The stimulation of UCP synthesis increases thermogenesis by uncoupling oxidative phosphorylation resulting in energy dissipation as heat. Interestingly, BAT also contains a type II deiodinase whose activity increases in response to cold, thereby enabling BAT to have the important ability to regulate intracellular T3 concentration in a tissue-specific manner (469, 470). This increase in T3 concentration likely saturates nuclear TRs and enhances norepinepinephrine stimulation of UCP. The adrenergic stimulation in BAT is predominantly, but not exclusively, mediated by brown fat specific adrenergic ␤3-receptors. The dual regulation of UCP by the type II deiodinase and the adrenergic system suggests convergence of nuclear- and membrane-signaling systems in the transcriptional regulation of these important target genes in BAT, but the precise relative contributions and interplay between these regulatory systems need to be further defined. Lowell et al. (313) used the UCP promoter to

July 2001

THYROID HORMONE ACTION

target diptheria toxin to BAT in transgenic mice. These animals had decreased amounts of BAT, resulting in decreased cold tolerance and obesity, and suggesting a critical role for BAT in these functions. Recently, UCP3 knockout mice were generated and had normal weight, thermogenesis, and response to T3, suggesting that UCP3 is not the main mediator for TH-mediated thermogenesis as originally proposed, or alternatively, compensatory mechanisms can overcome the lack of UCP3 (169, 538). Several human studies have shown that chronic hypo- and hyperthyroidism as well as acute T3 treatment did not affect serum leptin levels (100, 264, 319, 480). However, one study showed that hypothyroid patients had increased leptin levels, but the increase correlated with adiposity (399). Another study showed that hyperthyroid patients treated with thiamazole increased their leptin levels (610). Studies in the rat have shown that T3 can decrease leptin levels, but it is not known whether this is due to a direct effect or due to its effects on fat mass (125, 302, 497). D. Liver TH has multiple effects on liver function including stimulation of enzymes regulating lipogenesis and lipolysis as well as oxidative processes (375, 376). Some of the lipogenic enzymes that are regulated are malic enzyme, glucose-6-phosphate dehydrogenase, and fatty acid synthase. In the case of malic enzyme, which has been studied extensively, there is a biphasic induction of the malic enzyme mRNA at 4 and 24 h, suggesting that there may be an initial direct stimulation by T3 and a secondary effect due to stimulation by other gene products that are regulated by T3 (486). Indeed, it recently has been shown that Spot 14 (S14), a protein that originally was identified by two-dimensional gel electrophoresis of the translational products of total hepatic tissue mRNA from T3-treated rats, may regulate a number of lipogenic enzymes, including malic enzyme, in the liver (245, 452). Likewise, at least in the rat, a number of lipogenic enzymes also may be regulated by growth hormone, which is induced by T3 (375). Interestingly, malic enzyme is very sensitive to T3 in the liver, but it is unresponsive in the brain, suggesting that tissue-specific factors are important in determining T3-mediated stimulation of transcription. Nikodem and co-workers (395) identified a putative TRE in the promoter region of the malic enzyme gene that contains two half-sites arranged as direct repeats separated by four nucleotides. T3 regulation of malic enzyme gene transcription also can be regulated by carbohydrate intake, insulin, and cAMP. For instance, T3 effects on malic enzyme gene transcription are minimal in fasted animals but are most pronounced in animals fed a sucrose-containing fat-free

1119

(lipogenic) diet (375, 376). Similar interactions between T3 and dietary carbohydrate also occur in the gene regulation of other lipogenic enzymes. Another T3-regulated gene expressed in liver that has been studied extensively has been the one encoding S14 protein (376). Its mRNA is rapidly induced by T3 after 20 min in hypothyroid rats and precedes the expression of lipogenic enzymes. Additionally, it is coregulated by carbohydrate similar to lipogenic enzymes. Its tissue distribution is similar to those of lipogenic enzymes as it is expressed in liver, white and brown fat, and lactating mammary tissue. Recently, it has been shown that S14 may be localized in the nuclear matrix and thus may participate in regulating the transcription of lipogenic enzymes (245, 246). It has been appreciated for many years that hypothyroidism is associated with hypercholesterolemia with elevated serum intermediate and low-density lipoprotein (LDL) cholesterol concentrations (52). The major mechanism for these effects may be lower cholesterol clearance resulting from decreased LDL receptors. Furthermore, the genotype of the LDL receptor gene may influence the elevation of serum LDL cholesterol concentrations in hypothyroid patients and their response to thyroxine treatment (559). An additional mechanism may be decreased hepatic lipase activity in hypothyroidism which decreases conversion of intermediate-density lipoproteins to LDL and high-density lipoprotein metabolism (380, 508). It is not known whether these effects are mediated directly or indirectly by TH. Several putative TREs in the distal promoter region of the hepatic lipase and apoliporotein A1 genes have been identified (457, 513). TH also has been shown to regulate the expression of several important proteins and enzymes involved in cholesterol metabolism and synthesis such as the LDL receptor, cholesterol ester hydrolase, and cholesterol acyltransferase (423, 447, 461). TH also may regulate posttranscriptional editing of apolipoprotein mRNA (111). TR␤-1 is the predominant isoform expressed in liver, whereas TR␣-1 is the major isoform expressed in heart (128, 204, 487). These differences in TR isoform expression have spawned attempts to develop isoform-specific TH analogs that may have cholesterol-lowering effects but minimal cardiac toxicity (86, 512, 533). Recently, Hayashi and Refetoff (195) have created a mouse model of TH resistance in the liver by transfecting hepatocytes with adenovirus vectors encoding a mutant TR (195). This mutant receptor had dominant negative activity (see below) on wild-type receptor function. The mice that expressed the mutant TR had elevated serum cholesterol levels compared with control animals in both hypothyroid and hyperthyroid states. Additionally, they had blunted induction of S14 protein and 5⬘-deiodinase mRNA by T3. These findings suggest a direct role by TRs in regulating these genes. This model thus may be a useful

1120

PAUL M. YEN

tool for determining those hepatic genes that are directly regulated by TH. To identify novel hepatic target genes and examine gene profiles regulated by T3, Feng et al. (136) used a quantitative fluorescent cDNA microarray to identify hepatic genes regulated by TH. Fifty-five genes, 45 of which were not previously known to be TH responsive, were found to be regulated by TH (136). Among them, 14 were positively regulated by TH, and surprisingly, 41 were negatively regulated. TH had broad effects as it regulated gene expression of a diverse range of cellular pathways and functions such as gluconeogenesis, lipogenesis, insulin signaling, adenylate cyclase signaling, cell proliferation, and apoptosis. This application of the microarray technique to study hormonal regulation of gene expression in vivo demonstrates the value of large-scale gene expression analyses for future studies of hormone and drug action. E. Pituitary TH regulates the synthesis and secretion of several pituitary hormones. Absence of GH has been observed in the pituitaries of hypothyroid rats (440). Additionally, T3 can stimulate the transcription of GH mRNA and GH synthesis in rat pituitary tumor cells (322, 440, 458). Brent et al. (54) identified a rGH TRE than contains a direct repeat separated by four nucleotides and a palindromic sequence (101, 281). This HRE can also confer sensitivity to retinoids and vitamin D (156, 493). However, in contrast to rodents, T3 has limited ability to regulate GH synthesis in humans. For example, hypothyroid children have impaired growth but serum growth hormone levels are normal (424, 537). Cotransfection studies using the human growth hormone promoter have not shown stimulation by TH (55, 71). Studies in cultured human somatotrope adenomas showed that T3 stimulated GH release but had variable effects on transcription (90). TH also can negatively regulate thyrotropin (TSH) transcription by direct and indirect mechanisms (464). TH can negatively regulate TRH at the transcriptional level, which in turn decreases transcription of TSH mRNA (465, 573). T3 also can downregulate prolactin mRNA by a similar mechanism, and also by direct effects on transcription (565). The TRH promoter has been analyzed and contains several nTREs (206, 446). TH hormone also can negatively regulate TSH by decreasing transcription of the glycoprotein hormone ␣-subunit (common to TSH, luteinizing hormone, follicle-stimulating hormone, and human chorionogonadotropic hormone) and the TSH␤ subunit genes (44, 51, 77, 108, 318, 464, 466). Several nTREs in the promoters of these genes have been described. In some cases, they contain single half-sites, suggesting that TR monomers may be involved in negative regulation. Addi-

Volume 81

tionally, these genes display ligand-independent activation in cotransfection studies (207, 501). It also is possible that corepressors, rather than coactivators, may participate in this activation and negative regulation (207, 445, 501). Additionally, it has been shown that TH decreases the stability of TSH␤ mRNA by inducing shortening of its poly(A) tail (263). T3 can stimulate a cytosolic RNA-binding protein to bind to the 3⬘-untranslated region of TSH␤ mRNA and may thereby regulate mRNA stability at a posttranscriptional level (299). Recent cotransfection and knockout studies suggest that TR␤-2 isoform may be playing the predominant role in regulating TSH (2, 275). In situ hybridization and immunostaining studies have shown that TR␤-2 is highly expressed in thyrotropes in the pituitary (87, 590). Additionally, RXR␥ isoform appears to be selectively expressed in thyrotropes, suggesting that it also may play a functional role in the regulation of TSH via isoform-specific TR/RXR complexes or RXR␥ homodimers (193, 495). Recent findings of inappropriate TSH secretion in a RXR␥ knockout mice, and the suppression of TSH by RXRspecific agonist in humans are consistent with this model (192, 462). F. Brain TH has major effects on the developing brain in utero and during the neonatal period (38, 373). Neonatal hypothyroidism due to genetic causes and iodine deficiency in humans can cause mental retardation and neurological defects. Studies in hypothyroid neonatal rats have shown that absence of TH causes diminished axonal growth and dendritic arborization in the cerebral cortex, visual and auditory cortex, hippocampus, and cerebellum (409, 410). In the cerebellum, absence of TH also delays proliferation and migration of granule cells from the external to the internal granular layer. The critical role of TH is further demonstrated by a recent report in which a dominant negative TR was targeted to the cerebellum in transgenic mice. The Purkinje cells showed decreased dendritic arborization, while the granule cells had retarded migration to the internal granular layer (257). The developmental delays in the rat brain can be reversed if TH is administered within 2 wk after birth (539). These findings support the clinical observations that early T4 treatment of congenital hypothyroidism prevents intellectual impairment in humans and is the major impetus for neonatal screening for congenital hypothyroidism. In utero, monodeiodination of T4 to T3 by type II deiodinase and maternal-fetal transfer of T4 may help maintain normal T3 concentrations even when the fetus has congenital hypothyroidism (110, 180). Additionally, maternal transfer of thyroxine may be important, particularly during early fetal development (68, 542). Recent studies have suggested that mater-

July 2001

THYROID HORMONE ACTION

nal thyroid status may have significant effects on the neuropsychological outcome of children (38, 182, 403). The ontogeny of TR isoforms in the brain suggests that specific TR isoforms may be involved in transcription of target genes and in brain development (373, 487). TR␣-1 is expressed throughout the brain from early fetal development and accounts for total T3 binding in the fetal brain. TR␤-1 is absent or minimally expressed, except in a few selected areas such as the cochlea and cerebellum (47, 48, 488, 489). However, there is a dramatic 40-fold increase in TR␤-1 mRNA expression throughout the brain shortly after birth that reaches maximum levels 10 days afterward, and then persists until adulthood (487). In contrast, TR␣-1 and c-erbA␣-2 mRNA undergo a transient twofold increase that decreases to adult levels 2 wk after birth. This early rise in TR␤-1 expression coincides with the neonatal surge in serum T3 and suggests there may be a coordinated temporal developmental program in which critical target genes are regulated by specific TR isoforms. Similar temporal patterns of expression also have been observed in the chick and amphibian tadpole (127, 137, 473). Despite the importance of TH in brain development, there are relatively few genes known to be directly regulated by TH, and many have only been partially characterized. Farsetti and co-workers (129, 130) have shown that the gene for myelin basic protein (MBP) is directly regulated by TH and have identified a TRE at position ⫺186 to ⫺169 of the MBP promoter. Recent studies of brain-derived neutropic factor showed that TH can regulate its expression in a promoter-, developmental-, and region-specific manner (259). TH also regulates several genes that are involved in a wide range of cellular functions: glutamine synthase, protein kinase C, substrate RC3/neurogranin, prostaglandin D2 synthase, hairless (a potential transcription factor), and adhesion molecules such as neural cell adhesion molecule and matrix proteins such as tenascin, and proteins important for neuronal migration (14, 15, 155, 172, 323, 515). Nordquist et al. (355) have identified several genes that are expressed in the cerebellum: calbindin, myo-inositol trisphosphate (OP-3) receptor, and Purkinje cell protein-2 (Pcp2). Study of the mRNA expression of these genes and MBP in the cerebellums of hypothyroid and euthyroid neonatal mice showed that the expression of these genes was delayed in the absence of hormone but eventually reached similar expression levels (489). These data also suggested that there may be three phases in the regulation of these particular genes: a refractory prenatal period, a T3-responsive period typically from postnatal days 3–20, and a T3-independent period. Identification of a putative silencing element in the promoter of Pcp2 promoter that may be functional during fetal development provides support for this model (16). It is intriguing to speculate there may be developmentally and regionally expressed suppressors that may

1121

silence T3-responsive target genes during embryogenesis. One proposed candidate suppressor may be the orphan receptor, COUP-TF, which binds to the suppressor region in the Pcp2 promoter (16). It remains controversial as to whether these cerebellar genes are specifically regulated by TR␤-1, which is expressed in parallel. Studies in cultured oligodendrocytes have suggested that this may be the case (69, 425); however, no significant developmental delays in Pcp2 and MBP expression were observed in TR␤ knockout mice (443). Finally, it is possible that there may be cross-talk between TR and other transcription factors in the regulation of target genes in the brain. The knockout mouse for the orphan receptor, ROR (staggerer), has cerebeller defects that are almost identical to those observed in hypothyroid mice (258). In this connection, ROR has been shown to modulate transcriptional activity by TH in cotransfection studies (260). X. RESISTANCE TO THYROID HORMONE RTH is a syndrome in which patients have hyposensitivity to TH, elevated circulating serum T3 and T4, and elevated or nonsuppressed TSH levels. Refetoff et al. (414) first described this syndrome in two siblings who presented with deaf-mutism, delayed bone age with stippled epiphyses, goiter, and high protein-bound iodine levels. Since this initial report, over 350 subjects have been described who have RTH, with ⬃80% of the subjects inheriting this disorder (7, 60, 415). The clinical manifestations are variable among families with RTH and also among affected family members. Additionally, patients can have clinical symptoms that have features of hypoand hyperthyroidism, suggesting variable resistance in different tissues. Some of the clinical features that have been described include goiter, mental retardation, attention-deficit disorder, tachycardia, delayed bone growth and maturation, and hearing abnormalities. There also are examples of pituitary resistance to TH (PRTH), in which patients have resistance predominantly in the pituitary and have signs and symptoms of hyperthyroidism in peripheral tissues (7, 60, 415). With the exception of the index family, which had autosomal recessive inheritance, RTH displays autosomal dominant inheritance (415). In 1988, Usala et al. (535) demonstrated a tight linkage between the TR␤ gene locus and RTH by restriction fragment length polymorphism. Soon afterwards, two groups independently demonstrated mutations in the LBD of TR␤ in patients from two families with RTH: glycine-345 replaced by arginine (Mf1), or proline-453 replaced by histidine (438, 536). Subsequent characterization of other families with RTH have shown TR␤ point mutations in the two major “hot spots” that cluster near these original mutations (Fig. 13) (36, 415). Mutations also have been found in a third “hot spot”

1122

PAUL M. YEN

Volume 81

FIG. 13. Diagram of “hot spots” in the ligand-binding domain of TR␤ where natural mutations have clustered. Shown are some representative mutations. For a more extensive listing of mutations, see Refs. 7, 60, 415 and resistance to thyroid hormone (RTH) registry at the University of Chicago (via internet: gopher. uchicago.edu/subfolder medicine/RTH registry).

in the most amino-terminal portion of the LBD (37, 97, 370, 400, 571). Most patients have mutations due to single amino acid substitutions at a single codon, although single amino acid deletions, frameshift mutations, and truncations due to premature termination of translation from a mutation-generated stop codon also have been identified (7, 60, 415). Almost all mutations cluster around the ligand-binding pocket observed in the TR LBD crystal structure. In vitro transcription and translation of the mutant receptors typically show minimal or reduced T3binding affinity (415). Approximately 60 different mutations in TR␤ have been identified in RTH patients from over 100 families (7, 60, 415). In some cases, the same mutations have been described in different families. The clinical phenotype can vary among these families that harbor the same mutation and also vary within a family. This suggests that there may be other genetic modifiers that determine the phenotype. In this connection, the same mutation can cause either GRTH or PRTH in different individuals even within the same family. In general, there does not seem to be a strong correlation between particular mutations and the development of GRTH and PRTH. The R338W mutation, and a ninth heptad mutant, R429Q, may be more prone to a PRTH phenotype; however, patients with these mutations also can exhibit GRTH (7, 140, 415). Interestingly, no germline TR␣-1 mutants have been described thus far in humans. It is possible that TR␣-1 mutations are lethal in utero, silent, and/or exceedingly rare. Analyses of the TR␤ gene in the index family with RTH showed that the affected members were homozygous for the deletion of the entire coding region of TR␤ (502). Thus complete lack of TR␤ expression was compatible with life. Interestingly, heterozygous members of the family that contained only one deleted TR␤ allele had normal clinical and laboratory findings (Fig. 14). This

observation suggested that a single copy of TR␤ is sufficient for normal function. Furthermore, it suggests that reduction of TR␤ (i.e., gene dosage) did not account for the autosomal dominant inheritance seen in other RTH patients. Instead, it strongly suggested that TR␤ point mutations interfere with the normal function(s) of TRs. This interference of wild-type protein function by a mutant protein has been called “dominant negative activity” (223, 582). The amount of dominant negative activity by a mutant TR depends in part on the level of mutant receptor expression. For example, a patient who was homozygous for mutations in both TR␤ alleles had severe RTH and mental retardation (371). In contrast, his parents who had mutations in only one TR␤ allele had mild RTH. Within any given cell in a RTH patient, mutant TR␤ as well as wild-type TR␤ and TR␣ are expressed. The molecular mechanism(s) for the dominant negative activity by the mutant TR␤ on wild-type TR function has been the subject of numerous studies. Transient cotransfection studies show that natural TR␤-1 mutations not only fail to mediate normal T3-regulated transcription, but also block the T3-regulated transcription by normal TRs (78, 327, 415, 437). The mechanism for this dominant negative activity likely involves binding to TREs by inactive mutant homodimers or TR/RXR heterodimers that cannot bind T3 and hence cannot activate transcription of target genes. Indeed, DNA binding of mutant TRs and v-erbA is required for their dominant negative activity. Additionally, some natural mutant TR␤-1s, as well as v-erbA, constitutively repress basal transcription even in the presence of T3 (28, 104, 345, 398, 582, 592). Recent experiments also suggest that dimerization may play an important role in mediating dominant negative activity (94, 196, 344). However, it is not known whether a particular mutant TR complex (i.e., homodimer or heterodimer) mediates this activity in all cases. Heterodimer-specific mutants are able to mediate

July 2001

THYROID HORMONE ACTION

1123

FIG. 14. Gene dosage does not explain RTH phenotype. Top: point mutation in TR␤ gives RTH phenotype. Bottom: deletion of one TR␤ allele gives no phenotype. Deletion of both TR␤ alleles in patients gives severe RTH phenotype.

dominant negative activity, albeit more weakly than other mutants that can form heterodimers (189, 196). Amino acid substitutions in the ninth heptad of TR␤-1 mutants decreased heterodimerization and dominant negative activity of TR␤-1 mutants (21, 94, 344). These observations have been used to support functional roles for either mutant homo- or heterodimers. However, it may turn out that transcriptionally inactive homo- and heterodimers both can mediate dominant negative activity as long as they compete effectively with wild-type TRs for binding to TREs. Dominant negative activity in cotransfection studies and severity of clinical phenotype correlate well with impairment of in vitro T3 binding by mutant TR␤s (327, 415), although some exceptions have been reported (196, 343). Recent studies on TR␤ mutations in the AF-2 region and hinge region have shed some light on this issue. TR␤ mutations in the AF-2 region have normal T3 binding, DNA binding, and heterodimerization but are transcriptionally inactive in the presence of ligand due to their inability to interact with coactivators (521). Recently, several groups have described RTH patients who have TR␤ mutations in the AF-2 region (96, 498, 549). Furthermore, AF-2 mutants had potent dominant negative activity on wild-type TRs in cotransfection studies (96, 311, 506). Recently, several mutations in the third hot spot also have been characterized. Two mutants (R243Q and R243W) had normal T3-binding affinity but transactivated poorly in

the presence of T3 (97, 370, 435, 571). These mutants also exhibited dominant negative activity on wild-type TR. One study showed that mutant homodimers could not be readily dissociated by T3, suggesting that these receptors may have reduced T3-binding affinity after binding to DNA (571). Additionally, some of these mutants may have impaired corepressor release or interaction with coactivators (97, 435). Yoh et al. (593) have studied SMRT corepressor interaction with a battery of mutant TRs. They observed that mutant TRs had defective dissociation from this corepressor. In general, the release of SMRT correlated with the T3-binding affinity of the mutant receptors. However, two mutants that had only mildly impaired T3 binding affinity were unable to dissociate SMRT even at 1 ␮M T3. Additionally, two mutants, D432M and D432G, have enhanced association with SMRT. In general, the amount of dominant negative activity correlated with the impairment of SMRT dissociation in the presence of T3. The authors also showed that hinge region mutants that abrogate SMRT interaction also decrease the dominant negative activity. Tagami and Jameson (499) also found similar results when they studied NCoR interaction with a battery of TR mutants. They also observed that a hinge region mutant that abrogated NCoR interaction decreased basal repression of transcription of positively regulated genes and ligand-independent activation of negatively regulated genes. These findings suggest that NCoR could play a role

1124

PAUL M. YEN

in mediating dominant negative activity of mutant TRs in positively and negatively regulated target genes. Additionally, mutant TR␤s located between the two major hot spots or near the AF-2 region also had impaired corepressor release (92, 436, 498). Liu et al. (311) studied the interaction of mutant TRs with the corepressor NCoR and coactivator SRC-1. The G345H mutant, which has minimal T3 binding affinity, remained bound to NCoR in the presence of T3 and was unable to bind SRC-1. An AF-2 mutant could release NCoR in the presence of T3 but was unable to bind SRC-1. Both mutant receptors had potent dominant negative activity. A mutant receptor (R320H) with threefold lower T3 binding affinity than wild-type TR was able to release NCoR at higher T3 concentrations and recruit SRC-1 at higher T3 concentrations. Interestingly, this mutant had potent dominant negative activity at low T3 concentrations but weaker dominant negative activity at higher concentrations. Similarly, Chatterjee and co-workers (96, 97) have identified helix 3 and helix 12 mutants from patients with RTH that have impaired recruitment of coactivators. These findings and those showing impaired corepressor release by mutant TR␤s (435, 498, 593) reinforce the notion that inability to release corepressors and/or the inability to recruit coactivators (regardless of the mechanism) can result in TR complexes that cannot be activated by ligand and can mediate dominant negative activity. Refetoff and co-workers (401, 548) recently have reported families with RTH that did not contain TR␤ mutations. Additionally, linkage analyses suggested that RTH was not associated with TR␣. Nuclear extracts from affected patients showed an additional TR-associated band on electrophoretic mobility shift assay (548). These findings suggest the possibility that mutations in cofactors or dysregulation of their expression may be involved in the RTH phenotype of these families. Currently, there is no direct evidence for such “postreceptor” defects. In one example of a coactivator mutation associated with human disease, mutations in CBP were found in patients with Rubinstein-Taybi syndrome (393), an autosomal dominant disorder in which patients have mental retardation, short stature, and craniofacial abnormalities. However, thyroid function tests in these patients were surprisingly normal, suggesting one normal allele is sufficient for TH signaling (367). Ando et al. (18) recently observed an intraexonic splice variant of TR␤ in a TSH-secreting adenoma that may account for pituitary resistance to TH in that tumor. Thus it is possible that nongenomic mechanisms may account for RTH in some of these families. There also have been several somatic TR mutations described in tumors. Lin et al. (309) have described somatic mutations in TR␣ and TR␤ from a human hepatoma cell line. It is not known whether these mutant TRs contributed to oncogenesis, although they both exhibited

Volume 81

dominant negative activity on wild-type TR. In this connection, a transgenic mouse that overexpressed v-erbA also developed hepatomas (32). A somatic mutation of TR␤ has been identified in a thyrotropin-secreting tumor and may cause the defective negative regulation observed in these pituitary tumors (18). There have been two reported cases of hypersensitivity to TH (222, 320). One patient was euthyroid on the basis of thyroid function tests but had a marked tachycardia. Analyses of T3 binding in lymphocytes showed normal binding affinity but increased binding capacity. Family history showed several family members with paroxysmal tachycardia and elevated T3 binding in lymphocytes. Sequencing of exons 9 and 10 of TR␤ showed no mutations. Another patient had serum thyroid function tests suggestive of hypothyroidism but exhibited no clinical symptoms suggestive of hypothyroidism. This patient had a V444A substitution in TR␤ resulting in increased affinity for T3. A constitutively active estrogen receptor with a mutation in the AF-2 domain has been described (546), so it is theoretically possible that mutations that enhance interaction with coactivators could generate a TR with constitutive activity or increased ligand-mediated transcription. XI. GENETICALLY ENGINEERED MOUSE MODELS OF THYROID HORMONE ACTION Transgenic expression of dominant-negative mutant TRs, and the targeted gene inactivation or knockout of TR isoforms, have been used to study TH action in mice. These mouse models have provided new information on the developmental and physiological effects of TH. Two groups have examined the effects of ubiquitous expression of v-erbA and a natural mutant TR␤-1 in transgenic mice (32, 564). These transgene products have dominant negative activity on the actions of wild-type TR. The mice that expressed v-erbA had multiple abnormalities including hypothyroidism (due to follicular disorganization in the thyroid), inappropriate TSH response, enlarged seminal vesicles, hepatomas, decreased fertility, and reduced adipose tissue. Because v-erbA has dominant negative activity on retinoic acid-mediated transcription, it is possible that some of the observed effects may not be due solely to blockade of T3-mediated transcription. The transgenic mice that expressed mutant TR␤-1 had elevated T3, inappropriately normal TSH, behavioral abnormalities, decreased fertility, and decreased weight. These findings resembled the clinical phenotype observed in RTH patients harboring this mutation. Pituitary-specific targeting has been undertaken using natural dominant negative mutants (TR␤ G345R, ⌬337T) under the regulation of the TSH␤ or glycoprotein hormone ␣-subunit promoters (4, 197). These transgenic

July 2001

THYROID HORMONE ACTION

mice had slightly elevated T4, elevated TSH, inability to suppress TSH after T3 administration, and decreased cholesterol. These findings are consistent with TH resistance in the pituitary and TH sensitivity in the liver. Interestingly, one line (⌬337T) had a blunted rise in TSH compared with littermate controls, suggesting the mutant TR may block the ligand-independent activation of TSH (4). In contrast to these two studies, another transgenic line in which a frameshift mutant TR (448 frameshift) was targeted to the pituitary with the glycoprotein hormone ␣-subunit did not show any abnormalities in the HPT axis (606). It is possible that differences in the expression levels of the mutant TRs may account for this difference in phenotype. Cardiac-specific targeting of TR␤ ⌬337T has resulted in transgenic mice with abnormal papillary muscle contraction and a prolonged QRS on EKG (166). ␣-Myosin heavy chain and sarcoplasmic reticulum Ca2⫹-ATPase mRNA were decreased, whereas ␤-myosin heavy chain mRNA was increased in transgenic mice. These findings are similar to those observed in the hypothyroid heart; however, they contrast with the situation in patients with RTH who often have resting sinus tachycardia. The heart normally expresses mostly TR␣ and little TR␤, so the finding in RTH patients may be due to the relatively low amount of dominant negative TR␤ in the context of elevated circulating TH levels (415). Another study in which the same mutant TR␤ was targeted to the heart showed decreased contractility in isolated heart preparations (386). Hayashi et al. (195) have used an adenovirus-based expression system encoding a dominant negative TR␤-1 mutant, G345R, to create a liver-specific model of RTH (195). They utilized the selective clearing and uptake of injected adenovirus vector by the liver and enabled them to efficiently transfect hepatocytes with either TR␤ or G345R. They demonstrated resistance to T3 in G345Rtransfected mice by measuring T3 regulation of several liver enzymes. Interestingly, serum cholesterol increased more in the TR␤ and G345R transfected mice compared with controls. These findings suggest that unliganded wild-type TR␤ and G345R both may have effects on target genes in the cholesterol synthesis pathway. Two different groups generated TR␣ knockout mice that have different phenotypes (152, 552). The structure of the TR␣ gene is complex because it encodes TR␣-1, c-erbA␣-2 (which cannot bind T3), and rev-erbA (generated from the opposite strand encoding TR␣) so the locus of homologous recombination will determine which isoforms will be knocked out (293). Transgenic mice in which both TR␣-1 and c-erbA␣-2 have been deleted (TR␣ ⫺/⫺) have a more severe phenotype with hypothyroidism, intestinal malformation, growth retardation, and early death shortly after weaning (152). The early death can be partially rescued by T3 injection of pups. Trans-

1125

genic mice that lack only TR␣-1 (TR␣-1 ⫺/⫺) have a milder phenotype with decreased body temperature and heart and prolonged Q-T interval on EKG (552). These findings suggest a major role for TR␣-1 in regulating cardiac function. The differences between the two phenotypes could be due to specific functions of c-erbA␣-2, although specific knockout of c-erbA␣-2 did not affect survival of the pups (151). Samarut and co-workers (75) have reported generation of short TR isoforms from internal translation start sites that can block the actions of TR. It is likely that these TR isoforms may be responsible for the more severe phenotype of the TR␣ ⫺/⫺ knockout mice. Indeed, a TR␣ knockout that lacks both TR␣-1 and c-erbA␣-2 and does not express these isoforms (TR␣ o/o) has a milder phenotype than TR␣ ⫺/⫺ and increased T3 sensitivity in tissues expressing TR␤ (316a). Ablation of TR␤ by homologous recombination in mice (TR␤ ⫺/⫺) produced modest changes in phenotype with elevated TSH and T4, thyroid hyperplasia, as well as hearing defects as the major findings (149, 150). These findings involving the HPT axis resemble those seen in patients with RTH. Deafness was observed in the index cases of RTH which had deletion of TR␤ (414). Taken together, these findings suggest a critical role for TR␤ in the development of the auditory system. Interestingly, ligand-independent elevation of TSH is normal in hypothyroid TR␤ ⫺/⫺ mice, but the suppression of TSH by TH is impaired (547). Recently, TR␤-2 has been selectively knocked out (2). These mice had elevated levels of TH and TSH, implicating TR␤-2 as the major regulator of TSH. Interestingly, these mice did not have any hearing defects. These findings suggest that TR␤-2 may not be critical for auditory development, or its function may be compensated by TR␤-1. Finally, recent studies in TR␤ ⫺/⫺ mice suggest TR␤2 may be involved in retinal development (353a). Given the relatively mild phenotypes of the TR␣-1 and TR␤ knockout mice, it is likely that the two isoforms may have redundant transcriptional activity and can compensate for each other in most target genes. To examine the effects of abolishing all TR isoforms, TR␣-1 ⫺/⫺ TR␤ ⫺/⫺ knockouts have been generated (171). These mice lack TR␣-1 and TR␤, but still express c-erbA␣-2. These mice have markedly elevated T4, T3, and TSH with large goiters. These mice also have growth retardation and decreased fertility, as well as impaired bone development and reduced bone mineral content. These mice also have reduced heart rate and impaired control of body temperature, similar to the TR␣-1 ⫺/⫺ mice. Although these mice have many symptoms of hypothyroidism, these mice did not have any reduction in activity level. There was no measurable T3 binding in liver and brain nuclear extracts, confirming the absence of any TR in these mice. TR␣ ⫺/⫺//TR␤ ⫺/⫺ knockout mice which lack TR␣-1, c-erbA␣-2, and TR␤, but express short TR␣ iso-

1126

PAUL M. YEN

forms have been generated (157). They have a similar phenotype as the TR␣ ⫺/⫺ mice except for markedly elevated T4, T3, and TSH, and more pronounced malformation in the ileum. TR␣ o/o//TR␤ ⫺/⫺, which lack the TR␣-1, c-erbA␣-2, and TR␤-1 as well as the shorter TR␣ isoforms, survive until 6 mo of age and have a similar phenotype similar to the TR␣-1 ⫺/⫺//TR␤ ⫺/⫺ mice (171). However, the females are completely sterile, and the males have decreased fertility. They also have markedly elevated T4, T3, and TSH. Comparison of the the latter two double-knockout strains in addition to the c-erbA␣-2 knockout mice (151) should provide information on the specific role of c-erbA␣-2 on development and thyroid function. The preceding double-knockout mouse studies demonstrate that absence of TRs is not incompatible with life and that mice without TRs can survive suprisingly well. Many of the effects on peripheral tissues were milder in the double-knockout mice than those seen in congenital hypothyroidism. The reason(s) for these observations is not known. Given the lack of T3 binding in nuclear extracts of the TR␣ ⫺/⫺//TR␤ ⫺/⫺ mice, it is unlikely there is an additional TR isoform unless it is expressed during embryogenesis or in very limited subset of cells. It is possible that nongenomic effects of TH may be active in the double-knockout mice but not in congenital hypothyroidism. It also is possible that lack of TRs is less deleterious than having TRs present during hypothyroidism. Given the role of unliganded TRs and corepressors in repressing basal transcription, it is possible that critical target genes may be shut down in the hypothyroid mice, whereas a certain degree of “leaky” basal transcription occurs in the double-knockout mice. Recently, Cheng and co-workers (236) have generated a “knock-in” mouse model in which a mutant TR was introduced into the endogenous TR␤ gene locus. Similar to patients with RTH, the heterozygous mice had elevated serum T4 and TSH, mild goiter, hypercholesterolemia, impaired weight gain, and abnormal bone development. Homozygous mice had markedly elevated serum T4 and TSH and a much more severe phenotype. It thus appears that the mutant TR has dominant negative activity on TR function in this mouse model of RTH. It also will be interesting to compare the expression of target genes in these mice with the TR␣ o/o//TR␤ ⫺/⫺ knockout mice in the absence of TH, as the latter mice do not have TRs to mediate basal repression. Recently, Wondisford and colleagues (191a) have generated “knock-in” mice expressing mutant TR␤, and these mice have abnormal cerebellar development and function, as well as learning deficits. Finally, Weiss et al. (550) have shown that loss of a coactivator can also lead to mild RTH. Using SRC-1 knockout mice that previously had been shown to have have some resistance to steroid hormones in reproductive tissues, they found that the knockout mice had mildy

Volume 81

elevated T4, T3, and moderately elevated TSH levels. Interestingly, suppression of TSH by T3 was impaired in knockout mice, suggesting that SRC-1 may be needed for the negative regulation of TSH production. These findings have clinical implications because several familes with RTH have been described that do not have mutations in TR␣ or TR␤ genes. It is possible that mutations in cofactors may account for their RTH phenotype. Additionally, as knockout mice for various coactivators are generated, they will be useful tools in studying TH action on both positively and negatively regulated genes and the effects of coactivators on the function of the HPT axis. XII. CONCLUSION Just as our early knowledge of TH action was interwoven with many of the key developments in biomedical science, so it has been the case for the recent study of TH action. Even more than before, our knowledge has benefited from the contributions of outstanding investigators from many different fields and countries. With the recent sequencing of the human genome and the development of new technologies such as microarrays, proteomics, and genetically engineered mouse models, we will have powerful new tools to study the complexities of TH action in the future. It is with eagerness that we look forward to an even deeper understanding of TH action. I thank Drs. Sheue-Yann Cheng (National Cancer Institute), Edward Rall [National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health], Leonard Kohn (NIDDK), Samuel Refetoff (Univ. of Chicago), Nicholas Sarlis (NIDDK), and Roy Weiss (Univ. of Chicago) for their helpful discussions and criticisms. I also thank members of my laboratory: Drs. Stephen Angeloni, Shinichiro Ando, Xu Feng, Padma Maruvada, and Pnina Rotman for their constructive comments. Address for reprint requests and other correspondence: P. M. Yen, Molecular Regulation and Neuroendocrinology Section, Clinical Endocrinology Branch, NIDDK, NIH, Bethesda, MD 20892 (E-mail: [email protected]).

REFERENCES 1. ABE T, KAKYO M, TOKUI T, NAKAGOMI R, NISHIO T, NAKAI D, NOMURA H, UNNO M, SUZUKI M, NAITOH T, MATSUNO S, AND YAWO H. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274: 17159 –17163, 1999. 2. ABEL ED, BOERS ME, PAZOS-MOURA C, MOURA E, KAULBACH H, ZAKARIA M, LOWELL B, RADOVICK S, LIBERMAN MC, AND WONDISFORD F. Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. J Clin Invest 104: 291–300, 1999. 3. ABEL ED, KAULBACH E, BOERS HC, AND WONDISFORD FE. Elevated thyroid hormone levels in transgenic mice with pituitary overexpression of a mutant B1 thyroid hormone receptor. Thyroid 6: S-82, 1996. 4. ABEL ED, KAULBACH HC, CAMPOS-BARROS A, AHIMA RS, BOERS ME, HASHIMOTO K, FORREST D, AND WONDISFORD FE. Novel insight from

July 2001

5.

6.

7.

8.

9.

10. 12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

THYROID HORMONE ACTION

transgenic mice into thyroid hormone resistance and the regulation of thyrotropin. J Clin Invest 103: 271–279, 1999. ABU EO, BORD S, HORNER A, CHATTERJEE VK, AND COMPSTON JE. The expression of thyroid hormone receptors in human bone. Bone 21: 137–142, 1997. ABU EO, HORNER A, TETI A, CHATTERJEE VK, AND COMPSTON JE. The localization of thyroid hormone receptor mRNAs in human bone. Thyroid 10: 287–293, 2000. ADAMS M, MATHEWS C, COLLINGWOOD TN, TONE Y, BECK-PECCOZ P, AND CHATTERJEE VK. Genetic analyses of 29 kindreds with generalized and pituitary resistance to thyroid hormone: identification of thirteen novel mutations in the thyroid hormone receptor b gene. J Clin Invest 904: 506 –515, 1994. AILHAUD G, GRIMALDI P, AND NEGREL R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 12: 207–233, 1992. ALLAIN TJ, CHAMBERS TJ, FLANAGAN AM, AND MCGREGOR AM. Triiodothyronine stimulates rat osteoclastic bone resoprtion by an indirect effect. J Endocrinol 133: 327–331, 1992. ALLAIN TJ AND MCGREGOR AM. Thyroid hormones and bone. J Endocrinol 139: 9 –18, 1993. ALLAIN TJ, YEN PM, FLANAGAN AM, AND MCGREGOR AM. The isoformspecific expression of the tri-iodothyronine receptor in osteoblasts and osteoclasts. Eur J Clin Invest 26: 418 – 425, 1996. ALLAND L, MUHLE R, HOU H JR, POTES J, CHIN L, SCHREIBER-AGUS N, AND DEPINHO RA. Role for N-CoR and histone deacetylase in Sin3mediated transcriptional repression. Nature 387: 49 –55, 1997. ALVAREZ-DOLADO M, GONZALEZ-SANCHO JM, BERNAL J, AND MUNOZ A. Developmental expression of the tenascin-C is altered by hypothyroidism in the rat brain. Neuroscience 84: 309 –322, 1998. ALVAREZ-DOLADO M, RUIZ M, DEL RIO JA, ALCANTARA S, BURGAYA F, SHELDON M, NAKAJIMA K, BERNAL J, HOWELL BW, CURRAN T, SORIANO E, AND MUNOZ A. Thyroid hormone regulates reelin and dab1 expression during brain development. J Neurosci 19: 6979 – 6993, 1999. ANDERSON GW, LARSON RJ, OAS DR, SANDHOFER CR, SCHWARTZ HL, MARIASH CN, AND OPPENHEIMER JH. Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) modulates expression of the Purkinje cell protein-2 gene. A potential role for COUP-TF in repressing premature thyroid hormone action in the developing brain. J Biol Chem 273: 16391–16399, 1998. ANDERSSON ML, NORDSTROM K, DEMEZUK S, HARBERS M, AND VENNSTROM B. Thyroid hormone alters the DNA binding properties of chicken thyroid hormone receptors a and b. Nucleic Acids Res 20: 4803– 4870, 1992. ANDO S, SARLIS NJ, KRISHNAN J, FENG X, OLDFIELD E, AND YEN PM. Somatic mutation or aberrant alternative-splicing of thyroid hormone receptor ␤ can cause resistance to thyroid hormone in TSHsecreting pituitary adenomas. Proc Annu Meet Endocrine Soc 2001 Denver CO. ANZICK SL, KONONEN J, WALKER RL, AZORSA DO, TANNER MM, GUAN XY, SAUTER G, KALLIONIEMI OP, TRENT JM, AND MELTZER PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965–968, 1997. ASHIZAWA K, MCPHIE P, LIN KH, AND CHENG SY. An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1,6 bisphosphate. Biochemistry 30: 7105–7111, 1991. AU-FLIEGNER M, HELMER E, CASANOVA J, RAAKA BM, AND SAMUELS HH. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Mol Cell Biol 13: 5725– 5737, 1993. BALASUBRAMANIAN B AND MOORE DD. Interaction of thyroid hormone receptor with chromatin remodeling proteins (Abstract). In: Nuclear Receptors 2000, Keystone Symposium. Steamboat Springs, CO: Keystone, 2000, p. 403. BALKMAN C, OJAMAA K, AND KLEIN I. Time course of the in vivo effects of thyroid hormone on cardiac gene expression. Endocrinology 130: 2001–2006, 1992. BALL SG, IKEDA M, AND CHIN WW. Deletion of the thyroid hormone beta1 receptor increases basal and triiodothyronine-induced

25.

26.

27.

28.

29.

30. 31.

32.

33.

34.

35. 36. 37.

38. 39.

40. 41.

42.

43.

44.

45.

46.

1127

growth hormone messenger ribonucleic acid in GH3 cells. Endocrinology 138: 3125–3132, 1997. BANIAHMAD A, HA I, REINBERG D, TSAI MJ, TSAI SY, AND O’MALLEY BW. Interaction of human thyroid hormone receptor b with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA 90: 8832– 8836, 1993. BANIAHMAD A, KOHNE AC, AND RENKAWITZ R. A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product, and in the retinoic acid receptor. EMBO J 11: 1015–1023, 1992. BANIAHMAD A, LENG X, BURRIS TP, TSAI SY, TSAI MJ, AND O’MALLEY BW. The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Mol Cell Biol 15: 76 – 86, 1995. BANIAHMAD A, TSAI SY, O’MALLEY BW, AND TSAI MJ. Kindred S thyroid hormone receptor is an active and constitutive silencer and a repressor for thyroid hormone and retinoic acid responses. Proc Natl Acad Sci USA 89: 10633–10637, 1992. BANKER DE AND EISENMAN RN. Thyroid hormone receptor can modulate retinoic acid-mediated axis formation in frog embryogenesis. Mol Cell Biol 13: 7540 –7552, 1993. BARAN DT AND BRAVERMAN LE. Thyroid hormones and bone mass. J Clin Endocrinol Metab 72: 1182–1183, 1991. BARETTINO D, VIVANCO MMR, AND STUNNENBERG HG. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J 13: 3039 –3049, 1994. BARLOW C, MEISTER B, LARDELLI M, LENDAHL U, AND VENNSTROM B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J 13: 4241– 4250, 1994. BASSI MT, RAMESAR RS, CACIOTTI B, WINSHIP IM, DE GRANDI A, RIBONI M, TOWNES PL, BEIGHTON P, BALLABIO A, AND BORSANI G. X-linked late-onset sensorineural deafness caused by a deletion involving OA1 and a novel gene containing WD-40 repeats. Am J Hum Genet 64: 1604 –1616, 1999. BAUMANN CT, MARUVADA P, HAGER GL, AND YEN PM. Nuclear-cytoplasmic shuttling by thyroid hormone receptors: multiple protein interactions are required for nuclear retention. J Biol Chem 276: 11237–11245, 2001. BEATO M, HERRLICH P, AND SCHUTZ G. Steroid hormone receptors: many actors in search of a plot. Cell 83: 851– 857, 1995. BECK-PECCOZ P AND CHATTERJEE VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 4: 225–232, 1994. BEHR M AND LOOS U. A point mutation (Ala229 to Thr) in the hinge domain of the c-erbA beta thyroid hormone receptor gene in a family with generalized thyroid hormone resistance. Mol Endocrinol 6: 1119 –1126, 1992. BERNAL J. Iodine and brain development. Biofactors 10: 271–276, 1999. BHAT MK, ASHIZAWA K, AND CHENG SY. Phosphorylation enhances the target gene sequence-dependent dimerization of thyroid hormone receptor with retinoid X receptor. Proc Natl Acad Sci USA 91: 7927–7931, 1994. BIGLER J AND EISENMAN RN. Novel location and function of a thyroid hormone response element. EMBO J 14: 5710 –5723, 1995. BIGLER J, HOKANSON W, AND EISENMAN RN. Thyroid hormone receptor transcriptional activity is potentially autoregulated by truncated forms of the receptor. Mol Cell Biol 12: 2406 –2417, 1992. BLANCO JC, MINUCCI S, LU J, YANG XJ, WALKER KK, CHEN H, EVANS RM, NAKATANI Y, AND OZATO K. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 12: 1638 –1651, 1998. BLENNEMANN B, LEAHY P, KIM TS, AND FREAKE HC. Tissue-specific regulation of lipogenic mRNAs by thyroid hormone. Mol Cell Endocrinol 110: 1– 8, 1995. BODENNER DL, MROCZYNSKI MA, WEINTRAUB BD, RADOVICK S, AND WONDISFORD FE. A detailed functional and structural analysis of a major thyroid hormone inhibitory element in the human thyrotropin beta-subunit gene. J Biol Chem 266: 21666 –21673, 1991. BOGAZZI F, HUDSON LD, AND NIKODEM VM. A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor. J Biol Chem 269: 11683–11686, 1994. BOURGUET W, RUFF M, CHAMBON P, GRONEMEYER H, AND MORAS D.

1128

47.

48.

49.

50.

51.

52. 53.

54.

55.

56.

57.

58.

59.

60.

61.

62. 63.

64.

65.

PAUL M. YEN

Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375: 377–382, 1995. BRADLEY DJ, TOWLE HC, AND YOUNG WS. Spatial and temporal expression of a- and b-thyroid hormone receptor mRNAs, including the b2-subtype, in the developing mammalian system. J Neurosci 12: 2288 –2302, 1992. BRADLEY DJ, TOWLE HC, AND YOUNG WS. Alpha and beta thyroid hormone receptor (TR) gene expression during auditory neurogenesis: evidence for TR isoform-specific transcriptional regulation in vivo. Proc Natl Acad Sci USA 91: 439 – 443, 1994. BRANCO M, RIBEIRO M, NEGRAO N, AND BIANCO AC. 3,5,3⬘-Triiodothyronine actively stimulates UCP in brown fat under minimal sympathetic activity. Am J Physiol Endocrinol Metab 276: E179 –E187, 1999. BRAVERMAN LE, INGBAR SH, AND STERLING K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest 49: 855– 864, 1970. BREEN JJ, HICKOK NJ, AND GURR JA. The rat TSH␤ gene contains distinct response elements for regulation by retinoids and thyroid hormone. Mol Cell Endocrinol 131: 137–146, 1997. BRENT GA. The molecular basis of thyroid hormone action. N Engl J Med 331: 847– 853, 1994. BRENT GA, DUNN MK, HARNEY JW, GULICK T, LARSEN PR, AND MOORE DD. Thyroid hormone aporeceptor represses T3-inducible promoters and blocks activity of the retinoic acid receptor. New Biologist 1: 329 –336, 1989. BRENT GA, HARNEY JW, CHEN Y, WARNE RL, MOORE DD, AND LARSEN PR. Mutations of the rat growth hormone promoter which increase and decrease response to thyroid hormone promoter which increase and decrease response to thyroid hormone define a consensus thyroid hormone response element. Mol Endocrinol 3: 1996 – 2004, 1989. BRENT GA, HARNEY JW, MOORE DD, AND LARSEN PR. Multihormonal regulation of the human, rat, and bovine growth hormone promoters: differential effects of 3⬘,5⬘-cyclic adenosine monophosphate, thyroid hormone, and glucocorticoids. Mol Endocrinol 2: 792–798, 1988. BRENT GA, WILLIAMS GR, HARNEY JW, FORMAN BM, SAMUELS HH, MOORE DD, AND LARSEN PR. Capacity for cooperative binding of thyroid hormone (T3) receptor dimers defines wild type T3 response elements. Mol Endocrinol 6: 502–514, 1992. BRENT GA, WILLIAMS GR, HARNEY JW, FORMAN BM, SAMUELS HH, MOORE DD, AND LARSEN PR. Effects of varying the position of thyroid hormone response elements within the rat growth hormone promoter: implications for positive and negative regulation by 3,5,3⬘-triiodothyronine. Mol Endocrinol 5: 542–548, 1991. BRITTO JM, FENTON AJ, HOLLOWAY WR, AND NICHOLSON GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134: 169 –176, 1994. BROWN DD, WANG Z, KANAMORI A, ELICEIRI B, FURLOW JD, AND SCHWARTZMAN R. Amphibian metamorphoses: a complex program of gene expression changes controlled by the thyroid hormone. Rec Prog Horm Res 50: 309 –315, 1995. BRUCKER-DAVIS F, SKARULIS MC, GRACE MB, BENICHOU J, HAUSER P, WIGGS E, AND WEINTRAUB BD. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 123: 572–583, 1995. BRZOZOWSKI AM, PIKE AC, DAUTER Z, HUBBARD RE, BONN T, ENGSTROM O, OHMAN L, GREENE GL, GUSTAFSSON JA, AND CARLQUIST M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753–758, 1997. BURATOWSKI S. The basics of basal transcription by RNA polymerase II. Cell 77: 1–3, 1994. BURNSIDE J, DARLING DS, AND CHIN WW. A nuclear factor that enhances binding of thyroid hormone receptors to thyroid hormone response elements. J Biol Chem 265: 2500 –2504, 1990. BURRIS TP, NAWAZ Z, TSAI MJ, AND O’MALLEY BW. A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. Proc Natl Acad Sci USA 92: 9525–9529, 1995. BUTT TR AND WALFISH PG. Human nuclear receptor heterodimers:

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

77.

78.

79. 80.

81.

82.

83. 84.

85.

86.

Volume 81

opportunities for detecting targets of transcriptional regulation using yeast. Gene Exp 5: 255–268, 1996. CAIRA F, ANTONSON P, PELTO-HUIKKO M, TREUTER E, AND GUSTAFSSON JA. Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem 275: 5308 –5317, 2000. CAIRNS BR, LEVINSON RS, YAMAMOTO KR, AND KORNBERG RD. Essential role of Swp73p in the function of yeast Swi/Snf complex. Genes Dev 10: 2131–2144, 1996. CALVO R, OBREGON MJ, RUIZ DE ONA C, ESCOBAR DEL REY F, AND MORREALE DE ESCOBAR G. Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3,5,3⬘-triiodothyronine in the protection of the fetal brain. J Clin Invest 86: 889 – 899, 1990. CARRE JL, DEMERENS C, RODRIGUEZ-PENA A, FLOCH HH, VINCENDON G, AND SARLIEVE LL. Thyroid hormone receptor isoforms are sequentially expressed in oligodendrocyte lineage cells during rat cerebral development. J Neurosci Res 54: 584 –594, 1998. CASAS F, ROCHARD P, RODIER A, CASSAR-MALEK I, MARCHAL-VICTORION S, WIESNER RJ, CABELLO G, AND WRUTNIAK C. A variant form of the nuclear triiodothyronine receptor c-ErbAalpha1 plays a direct role in regulation of mitochondrial RNA synthesis. Mol Cell Biol 19: 7913–7924, 1999. CATTINI PA, ANDERSON TR, BAXTER JD, MELLON P, AND EBERHARDT NL. The human growth hormone gene is negatively regulated by triiodothyronine when transfected into rat pituitary tumor cells. J Biol Chem 261: 13367–13372, 1986. CAVAILLES V, DAUVOIS S, L’HORSET F, LOPEZ G, HOARE S, KUSHNER PJ, AND PARKER MG. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14: 3741–3751, 1995. CHAKRAVARTI D, LAMORTE VJ, NELSON MC, NAKAJIMA T, SCHULMAN IG, JUGUILON HJ, MONTMINY M, AND EVANS RM. Role of CBP/P300 in nuclear receptor signaling. Nature 383: 99 –102, 1996. CHANG KH, CHEN Y, CHEN TT, CHOU WH, CHEN PL, MA YY, YANG-FENG TL, LENG X, TSAI MJ, O’MALLEY BW, AND LEE WH. A thyroid hormone receptor coactivator negatively regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 94: 9040 –9045, 1997. CHASSANDE O, FRAICHARD A, GAUTHIER K, FLAMANT F, LEGRAND C, SAVATIER P, LAUDET V, AND SAMARUT J. Identification of transcripts initiated from an internal promoter in the c-erbA alpha locus that encode inhibitors of retinoic acid receptor-alpha and triiodothyronine receptor activities. Mol Endocrinol 11: 1278 –1290, 1997. CHATTERJEE VK, LEE JK, RENTOUMIS A, AND JAMESON JL. Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. Proc Natl Acad Sci USA 86: 9114 –9118, 1989. CHATTERJEE VK, NAGAYA T, MADISON LM, DATTA S, RENTOUMIS A, AND JAMESON JL. Thyroid hormone resistance: inhibition of normal receptor function by mutant thyroid hormone receptors. J Clin Invest 87: 1977–1984, 1991. CHATTERJEE VK AND TATA JR. Thyroid hormone receptors and their role in development. Cancer Survey 14: 147–167, 1992. CHAWLA A AND LAZAR MA. Induction of Rev-erbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. J Biol Chem 268: 16265–16269, 1993. CHEN D, MA H, HONG H, KOH SS, HUANG SM, SCHURTER BT, ASWAD DW, AND STALLCUP MR. Regulation of transcription by a protein methyltransferase. Science 284: 2174 –2177, 1999. CHEN H, LIN RJ, SCHILTZ RL, CHAKRAVARTI D, NASH A, NAGY L, PRIVALSKY ML, NAKATANI Y, AND EVANS RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90: 569 –580, 1997. CHEN JD AND EVANS RM. A transcriptional corepressor that interacts with nuclear hormone receptors. Nature 377: 454 – 457, 1995. CHENG SY. Multiple mechanisms for regulation of the transcriptional activity of tyroid hormone receptors. Rev Endocr Metabolic Disorders 1/2: 9 –18, 2000. CHENG SY, GONG QH, PARKISON C, ROBINSON EA, APPELLA E, MERLINO GT, AND PASTAN I. The nucleotide sequence of a human cellular thyroid hormone binding protein present in endoplasmic reticulum. J Biol Chem 262: 11221–11227, 1987. CHIELLINI G, APRILETTI JW, AL YOSHIHARA H, BAXTER JD, RIBEIRO RC,

July 2001

THYROID HORMONE ACTION

SCANLAN TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 5: 299 –306, 1998. 87. CHILDS GV, TAUB K, JONES KE, AND CHIN WW. Triiodothyronine receptor beta-2 messenger ribonucleic acid expression by somatotropes and thyrotropes: effect of propylthiouracil-induced hypothyroidism in rats. Endocrinology 129: 2767–2773, 1991. 88. CHIN WW, CARR FE, BURNSIDE J, AND DARLING DS. Thyroid hormone regulation of thyrotropin gene expression. Rec Prog Horm Res 48: 393– 414, 1993. 89. CHIN WW AND YEN PM. T3 or not T3—the slings and arrows of outrageous TR function. Endocrinology 137: 387–388, 1996. 90. CHOMCZYNSKI P, SOSZYNSKI PA, AND FROHMAN LA. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. J Clin Endocrinol Metab 77: 281–285, 1993. 91. CLARET X, ANTAKLY T, KARIN M, AND SAATCIOGLU F. A shift in the ligand responsiveness of thyroid hormone receptor a induced by heterodimerization with retinoid X receptor a. Mol Cell Biol 16: 219 –227, 1996. 92. CLIFTON-BLIGH RJ, DE ZEGHER F, WAGNER RL, COLLINGWOOD TN, FRANCOIS I, VAN HELVOIRT M, FLETTERICK RJ, AND CHATTERJEE VK. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation. Mol Endocrinol 12: 609 – 621, 1998. 93. COHEN RN, WONDISFORD FE, AND HOLLENBERG AN. Two separate NCoR (nuclear receptor corepressor) interaction domains mediate corepressor action on thyroid hormone response elements. Mol Endocrinol 12: 1567–1581, 1998. 94. COLLINGWOOD TN, ADAMS N, AND CHATTERJEE VK. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome. Mol Endocrinol 8: 1261–1277, 1994. 95. COLLINGWOOD TN, BUTLER A, TONE Y, CLIFTON-BLIGH RJ, PARKER MG, AND CHATTERJEE VK. Thyroid hormone-mediated enhancement of heterodimer formation between thyroid hormone receptor beta and retinoid X receptor. J Biol Chem 272: 13060 –13065, 1997. 96. COLLINGWOOD TN, RAJANAYAGAM O, ADAMS M, WAGNER R, CAVAILLES V, KALKHOVEN E, MATHEWS C, NYSTROM E, STENLOF K, LINDSTEDT G, TISELL L, FLETTERICK RJ, PARKER MG, AND CHATTERJEE VK. A natural transactivation mutation in the thyroid hormone b receptor: impaired interaction with putative transcriptional mediators. Proc Natl Acad Sci USA 94: 248 –253, 1997. 97. COLLINGWOOD TN, WAGNER R, MATTHEWS CH, CLIFTON-BLIGH RJ, GURNELL M, RAJANAYAGAM O, AGOSTINI M, FLETTERICK RJ, BECK-PECCOZ P, REINHARDT W, BINDER G, RANKE MB, HERMUS A, HESCH RD, LAZARUS J, NEWRICK P, PARFITT V, RAGGATT P, DE ZEGHER F, AND CHATTERJEE VK. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. EMBO J 17: 4760 – 4770, 1998. 97a.COMMITTEE OF THE CLINICAL SOCIETY OF LONDON. Report of a committee of the Clinical Society of London nominated December 1883, to investigate the subject of myxoedema. Trans Clin Soc Lond 21 Suppl: 1888. 98. COOK CB, KAKUCSKA I, LECHAN RM, AND KOENIG RJ. Expression of thyroid hormone receptor b2 in rat hypothalamus. Endocrinology 130: 1077–1079, 1992. 99. COONEY AJ, TSAI SY, O’MALLEY BW, AND TSAI MJ. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors. Mol Cell Biol 12: 4153– 4163, 1992. 100. CORBETTA S, ENGLARO P, GIAMBONA S, PERSANI L, BLUM WF, AND BECK-PECCOZ P. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur J Endocrinol 137: 659 – 663, 1997. 101. CREW CD AND SPINDLER SR. Thyroid hormone regulation of the transfected rat growth hormone promoter activity. J Biol Chem 261: 5018 –5022, 1986. 102. DAI G, LEVY O, AND CARRASCO N. Cloning and characterization of the thyroid iodide transporter. Nature 379: 458 – 460, 1996. 103. DALMAN FC, KOENIG RJ, PERDEW GH, MASSA E, AND PRATT WB. In contrast to the glucocorticoid receptor, the thyroid hormone reAND

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114. 115.

116. 117.

118.

119.

120. 121. 122.

123.

124. 125.

126. 127.

1129

ceptor is translated in the DNA binding state and is not associated with hsp90. J Biol Chem 265: 3615–3618, 1990. DAMM K, THOMPSON CC, AND EVANS RM. Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature 339: 593–597, 1989. DANIELIAN PS, WHITE R, LEES JA, AND PARKER MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025–1033, 1992. DANIELSON M, HINCK L, AND RINGOLD G. Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor. Cell 57: 1131–1138, 1989. DARIMONT BD, WAGNER RL, APRILETTI JW, STALLCUP MR, KUSHNER PJ, BAXTER JD, FLETTERICK RJ, AND YAMAMOTO KR. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12: 3343–3356, 1998. DARLING DS, BURNSIDE J, AND CHIN WW. Binding of thyroid hormone receptors to the rat thyrotropin-beta gene. Mol Endocrinol 3: 1359 – 1368, 1989. DARLING DS, CARTER RL, YEN PM, WELBORN JM, CHIN WW, AND UMEDA PK. Different dimerization activities of a and b thyroid hormone receptor isoforms. J Biol Chem 268: 10221–10227, 1993. DARRAS VM, HUME R, AND VISSER TJ. Regulation of thyroid hormone metabolism during fetal development. Mol Cell Endocrinol 151: 37– 47, 1999. DAVIDSON NO, CARLOS RC, AND LUKASZEWICZ AM. Apolipoprotein B mRNA editing is modulated by thyroid hormone analogs but not growth hormone administration in the rat. Mol Endocrinol 4: 779 – 785, 1990. DAVIS FB, DAVIS PJ, AND BLAS SD. Role of calmodulin in thyroid hormone stimulation of in vitro human erythrocyte Ca2⫹-ATPase activity. J Clin Invest 71: 579 –586, 1983. DAVIS FB, SHIH Y, LIN A, AND DAVIS PJ. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. Proc Endocr Soc Meet 81st San Diego CA 1999, p. OR7–1. DAVIS KD AND LAZAR MA. Selective antagonism of thyroid hormone action by retinoic acid. J Biol Chem 267: 3185–3189, 1992. DAVIS PJ AND BLAS SD. In vitro stimulation of human red blood cell Ca2⫹-ATPase by thyroid hormone. Biochem Biophys Res Commun 99: 1073–1080, 1981. DAVIS PJ AND DAVIS FB. Nongenomic actions of thyroid hormone. Thyroid 6: 497–504, 1996. DE VIJLDER JJ, RIS-STALPERS C, AND VULSMA T. Inborn errors of thyroid hormone biosynthesis. Exp Clin Endocrinol Diabetes 4: 32–37, 1997. DEY A, MINUCCI S, AND OZATO K. Ligand-dependent occupancy of the reinoic acid receptor beta 2 promoter in vivo. Mol Cell Biol 14: 8191– 8201, 1994. DIAMOND MI, MINER JM, YOSHINAGA SK, AND YAMAMOTO KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249: 1266 –1272, 1990. DILLMANN WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 88: 626 – 630, 1990. DILLMANN WH. Thyroid hormone action and cardiac contractility—a complex affair. Endocrinology 137: 799 – 801, 1996. DING XF, ANDERSON CM, MA H, HONG H, UHT RM, KUSHNER PJ, AND STALLCUP MR. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12: 302–313, 1998. DOZIN B, CAHNMANN HJ, AND NIKODEM VM. Identification of thyroid hormone receptors in rat liver nuclei by photoafffinity labeling with L-thyroxine and triiodothyronine. Biochemistry 24: 5197–5202, 1985. ENGLER D AND BURGER AG. The deiodination of the iodothyronines and of their derivatives in man. Endocr Rev 5: 151–184, 1984. ESCOBAR-MORREALE HF, ESCOBAR DEL REY F, AND MORREALE DE ESCOBAR G. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology 138: 4485– 4488, 1997. EVANS RM. The steroid and thyroid hormone receptor superfamily. Science 240: 889 – 895, 1988. FAIRCLOUGH L AND TATA JR. An immunocytochemical analysis of the

1130

128.

129.

130.

131.

132.

133.

134.

135.

136.

137. 138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

PAUL M. YEN

expression of thyroid hormone receptor alpha and beta proteins during natural and thyroid hormone-induced metamorphosis in Xenopus. Dev Growth Differ 39: 273–283, 1997. FALCONE M, MIYAMOTO T, FIERRO-RENOY F, MACCHIA E, AND DEGROOT LJ. Antipeptide polyclonal antibodies specifically recognize each human thyroid hormone receptor isoform. Endocrinology 131: 2419 –2429, 1992. FARSETTI A, DESVERGNE B, HALLENBECK P, ROBBINS J, AND NIKODEM VM. Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter. J Biol Chem 267: 15784 –15788, 1992. FARSETTI A, MITSUHASHI T, DESVERGNE B, ROBBINS J, AND NIKODEM VM. Molecular basis of thyroid hormone regulation of myelin basic protein gene expression in rodent brain. J Biol Chem 266: 23226 – 23232, 1991. FARWELL AP, DIBENEDETTO DJ, AND LEONARD JL. Thyroxine targets different pathways of internalization of type II iodothyronine 5⬘deiodinase in astrocytes. J Biol Chem 268: 50 –55, 1993. FARWELL AP, SAFRAN M, DUBORD S, AND LEONARD JL. Degradation and recycling of the substrate-binding subunit of type II iodothyronine 5⬘deiodonase in astrocytes. J Biol Chem 271: 16369 –16374, 1996. FARWELL AP, TRANTER MP, AND LEONARD JL. Thyroxine-dependent regulation of integrin-laminin interactions in astrocytes. Endocrinology 136: 3909 –3915, 1995. FENG W, RIBEIRO RC, WAGNER RL, NGUYEN H, APRILETTI JW, FLETTERICK RJ, BAXTER JD, KUSHNER PJ, AND WEST BL. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280: 1747–1749, 1998. FENG X, JIANG Y, MELTZER P, AND YEN PM. Transgenic targeting of a dominant negative co-repressor to liver blocks basal repression by the thyroid hormone receptor and increases cell proliferation. J Biol Chem. In press. FENG X, JIANG Y, MELTZER P, AND YEN PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 14: 947–955, 2000. FLAMANT F AND SAMARUT J. Involvement of thyroid hormone and its alpha receptor in avian neurulation. Dev Biol 197: 1–11, 1998. FLINK IL, EDWARDS JG, BAHL C, LIEW JJ, SOLE M, AND MORKIN E. Characterization of a strong positive cis-acting element of the human b myosin heavy chain gene in fetal rat heart cells. J Biol Chem 267: 9917–9924, 1992. FLORES-DELGADO G, MARSCH-MORENO M, AND KURI-HARCUCH W. Thyroid hormone stimulates adipocyte differentiation of 3T3 cells. Mol Cell Biochem 76: 35– 43, 1987. FLYNN TR, HOLLENBERG AN, COHEN O, MENKE JB, USALA SJ, TOLLIN S, HEGARTY MK, AND WONDISFORD FE. A novel C-terminal domain in the thyroid hormone receptor selectively mediates thyroid hormone inhibition. J Biol Chem 269: 32713–32716, 1994. FONDELL JD, GE J, AND ROEDER RG. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 93: 8329 – 8333, 1996. FONDELL JD, ROY AL, AND ROEDER RG. Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: implications for active repression. Genes Dev 7: 1400 –1410, 1993. FORCE WR AND SPINDLER SR. 3,5,3⬘-L-Triiodothyronine (thyroid hormone)-induced protein-DNA interactions in the thyroid hormone response elements and cell type-specific elements of the rat growth hormone gene revealed by in vivo dimethyl sulfate footprinting. J Biol Chem 269: 9682–9686, 1994. FORMAN BM, CASANOVA J, RAAKA BM, GHYSDAEL J, AND SAMUELS HH. Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptor and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Mol Endocrinol 6: 429 – 442, 1992. FORMAN BM AND SAMUELS HH. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Mol Endocrinol 4: 1293–1301, 1990. FORMAN BM, TOTONOZ P, CHEN J, BRUN RP, SPIEGELMAN BM, AND EVANS RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803– 812, 1995. FORMAN BM, UMESONO K, CHEN J, AND EVANS RM. Unique response

148.

149.

150.

151. 152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

Volume 81

pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81: 541–550, 1995. FORMAN BM, YANG CR, STANLEY F, AND CASANOVA J. c-erbA protoncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes. Mol Endocrinol 2: 902–911, 1988. FORREST D, ERWAY LC, NG L, ALTSCHULER R, AND CURRAN T. Thyroid hormone receptor beta is essential for development of auditory function. Nat Genet 13: 354 –357, 1996. FORREST D, HANEBUTH E, SMEYNE RJ, EVAERDS N, STEWART CL, WEHNER JM, AND CURRAN T. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissuespecific modulation of receptor function. EMBO J 15: 3006 –3015, 1996. FORREST D AND VENNSTROM B. Functions of thyroid hormone receptors in mice. Thyroid 10: 41–52, 2000. FRAICHARD A, CHASSANDE O, PLATEROTI M, ROUX JP, TROUILLAS J, DEHAY C, LEGRAND C, GAUTHIER K, KEDINGER M, MALAVAL L, ROUSSET B, AND SAMARUT J. The T3R alpha gene encoding a thyroid hormone receptor is essential for postnatal development and thyroid hormone production. EMBO J 16: 4412– 4420, 1997. FREEDMAN LP, ARCE V, AND FERNANDEZ RP. DNA sequences that act as high affinity targets for the vitamin D3 receptor in the absence of the retinoid X receptor. Mol Endocrinol 8: 265–273, 1994. FRIESEMA EC, DOCTER R, MOERINGS EP, STIEGER B, HAGENBUCH B, MEIER PJ, KRENNING EP, HENNEMANN G, AND VISSER TJ. Identification of thyroid hormone transporters. Biochem Biophys Res Commun 254: 497–501, 1999. GARCIA-FERNANDEZ LF, RAUSELL E, URADE Y, HAYAISHI O, BERNAL J, AND MUNOZ A. Hypothyroidism alters the expression of prostaglandin D2 synthase/beta trace in specific areas of the developing rat brain. Eur J Neurosci 9: 1566 –1573, 1997. GARCIA-VILLALBA P, JIMENEZ-LARA AM, AND ARANDA A. Vitamin D interferes with transactivation of the growth hormone gene by thyroid hormone and retinoic acid. Mol Cell Biol 16: 318 –327, 1996. GAUTHIER K, CHASSANDE O, PLATEROTI M, ROUX JP, LEGRAND C, PAIN B, ROUSSET B, WEISS R, TROUILLAS J, AND SAMARUT J. Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. EMBO J 18: 623– 631, 1999. GELMETTI V, ZHANG J, FANELLI M, MINUCCI S, PELICCI PG, AND LAZAR MA. Aberrant recruitment of the nuclear receptor corepressorhistone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185–7191, 1998. GHARBI-CHIHI J, FACCHINETTI T, BERGE-LEFRANC J, BONNE J, AND TORRESANI J. Triiodothyronine control of ATP-citrate lyase and malic enzyme during differentiation of a murine preadipocyte cell line. Horm Metab Res 23: 423– 427, 1991. GLASS CK. Differential recognition of target genes by nuclear receptor monomers, dimers and heterodimers. Endocr Rev 15: 391– 407, 1994. GLASS CK, HOLLOWAY JM, DEVARY OV, AND ROSENFELD MG. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyrioid hormone and estrogen response elements. Cell 54: 313–323, 1988. GLASS CK, LIPKIN SM, DEVARY OV, AND ROSENFELD MG. Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer. Cell 59: 697–708, 1989. GLAUTCHNIG H, VARGA F, AND KLAUSHOFER K. Thyroid hormone and retinoic acid induce the synthesis of insulin-like growth factorbinding protein 4 in mouse osteoblastic cells. Endocrinology 137: 281–286, 1996. GLICK Z, WU SY, LUPIEN J, REGGIO R, BRAY GA, AND FISHER DA. Meal-induced brown fat thermogenesis and thyroid hormone metabolism in rats. Am J Physiol Endocrinol Metab 249: E519 –E524, 1985. GLINEUR C, BAILLY M, AND GHYSDAEL J. The c-erbA alpha-encoded thyroid hormone receptor is phosphorylated in its amino-terminal domain by casein kinase II. Oncogene 4: 1247–1254, 1989. GLOSS B, SAYEN MR, TROST SU, BLUHM WF, MEYER M, SWANSON EA, USALA SJ, AND DILLMANN WH. Altered cardiac phenotype in transgenic mice carrying the delta337 threonine thyroid hormone recep-

July 2001

167.

168.

169.

170.

171.

172.

173.

174.

175. 176.

177.

178. 179.

180.

181.

182.

183.

184.

THYROID HORMONE ACTION

tor beta mutant derived from the S family. Endocrinology 140: 897–902, 1999. GOLDBERG Y, GLINEUR C, RESQUIERE C, RICOUART A, SAP J, VENNSTROM B, AND GHYSDAEL J. Activation of protein kinase C or cAMP-dependent protein kinase increases phosphorylation of the c-erbA-encoded thyroid hormone receptor and of the v-erbA-encoded protein. EMBO J 7: 2425–2433, 1988. GONG DW, HE Y, KARAS M, AND REITMAN M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3adrenergic agonists, and leptin. J Biol Chem 272: 24129 –24132, 1997. GONG DW, MONEMDJOU S, GAVRILOVA O, LEON LR, MARCUS-SAMUELS B, CHOU CJ, EVERETT C, KOZAK LP, LI C, DENG C, HARPER ME, AND REITMAN ML. Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3. J Biol Chem. In press. GOODRICH JA, HOEY T, THUR CJ, ADMON A, AND TJIAN R. Drosophila TAFII40 interacts with both a VP16 activation domain and the basal transcription factor TFIIB. Cell 75: 513–530, 1993. GOTHE S, WANG Z, NG L, KINDBLOM JM, BARROS AC, OHLSSON C, VENNSTROM B, AND FORREST D. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitarythyroid axis, growth, and bone maturation. Genes Dev 13: 1329 – 1341, 1999. GRAFF MN, BAAS D, PUYMIRAT J, SARLIEVE LL, AND DELAUNOY JP. The alpha and beta thyroid receptors are expressed by cultured ependymal cells. Correlation with the effect of L-3,5,3⬘-triiodothyronine on glutamine synthetase mRNAs. Neurosci Lett 150: 174 –178, 1993. GREEN S, KUMAR V, THEULAZ I, WAHLI W, AND CHAMBON P. The N-terminal DNA-binding “zinc finger” of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO J 7: 3037–3044, 1988. GREEN S, WALTER P, KUMAR V, KRUST A, BORNERT JM, ARGOS P, AND CHAMBON P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134 –139, 1986. GREENSPAN SL AND GREENSPAN FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 130: 750 –758, 1999. GRIGNANI F, DE MATTEIS S, NERVI C, TOMASSONI L, GELMETTI V, CIOCE M, FANELLI M, RUTHARDT M, FERRARA FF, ZAMIR I, SEISER C, LAZAR MA, MINUCCI S, AND PELICCI PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815– 818, 1998. GRIMALDI P, DJIAN P, NEGREL R, AND AILHAUD G. Differentiation of Ob 17 preadipocytes to adipocytes: requirment of adipose conversion factor(s) for fat cell cluster formation. EMBO J 1: 687– 692, 1982. GROSS J AND PITT-RIVERS R. Triiodothyronine in relation to thyroid physiology. Rec Prog Horm Res 10: 109 –128, 1954. GU W, MALIK S, ITO M, YUAN CX, FONDELL JD, ZHANG X, MARTINEZ E, QIN J, AND ROEDER RG. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell 3: 97–108, 1999. GUADANO-FERRAZ A, OBREGON MJ, ST GERMAIN DL, AND BERNAL J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci USA 94: 10391–10396, 1997. GUISSOUMA H, GHORBEL MT, SEUGNET I, OUATAS T, AND DEMENEIX BA. Physiological regulation of hypothalamic TRH transcription in vivo is T3 receptor isoform specific. FASEB J 12: 1755–1764, 1998. HADDOW JE, PALOMAKI GE, ALLAN WC, WILLIAMS JR, KNIGHT GJ, GAGNON J, O’HEIR CE, MITCHELL ML, HERMOS RJ, WAISBREN SE, FAIX JD, AND KLEIN RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341: 549 –555, 1999. HADZIC E, DESAI-YAJNIK V, HELMER E, GUO S, WU S, KOUDINOVA N, CASANOVA J, RAAKE BM, AND SAMUELS HH. A 10 amino acid sequence in the N-terminal A/B domain of thyroid hormone receptor alpha is essential for transcriptional activation and interaction with the general transcription factor TFIIB. Mol Cell Biol 15: 4507– 4517, 1995. HADZIC E, HABEOS I, RAAKA BM, AND SAMUELS HH. A novel multifunctional motif in the amino-terminal A/B domain of T3Ralpha modulates DNA binding and receptor dimerization. J Biol Chem 273: 10270 –10278, 1998.

1131

185. HAFNER RP, BROWN GC, AND BRAND MD. Thyroid hormone control of state-3 respiration in isolated rat liver mitochondria. Biochem J 265: 731–734, 1990. 186. HALACHMI S, MARDEN E, MARTIN G, MACKAY H, ABBONDANZE C, AND BROWN M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264: 1455–1458, 1994. 187. HALL BL, SMIT-MCBRIDE Z, AND PRIVALSKY ML. Reconstitution of retinoid X receptor function and combinatorial regulation of other nuclear hormone receptors in yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA 90: 6929 – 6933, 1993. 188. HAMMER GD, KRYLOVA I, ZHANG Y, DARIMONT BD, SIMPSON K, WEIGEL NL, AND INGRAHAM HA. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell 3: 521–526, 1999. 189. HAO E, MENKE JB, SMITH AM, JONES C, GEFFNER ME, HERSHMAN-P WUERTH JM, SAMUELS HH, WAYS KD, AND USALA SJ. Divergent dimerization properties of mutant TRb1 thyroid hormone receptors are associated with different dominant negative activities. Mol Endocrinol 8: 841– 851, 1994. 190. HARDING HP AND LAZAR MA. The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat. Mol Cell Biol 15: 4791– 4802, 1995. 191. HARTONG R, WANG N, KUROKAWA R, LAZAR MA, GLASS CK, APRILETTI JW, AND DILLMANN WH. Delineation of three different thyroid hormone-response elements in promoter of rat sarcoplasmic reticulum Ca2⫹-ATPase gene. Demonstration that retinoid X receptor binds 5⬘ to thyroid hormone receptor in response element 1. J Biol Chem 269: 13021–13029, 1994. 191a.HASHIMOTO K, CURTY FH, BORGES PP, LEE CE, ABEL ED, ELMQUIST JK, COHEN RN, AND WONDISFORD FE. An unliganded thyroid hormone receptor causes severe neurological dysfunction. Proc Natl Acad Sci USA 98: 3998 – 4003, 2001. 192. HAUGEN B, BROWN N, BRINKMEIER M, CAMPER S, GREENLEE L, KREZEL W, AND CHAMBON P. Retinoid X receptor gamma deficient mice have a biochemical phenotype consistent with mild thyroid hormone resistance. Proc Annu Meet Endocr Soc 81st San Diego CA 1999, p. P2– 660. 193. HAUGEN BR, BROWN NS, WOOD WM, GORDON DF, AND RIDGWAY EC. The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol 11: 481– 489, 1997. 194. HAYASHI Y, OHMORI S, ITO T, AND SEO H. A splicing variant of Steroid Receptor Coactivator-1 (SRC-1E): the major isoform of SRC-1 to mediate thyroid hormone action. Biochem Biophys Res Commun 236: 83– 87, 1997. 195. HAYASHI Y AND REFETOFF S. A mouse model of resistance to thyroid hormone in liver produced by somatic gene transfer of a mutant thyroid hormone receptor. Proc Endocr Soc Meet Washington DC 1995, p. OR34 – 6. 196. HAYASHI Y, WEISS RE, SARNE DH, YEN PM, SUNTHORNTHEPVARAKUL T, MARCOCCI C, CHIN WW, AND REFETOFF S. Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-beta receptors? J Clin Endocrinol Metab 80: 3246 –3256, 1995. 197. HAYASHI Y, XIE J, WEISS RE, POHLENZ J, AND REFETOFF S. Selective pituitary resistance to thyroid hormone produced by expression of a mutant thyroid hormone receptor beta gene in the pituitary gland of transgenic mice. Biochem Biophys Res Commun 245: 204 –210, 1998. 198. HAYASHI Y, YAMAMOTO M, OHMORI S, KIKUMORI T, IMAI T, FUNAHASHI H, AND SEO H. Polymorphism of homopolymeric glutamines in coactivators for nuclear hormone receptors. Endocr J 46: 279 –284, 1999. 199. HEERY DM, KALKHOVEN E, HOARE S, AND PARKER MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733–736, 1997. 200. HEINZEL T, LAVINSKY RM, MULLEN TM, SODERSTROM M, LAHERTY CD, TORCHIA J, YANG WM, BRARD G, NGO SD, DAVIE JR, SETO E, EISENMAN RN, ROSE DW, GLASS CK, AND ROSENFELD MG. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43– 48, 1997. 201. HELMER EB, RAAKA BM, AND SAMUELS HH. Hormone-dependent and -independent transcriptional activation by thyroid hormone recep-

1132

202.

203. 204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

215.

216.

217.

218.

219.

220.

221.

PAUL M. YEN

tors are mediated by different mechanisms. Endocrinology 137: 390 –399, 1996. HEYMAN RA, MANGELSDORF DJK, DYK JA, STEIN RB, EICHELE G, EVANS RM, AND THALLER C. 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68: 397– 440, 1992. HIMMS-HAGEN J. Brown adipose tissue thermogenesis and obesity. Prog Lipid Res 28: 67–115, 1989. HODIN RA, LAZAR MA, AND CHIN WW. Differential and tissue-specific regulation of the multiple rat c-erbA mRNA species by thyroid hormone. J Clin Invest 85: 101–105, 1990. HODIN RA, LAZAR MA, WINTMAN BI, DARLING DS, KOENIG RJ, LARSEN PR, MOORE DD, AND CHIN WW. Identification of a novel thyroid hormone receptor that is pituitary-specific. Science 244: 76 –79, 1989. HOLLENBERG AN, MONDEN T, FLYNN TR, BOERS ME, COHEN O, AND WONDISFORD FE. The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Mol Endocrinol 9: 540 – 550, 1995. HOLLENBERG AN, MONDEN T, MADURA JP, LEE K, AND WONDISFORD FE. Function of nuclear co-repressor protein on thyroid hormone response elements is regulated by the receptor A/B domain. J Biol Chem 271: 28516 –28520, 1996. HOLLENBERG AN, MONDEN T, AND WONDISFORD FE. Ligand-independent and -dependent functions of thyroid hormone receptor isoforms depend upon on their distinct amino terminal. J Biol Chem 270: 14272–14280, 1995. HOLLENBERG SM, WEINBERGER C, AND ONG ES. Primary structure and expression of a functional glucocorticoid receptor cDNA. Nature 318: 635– 641, 1985. HONG H, KOHLI K, GARABEDIAN MJ, AND STALLCUP MR. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17: 2735–2744, 1997. HORLEIN AJ, NAAR AM, HEINZEL T, TORCHIA J, GLOSS B, KUROKAWA R, RYAN A, KAMEL Y, SODERSTROM M, GLASS CK, AND ROSENFELD MG. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear co-repressor. Nature 377: 397– 404, 1995. HORWITZ KB, JACKSON TA, BAIN DL, RICHER JK, TAKIMOTO GS, AND TUNG L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167–1177, 1996. HTUN H, HOLTH LT, WALKER D, DAVIE JR, AND HAGER GL. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 10: 471– 486, 1999. HU X AND LAZAR MA. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402: 93–96, 1999. HUANG BK, GOLDEN LA, TARJAN G, MADISON LD, AND STERN PH. Insulin-like growth factor I production is essential for anabolic effects of thyroid hormone in osteoblasts. J Bone Miner Res 15: 188 –197, 2000. IKEDA M, WILCOX EC, AND CHIN WW. Thyroid hormone receptor heterodimer on some DR4s can mediate basal repression but may not be sufficient for transcriptional activation. Proc Endocr Soc Meet Washington DC 1995, p. P3– 439. ING NH, BECKMAN JM, TSAI SY, TSAI MJ, AND O’MALLEY BW. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267: 17617–17623, 1992. ISHIKAWA Y, GENGE BR, WUTHIER RE, AND WU LN. Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. J Bone Miner Res 13: 1398 –1411, 1998. ITO M, YUAN CX, MALIK S, GU W, FONDELL JD, YAMAMURA S, FU ZY, ZHANG X, QIN J, AND ROEDER RG. Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3: 361–370, 1999. IZUMO S AND MAHDAVI V. Thyroid hormone receptor a isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature 334: 539 –542, 1988. JACQ X, BROU C, LUTZ Y, DAVIDSON I, CHAMBON P, AND TORA L. Human TAFII30 is present in a distinct TFIID complex and is required for

222.

223.

224.

226.

227.

228.

229.

230.

231.

232.

233.

234.

235.

236.

237.

238.

239.

240.

241.

Volume 81

transcriptional activation by the estrogen receptor. Cell 79: 107– 117, 1994. JAFFIOL C, BALDET L, TORRESANI J, BISMUTH J, AND PAPACHRISTOU C. A case of hypersensitivity to thyroid hormones with normally functioning thyroid gland and increased nuclear triiodothyronine receptors. J Endocrinol Invest 13: 839 – 845, 1990. JAMESON JL. Mechanisms by which thyroid hormone receptor mutations cause clinical syndromes of resistance to thyroid hormone. Thyroid 4: 485– 492, 1994. JEANNIN E, ROBYR D, AND DESVERGNE B. Transcriptional regulatory patterns of the myelin basic protein and malic enzyme genes by the thyroid hormone receptors alpha1 and beta1. J Biol Chem 273: 24239 –24248, 1998. JEKABSONS MB, GREGOIRE FM, SCHONFELD-WARDEN NA, WARDEN CH, AND HORWITZ BA. T(3) stimulates resting metabolism and UCP-2 and UCP-3 mRNA but not nonphosphorylating mitochondrial respiration in mice. Am J Physiol Endocrinol Metab 277: E380 –E389, 1999. JEYAKUMAR M, TANEN MR, AND BAGCHI MK. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Mol Endocrinol 11: 755–767, 1997. JOHANSSON C, GOTHE S, FORREST D, VENNSTROM B, AND THOREN P. Cardiovascular phenotype and temperature control in mice lacking thyroid hormone receptor-beta or both alpha1 and beta. Am J Physiol Heart Circ Physiol 276: H2006 –H2012, 1999. JONES KE, BRUBAKER JH, AND CHIN WW. Evidence that phosphorylation events participate in thyroid hormone action. Endocrinology 134: 543–548, 1994. JONES KE AND CHIN WW. Differential regulation of thyroid hormone receptor messenger ribonucleic acid levels by thyrotropin-releasing hormone. Endocrinology 128: 1763–1768, 1991. JONES KE, YAFFE BM, AND CHIN WW. Regulation of thyroid hormone receptor b-2 mRNA levels by retinoic acid. Mol Cell Endocrinol 91: 113–118, 1993. JUDELSON C AND PRIVALSKY ML. DNA recognition by normal and oncogenic thyroid hormone receptors. Unexpected diversity in half-site specificity controlled by non-zinc finger determinants. J Biol Chem 271: 10800 –10805, 1996. JUGE-AUBRY CE, GORLA-BAJSZCZAK A, PERNIN A, LEMBERGER T, WAHLI W, BURGER AG, AND MEIER CA. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. J Biol Chem 270: 18117–18122, 1995. KAKIZAWA T, MIYAMOTO T, KANEKO A, YAJIMA H, ICHIKAWA K, AND HASHIZUME K. Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor. J Biol Chem 272: 23799 – 23804, 1997. KAMEI Y, XU L, HEINZEL T, TORCHIA J, KUROKAWA R, GLOSS C, LIN B, HEYMAN RA, ROSE DW, GLASS CK, AND ROSENFELD MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403– 414, 1996. KANESHIGE M, KANESHIGE K, ZHU X, DACE A, GARRETT L, CARTER TA, KAZLAUSKAITE R, PANKRATZ DG, WYNSHAW-BORIS A, REFETOFF S, WEINTRAUB B, WILLINGHAM MC, BARLOW C, AND CHENG S. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97: 13209 –13214, 2000. KATO H, FUKUDA T, PARKISON C, MCPHIE P, AND CHENG SY. Cytoplasmic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc Natl Acad Sci USA 86: 7681–7685, 1990. KATO S, ENDOH H, MASUHIRO Y, KITAMOTO T, UCHIYAMA S, SASAKI H, MASUHIGE S, GOTOH Y, NISHIDA E, KAWASHIMA H, AND CHAMBON P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491–1494, 1995. KATZ D, REGINATO MJ, AND LAZAR MA. Functional regulation of thyroid hormone receptor variant TR alpha 2 by phosphorylation. Mol Cell Biol 15: 2341–2348, 1995. KATZ RW AND KOENIG RJ. Specificity and mechanism of thyroid hormone induction from an octamer response element. J Biol Chem 269: 18915–18920, 1994. KENDALL EC. The isolation in crystalline form of the compound containing iodine which occurs in the thyroid: its chemical nature

July 2001

242.

243.

244.

245.

246.

247.

248. 249.

250.

251. 252.

253.

254.

255.

256.

257.

258.

259.

260.

261. 262.

263.

THYROID HORMONE ACTION

and physiological activity. Trans Assoc Am Physicians 30: 420 – 449, 1915. KIM HS, CRONE DE, SPRUNG CN, TILLMAN JB, FORCE WR, CREW MD, MOTE PL, AND SPINDLER SR. Positive and negative thyroid hormone response elements are composed of strong and weak half-sites 10 nucleotides in length. Mol Endocrinol 6: 1489 –1501, 1992. KIM SW, AHN IM, AND LARSEN PR. In vivo genomic footprinting of thyroid hormone-responsive genes in pitutiary tumor cell lines. Mol Cell Biol 16: 4465– 4477, 1996. KING IN, DESOYZA T, CATANZARO D, AND LAVIN TN. Thyroid hormone receptor-induced bending of specific DNA sequences is modified by an accessory factor. J Biol Chem 268: 495–501, 1993. KINLAW WB, CHURCH JL, HARMON J, AND MARIASH CN. Direct evidence for a role of the “spot 14” protein in the regulation of lipid synthesis. J Biol Chem 270: 16615–16618, 1995. KINLAW WB, TRON P, AND FRIEDMAN AS. Nuclear localization and hepatic zonation of rat “spot 14” protein: immunohistochemical investigation employing anti-fusion protein antibodies. Endocrinology 131: 3120 –3122, 1992. KLAUSHOFER K, VARGA F, GLANTSCHNIG H, FRATZL-ZELMAN N, CZERWENKA E, LEIS HJ, KOLLER K, AND PETERLIK M. The regulatory role of thyroid hormones in bone cell growth and differentiation. J Nutr 125: 1996S–2003S, 1995. KLEIN I AND OJAMAA K. Thyrotoxicosis and the heart. Endocrinol Metab Clin N Am 27: 51– 62, 1998. KLEMPERER JD, KLEIN I, GOMEZ M, HELM RE, OJAMAA K, THOMAS SJ, ISOM OW, AND KRIEGER K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333: 1522–1527, 1995. KLIEWER SA, UMESONO K, NOONAN DJ, HEYMAN RA, AND EVANS RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358: 771–774, 1992. KLIEWER SA AND WILLSON TM. The nuclear receptor PPAR␥: bigger than fat. Curr Opin Genet Dev 8: 576 –581, 1998. KO L, CARDONA GR, AND CHIN WW. Thyroid hormone receptorbinding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97: 6212– 6217, 2000. KOENIG RJ, LAZAR MA, HODIN RA, BRENT GA, LARSEN PR, CHIN WW, AND MOORE DD. Inhibition of thyroid hormone action by a nonhormone binding c-erbA protein generated by alternative mRNA splicing. Nature 337: 659 – 661, 1989. KOENIG RJ, WARNE RL, BRENT GA, HARNEY JW, LARSEN PR, AND MOORE DD. Isolation of a cDNA clone encoding a biologically active thyroid hormone receptor. Proc Natl Acad Sci USA 85: 5031–5035, 1988. KOHN LD, SHIMURA H, SHIMURA Y, HIDAKA A, GIULIANI C, NAPOLITANO G, OHMORI M, LAGLIA G, AND SAJI M. The thyrotropin receptor. Vitam Horm 50: 287–384, 1995. KOHRLE J. The selenoenzyme family of deiodinase isozymes controls local thyroid hormone availability. Rev Endocr Metabolic Disorders 1: 49 –58, 2000. KOIBUCHI N AND CHIN W. Aberrant postnatal cerebellar development in transgenic mouse expressing a dominant negative thyrid hormone receptor. Proc Annu Meet Endocr Soc 81d Toronto Canada 2000, p. 374. KOIBUCHI N AND CHIN WW. ROR alpha gene expression in the perinatal rat cerebellum: ontogeny and thyroid hormone regulation. Endocrinology 139: 2335–2341, 1998. KOIBUCHI N, FUKUDA H, AND CHIN WW. Promoter-specific regulation of the brain-derived neurotropic factor gene by thyroid hormone in the developing rat cerebellum. Endocrinology 140: 3955–3961, 1999. KOIBUCHI N, LIU Y, FUKUDA H, TAKESHITA A, YEN PM, AND CHIN WW. ROR alpha augments thyroid hormone receptor-mediated transcriptional activation. Endocrinology 140: 1356 –1364, 1999. KOPP P. Pendred’s syndrome and genetic defects in thyroid hormone synthesis. Rev Endocr Metabolic Disorders 1: 109 –121, 2000. KORZUS E, TORCHIA J, ROSE DW, XU L, KUROKAWA R, MCINERNEY EM, MULLEN TM, GLASS CK, AND ROSENFELD MG. Transcription factorspecific requirements for coactivators and their acetyltransferase functions. Science 279: 703–707, 1998. KRANE IM, SPINDEL ER, AND CHIN WW. Thyroid hormone decreases

264.

265.

266.

267.

268.

269.

270.

271.

272.

273.

274.

275.

276.

277.

278.

279.

280. 281.

282.

283.

1133

the stability and the poly(A) tract length of rat thyrotropin betasubunit messenger RNA. Mol Endocrinol 5: 469 – 475, 1991. KRISTENSEN K, PEDERSEN SB, LANGDAHL BL, AND RICHELSEN B. Regulation of leptin by thyroid hormone in humans: studies in vivo and in vitro. Metabolism 48: 1603–1607, 1999. KUIPER GG, ENMARK E, PELTO-HUIKKO M, NILSSON S, AND GUSTAFSSON JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925–5930, 1996. KUROKAWA R, DIRENZO J, BOEHM M, SUGARMAN J, GLOSS B, ROSENFELD MG, HEYMAN RA, AND GLASS CK. Regulation of retinoid signaling by receptor polarity and allosteric control of ligand binding. Nature 371: 528 –531, 1994. KUROKAWA R, SODERSTROM M, HORLEIN A, HALACHMI S, BROWN M, ROSENFELD MG, AND GLASS CK. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377: 451– 454, 1995. KUROKAWA R, YU VC, NAAR A, KYAKUMOTO S, HAN Z, SILVERMAN S, ROSENFELD MG, AND GLASS CK. Differential orientations of the DNAbinding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Gene Dev 7: 1423–1435, 1993. KWOK RP, LUNDBLAD JR, CHRIVIA JC, RICHARDS JP, BACHINGER HP, BRENNAN RG, ROBERTS SG, GREEN MR, AND GOODMAN RH. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370: 223–226, 1994. LADENSON PW, SHERMAN IS, BAUGHMAN KL, RAY PE, AND FELDMAN AM. Reversible alterations in the myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 89: 5251–5255, 1992. LAHERTY CD, YANG WM, SUN JM, DAVIE JR, SETO E, AND EISENMAN RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349 –356, 1997. LAKATOS P, FOLDES J, HORVATH C, KISS L, TATRAI A, TAKACS I, TARJAN G, AND STERN PH. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82: 78 – 81, 1997. LAKATOS P AND STERN PH. Effects of cyclosporins and transforming growth factor beta 1 on thyroid hormone action in cultured fetal rat limb bones. Calcif Tissue Int 50: 123–128, 1992. LAKSHMANAN M, GONCALVES E, LESSLY G, FOTI D, AND ROBINS J. The transport of thyroxine into mouse neuroblastoma cells, NB41A3: the effect of L-system amino acids. Endocrinology 126: 3245–3250, 1990. LANGLOIS MF, ZANGER K, MONDEN T, SAFER JD, HOLLENBERG AN, AND WONDISFORD FE. A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone. Mapping of a novel amino-terminal domain important for ligand-independent activation. J Biol Chem 272: 24927–33, 1997. LANNI A, MORENO M, LOMBARDI A, AND GOGLIA F. Rapid stimulation in vitro of rat liver cytochrome oxidase activity by 3,5-diiodo-L-thyronine and by 3,3⬘-diiodo-L-thyronine. Mol Cell Endocrinol 99: 89 –94, 1994. LANZ RB, MCKENNA NJ, ONATE SA, ALBRECHT U, WONG J, TSAI SY, TSAI MJ, AND O’MALLEY BW. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17–27, 1999. LANZ RB AND RUSCONI S. A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinology 135: 2183–2195, 1994. LARKIN S, MULL E, MIAO W, PITTNER R, ALBRANDT K, MOORE C, YOUNG A, DENARO M, AND BEAUMONT K. Regulation of the third member of the uncoupling protein family, UCP3, by cold and thyroid hormone. Biochem Biophys Res Commun 240: 222–227, 1997. LARSEN PR AND BERRY MJ. Nutritional and hormonal regulation of thyroid hormone deiodinases. Annu Rev Nutr 15: 323–352, 1995. LARSEN PR, HARNEY JW, AND MOORE DD. Sequences required for cell-specific thyroid hormone regulation of rat growth hormone promoter activity. J Biol Chem 261: 14733–14736, 1986. LAVIN TN, BAXTER JD, AND HORITA S. The thyroid hormone receptor binds to multiple domains of the rat growth hormone 5⬘-flanking sequence. J Biol Chem 263: 9418 –9426, 1988. LAZAR MA. Sodium butyrate selectively alters thyroid hormone

1134

284. 285. 286.

287.

288.

289. 290.

291.

292.

293.

294.

295.

296.

297.

298.

299.

300.

301.

302.

303.

PAUL M. YEN

receptor gene expression in GH3 cells. J Biol Chem 265: 17474 – 17477, 1990. LAZAR MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14: 348 –399, 1993. LAZAR MA. Nuclear hormone receptors: from molecules to diseases. J Invest Med 47: 364 –368, 1999. LAZAR MA. Transcriptional repression by thyroid hormone receptor (Abstract). Proc Int Symp Mol Thyroidol 7th Hamamatsu Japan 2000, p. 10. LAZAR MA AND BERRODIN TJ. Thyroid hormone receptors form distinct nuclear protein-dependent and independent complexes with a thyroid hormone response element. Mol Endocrinol 4: 1627–1635, 1990. LAZAR MA, BERRODIN TJ, AND HARDING HH. Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor. Mol Cell Biol 11: 5005–5015, 1991. LAZAR MA AND CHIN WW. Nuclear thyroid hormone receptors. J Clin Invest 86: 1777–1782, 1990. LAZAR MA, HODIN RA, CARDONA GR, AND CHIN WW. Gene expression from the c-erbAa/Rev-erbAa genomic locus: potential regulation of alternative splicing by complementary transcripts from opposite DNA strands. J Biol Chem 265: 12859 –12863, 1990. LAZAR MA, HODIN RA, AND CHIN WW. Human carboxyl-terminal variant of a-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone. Proc Natl Acad Sci USA 86: 7771–7774, 1989. LAZAR MA, HODIN RA, DARLING DS, AND CHIN WW. Identification of a rat c-erbAa-related protein which binds deoxyribonucleic acid and does not bind thyroid hormone. Mol Endocrinol 2: 893–901, 1989. LAZAR MA, HODIN RA, DARLING DS, AND CHIN WW. A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbAa transcriptional unit. Mol Cell Biol 9: 1128 –1136, 1989. LEE IJ, DRIGGERS PH, MEDIN JA, NIKODEM VM, AND OZATO K. Recombinant thyroid hormone receptor and retinoid X receptor stimulate ligand-dependent transcription in vitro. Proc Natl Acad Sci USA 91: 1647–1651, 1994. LEE JW, CHOI HS, GYURIS J, BRENT R, AND MOORE DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol 9: 243–254, 1995. LEE JW, RYAN F, SWAFFIELD JC, JOHNSTON SA, AND MOORE DD. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374: 91–94, 1995. LEE LR, MORTENSEN RM, LARSON CA, AND BRENT GA. Thyroid hormone receptor-alpha inhibits retinoic acid-responsive gene expression and modulates retinoic acid-stimulated neural differentiation in mouse embryonic stem cells. Mol Endocrinol 8: 746 –756, 1994. LEE SK, ANZICK SL, CHOI JE, BUBENDORF L, GUAN XY, JUNG YK, KALLIONIEMI OP, KONONEN J, TRENT JM, AZORSA D, JHUN BH, CHEONG JH, LEE YC, MELTZER PS, AND LEE JW. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for liganddependent transactivation by nuclear receptors in vivo. J Biol Chem 274: 34283–34293, 1999. LEEDMAN PJ, STEIN AR, AND CHIN WW. Regulated specific protein binding to a conserved region of the 3⬘-untranslated region of thyrotropin beta-subunit mRNA. Mol Endocrinol 9: 375–387, 1995. LEID M, KASTNER P, LYONS R, NAKSATRI H, SAUNDERS M, ZACHAREWSKI T, CHEM JY, STAUB M, GARNIER A, MADER S, AND CHAMBON P. Purification, cloning and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68: 377–395, 1992. LEITMAN DC, COSTA CHRM, GRAF H, BAXTER JD, AND RIBEIRO RCJ. Thyroid hormone activation of transcription is potentiated by activators of cAMP-dependent protein kinase. J Biol Chem 271: 21950 –21955, 1996. LEONHARDT U, GERDES E, RITZEL U, SCHAFER G, BECKER W, AND RAMADORI G. Immunoreactive leptin and leptin mRNA expression are increased in rat hypo- but not hyperthyroidism. J Endocrinol 163: 115–121, 1999. LEVACHER C, SZTALRYD C, KINEBANYAN MF, AND PICON L. Effects of thyroid hormones on adipose tissue development in Sherman and Zucker rats. Am J Physiol Cell Physiol 246: C50 –C56, 1984.

Volume 81

304. LEVIN AA, STURZENBECKER LJ, KAXMER S, BOSAKOWSKI T, HUSELTON C, ALLENBY G, SPECK L, KRATZEISEN C, ROSENBERGER M, LOVEY A, AND GRIPPO JF. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRa. Nature 355: 359 –361, 1992. 305. LEZOUALC’H F, HASSAN AH, GIRAUD P, LOEFFLER JP, LEE SL, AND DEMENEIX BA. Assignment of the beta-thyroid hormone receptor to 3,5,3⬘-triiodothyronine-dependent inhibition of transcription from thyrotropin-releasing hormone promoter in chick hypothalamic neurons. Mol Endocrinol 6: 1797–1804, 1992. 306. LI H, GOMES PJ, AND CHEN JD. RAC3, a steroid/nuclear receptorassociated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94: 8479 – 8484, 1997. 307. LIN Y, THACORE HR, DAVIS PJ, AND DAVIS FB. Thyroid hormone potentiates the antiviral action of interferon-gamma in cultured human cells. J Clin Endocrinol Metab 79: 62– 65, 1994. 308. LIN KH, ASHIZAWA K, AND CHENG SY. Phosphorylation stimulates the transcriptional activity of the human beta 1 thyroid hormone receptor. Proc Natl Acad Sci USA 89: 7737–7741, 1992. 309. LIN ZHU Y, SHIEH C, HSU T, CHEN G, MCPHIE P, AND CHENG SY. Identification of naturally occurring dominant negative mutants of thyroid hormone a1 and b1 receptors in a human hepatocellular carcinoma cell lines. Endocrinology 137: 4073– 4081, 1996. 310. LIN S AND GREEN MR. Mechanism of action of an acidic transcriptional activator in vitro. Cell 64: 971–981, 1991. 311. LIU Y, TAKESHITA A, MISITI S, CHIN WW, AND YEN PM. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. Endocrinology 139: 4197– 4204, 1998. 312. LOPEZ G, SCHAUFELE F, WEBB P, HOLLOWAY JM, BAXTER JD, AND KUSHNER PJ. Positive and negative modulation of jun action by thyroid hormone receptor at a unique AP1 site. Mol Cell Biol 13: 3042–3049, 1993. 313. LOWELL BB, SUSULIC VS, HAMANN A, LAWITTS JA, HIMMS-HAGEN J, BOYER BB, KOZAK LP, AND FLIER JS. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366: 740 –742, 1993. 314. LUCAS PC, FORMAN BM, SAMUELS HH, AND GRANNER DK. Specificity of a retinoic acid response element in the phosphoenolpyruvate carboxykinase gene promoter: consequences of both retinoic acid and thyroid hormone receptor binding. Mol Cell Biol 11: 5164 –5170, 1991. 315. LUISI BF, SCHWABE JW, AND FREEDMAN LP. The steroid/nuclear receptors: from three-dimensional structure to complex function. Vitam Horm 49: 1– 47, 1994. 316. MA H, HONG H, HUANG SM, IRVINE RA, WEBB P, KUSHNER PJ, COETZEE GA, AND STALLCUP MR. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 19: 6164 – 6173, 1999. 316a.MACCHIA PE, TAKEUCHI Y, KAWAI T, CUA K, GAUTHIER K, CHASSANDE O, SEO H, HAYASHI Y, SAMARUT J, MURATA Y, WEISS RE, AND REFETOFF S. Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. Proc Natl Acad Sci USA 98: 349 –354, 2001. 317. MADER S, KUMAR V, VERNEUIL DH, AND CHAMBON P. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element. Nature 338: 271–274, 1989. 318. MADISON LD, AHLQUIST JA, ROGERS SD, AND JAMESON JL. Negative regulation of the glycoprotein hormone alpha gene promoter by thyroid hormone: mutagenesis of a proximal receptor binding site preserves transcriptional repression. Mol Cell Endocrinol 94: 129 – 136, 1993. 319. MANTZOROS CS, ROSEN HN, GREENSPAN SL, FLIER JS, AND MOSES AC. Short-term hyperthyroidism has no effect on leptin levels in man. J Clin Endocrinol Metab 82: 497– 499, 1997. 320. MARGOTAT A, LENOIR C, SARKISSIAN G, MALEZET-DESMOULIN C, BALDET L, JAFFIOL C, AND TORRESANI J. Hypersensitivity to thyroid hormone action. Proc Int Workshop Thyroid Hormone Resistance 1d Padua Italy 1995. 321. MARKS M, HALLENBECK PL, NAGATA T, SEGARS JH, APEPELLA E, NIKODEM VM, AND OZATO K. H-2RIIBP (RXRb) heterodimerization provides a mechanism for combinatorial diversity in the regulation

July 2001

322.

323.

324.

325.

326.

327.

328.

329.

330.

331.

332.

333.

334.

335.

336. 337.

338.

339.

340.

341.

THYROID HORMONE ACTION

of retinoic acid and thyroid hormone responsive genes. EMBO J 11: 1419 –1435, 1992. MARTIAL JA, SEEBURG PH, GUENZI D, GOODMAN HM, AND BAXTER JD. Regulation of growth hormone gene expression: synergistic effects of thyroid and glucocorticoid hormones. Proc Natl Acad Sci USA 74: 4293– 4295, 1977. MARTINEZ DE ARRIETA C, MORTE B, COLOMA A, AND BERNAL J. The human RC3 gene homolog, NRGN contains a thyroid hormoneresponsive element located in the first intron. Endocrinology 140: 335–343, 1999. MAWAZ Z, TSAI MJ, AND O’MALLEY BW. Specific mutations in the ligand binding domain selectively abolish the silencing function of human thyroid hormone receptor beta. Proc Natl Acad Sci USA 92: 11691–11695, 1995. MCINERNEY EM, ROSE DW, FLYNN SE, WESTIN S, MULLEN TM, KRONES A, INOSTROZA J, TORCHIA J, NOLTE RT, ASSA-MUNT N, MILBURN MV, GLASS CK, AND ROSENFELD MG. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12: 3357–3368, 1998. MCKENNA NJ, LANZ RB, AND O’MALLEY BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321–344, 1999. MEIER CA, DICKSTEIN BM, ASHIZAWA K, MCCLASKEY JH, MUCHMORE P, RANSOM SC, MENKE JB, HAO EH, USALA SJ, BERCU BB, CHENG SY, AND WEINTRAUB BD. Variable transcriptional activity and ligand binding of mutant b1–3,5,3⬘ triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol 6: 248 –258, 1992. MEUNIER PJ, BIANCHI GGS, EDOUARD CM, BERNARD JC, COURPRON P, AND VIGNON GE. Bony manifestations of thyrotoxicosis. Orthoped Clin N Am 3: 745–774, 1972. MILNE M, KANG MI, CARDONA G, QUAIL JM, BRAVERMAN LE, CHIN WW, AND BARAN DT. Expression of multiple thyroid hormone receptor isoforms in rat femoral and vertebral bone and in bone marrow osteogenic cultures. J Cell Biochem 74: 684 – 693, 1999. MITSUHASHI TG, TENNYSON GE, AND NIKODEM VM. Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone. Proc Natl Acad Sci USA 85: 5804 –5808, 1988. MIYAJIMA N, HORIUCHI R, SHIBUYA Y, FUKUSHIGE S, MATSUBARA K, TOYOSHIMA K, AND YAMAMOTO T. Two erbA homologs encoding proteins with different T3 binding capacities are transcribed from opposite DNA strands of the same genetic locus. Cell 57: 31–39, 1989. MIYAMOTO T, KANEKO A, KAKIZAWA T, YAJIMA H, KAMIJO K, SEKINE R, HIRAMATSU K, NISHII Y, HASHIMOTO T, AND HASHIZUME K. Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. Competitive binding to the response element. J Biol Chem 272: 7752–7758, 1997. MIYAMOTO T, SUZUKI S, AND DEGROOT LJ. High affinity and specificity of dimeric binding of thyroid hormone receptors to DNA and their ligand dependent dissociation. Mol Endocrinol 7: 224 –231, 1993. MONDEN T, WONDISFORD FE, AND HOLLENBERG AN. Isolation and characterization of a novel ligand-dependent thyroid hormone receptor-coactivating protein. J Biol Chem 272: 29834 –29841, 1997. MOORADIAN AD, SCHWARTZ HL, MARIASH CN, AND OPPENHEIMER JH. Transcellular and transnuclear transport of 3,5,3⬘-triiodothyronine in isolated hepatocytes. Endocrinology 117: 2449 –2456, 1985. MORKIN E. Regulation of myosin heavy chain genes in the heart. Circulation 87: 1451–1450, 1993. MOSEKILDE L, ERIKSEN EF, AND CHARLES P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin N Am 19: 35– 63, 1990. MOUSTAID N AND SUL HS. Regulation of expression of the fatty acid synthase gene in 3T3–L1 cells by differentiation and triiodothyronine. J Biol Chem 266: 18550 –18554, 1991. MUNDY GR, SHAPIRO JL, BANDELIN JG, CANALIS EM, AND RAISZ LG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58: 529 –534, 1976. MUNOZ A, ZENKE M, GEHERING U, SAP J, BEUG H, AND VENNSTROM B. Characterization of the hormone binding domain of the chicken c-erbA/thyroid hormone receptor protein. EMBO J 17: 155–159, 1988. MURRAY M AND TOWLE H. Identification of nuclear factors that

1135

enhance binding of the thyroid hormone receptor to a thyroid hormone response element. Mol Endocrinol 3: 1434 –1442, 1989. 342. NAAR AM, BOUTIN JM, LIPKIN SM, YU VC, HOLLOWAY JM, GLASS CK, AND ROSENFELD MG. The orientation and spacing of core DNAbinding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 65: 1255–1266, 1991. 343. NAGAYA T, EBERHARDT NL, AND JAMESON JL. Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutations. J Clin Endocrinol Metab 77: 982–990, 1993. 344. NAGAYA T AND JAMESON JL. Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem 268: 15766 –15771, 1993. 345. NAGAYA T, MADISON LD, AND JAMESON JL. Thyroid hormone receptor mutants that cause resistance to thyroid hormone: evidence for receptor competition for DNA sequences in target genes. J Biol Chem 27: 13014 –13019, 1992. 346. NAGL SB, NELSON CC, ROMANIUK PJ, AND ALLISON LA. Constitutive transactivation by thyroid hormone receptor and a novel pattern of activity of its ongenic homolog v-erbA in Xenopus oocytes. Mol Endocrinol 9: 1522–1532, 1995. 347. NAGY L, KAO HY, CHAKRAVARTI D, LIN RJ, HASSIG CA, AYER DE, SCHREIBER SL, AND EVANS RM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89: 373–380, 1997. 348. NAGY L, KAO HY, LOVE JD, LI C, BANAYO E, GOOCH JT, KRISHNA V, CHATTERJEE K, EVANS RM, AND SCHWABE JW. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 13: 3209 –3216, 1999. 349. NAKAI AS, SEINO A, SAKURAI A, SZILAK I, BELL GI, AND DEGROOT LJ. Characterization of a thyroid hormone receptor expressed in human kidney and other tissues. Proc Natl Acad Sci USA 85: 2781– 2785, 1988. 350. NAKAJIMA T, UCHIDA C, ANDERSON SF, LEE CG, HURWITZ J, PARVIN JD, AND MONTMINY M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90: 1107–1112, 1997. 351. NAN X, NG HH, JOHNSON CA, LAHERTY CD, TURNER BM, EISENMAN RN, AND BIRD A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386 –389, 1998. 352. NAWAZ Z, BANIAHMAD C, BURRIS TP, STILLMAN DJ, O’MALLEY BW, AND TSAI MJ. The yeast SIN3 gene product negatively regulates the activity of the human progesterone receptor and positively regulates the activities of GAL4 and the HAP1 activator. Mol Gen Genet 245: 724 –733, 1994. 353. NELSON CC, HENDY SC, AND ROMANIUK PJ. Relationship between P-box amino acid sequence and DNA binding specificity of the thyroid hormone receptor. The effects of sequences flanking halfsites in thyroid hormone response elements. J Biol Chem 270: 16988 –16994, 1995. 353a.NG L, HURLEY JB, DIERKS B, SRINIVAS M, SALTO C, VENNSTROM B, REH TA, AND FORREST D. A thyroid hormone receptor that is required for the development of green cone photoreceptors. Nat Genet 27: 94 –98, 2001. 354. NOMURA T, KHAN MM, KAUL SC, DONG HD, WADHWA R, COLMENARES C, KOHNO I, AND ISHII S. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev 13: 412– 423, 1999. 355. NORDQUIST DT, KOZAK CA, AND ORR HT. cDNA cloning and characterization of three genes uniquely expressed in cerebellum by Purkinje neurons. J Neurosci 8: 4780 – 4789, 1988. 356. NOVITZKY D. Triiodothyronine replacement, the euthyroid sick syndrome, and organ transplantation. Transplant Proc 23: 2460 –2462, 1991. 357. NOVITSKY D, COOPER DKC, BARTON CI, GREER A, CHAFFIN J, GRIM J, AND ZUHDI N. Triiodothyronine as an inotropic agent after open heart surgery. J Thorac Cardiovasc Surg 98: 972–978, 1989. 358. OBERSTE-BERGHAUS C, ZANGER K, HASHIMOTO K, COHEN RN, HOLLENBERG AN, AND WONDISFORD FE. Thyroid hormone-independent interaction between the thyroid hormone receptor beta2 amino terminus and coactivators. J Biol Chem 275: 1787–1792, 2000. 359. OBREGON MJ, CALVO R, HERNANDEZ A, ESCOBAR DEL REY F, AND MORREALE DE ESCOBAR G. Regulation of uncoupling protein messen-

1136

360.

361.

362.

363.

364.

365.

366.

367. 368.

369.

370.

371.

372.

373.

374.

375.

376.

377.

378.

379.

380.

PAUL M. YEN

ger ribonucleic acid and 5⬘-deiodinase activity by thyroid hormones in fetal brown adipose tissue. Endocrinology 137: 4721– 4729, 1996. O’DONNELL AL, ROSEN ED, DARLING DS, AND KOENIG R. Thyroid hormone receptor mutations that interfere with transcriptional activation also interfere with receptor interaction with a nuclear protein. Mol Endocrinol 5: 94 –99, 1991. OGRYZKO VV, KOTANI T, ZHANG X, SCHLITZ RL, HOWARD T, YANG XJ, HOWARD BH, QIN J, AND NAKATANI Y. Histone-like TAFs within the PCAF histone acetylase complex. Cell 94: 35– 44, 1998. OGRYZKO VV, SCHILTZ RL, RUSSANOVA V, HOWARD BH, AND NAKATANI Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953–959, 1996. OIKE Y, TAKAKURA N, HATA A, KANAME T, AKIZUKI M, YAMAGUCHI Y, YASUE H, ARAKI K, YAMAMURA K, AND SUDA T. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood 93: 2771–2779, 1999. OJAAMA K, KLEMPERER JD, MACGILVRAY SS, KLEIN I, AND SAMAREL A. Thyroid hormone, hemodynamic regulation of b-myosin heavy chain promoter in the heart. Endocrinology 137: 802– 808, 1996. OJAMAA K, SABET A, KENESSEY A, SHENOY R, AND KLEIN I. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 140: 3170 –3176, 1999. OLSON DP AND KOENIG RJ. 5⬘-Flanking sequences in thyroid hormone response element half-sites determine the requirement of retinoid X receptor for receptor-mediated gene expression. J Biol Chem 272: 9907–9914, 1997. OLSON DP AND KOENIG RJ. Thyroid function in Rubinstein-Taybi syndrome. J Clin Endocrinol Metab 82: 3264 –3266, 1997. OLSON DP, SUN B, AND KOENIG RJ. Thyroid hormone response element architecture affects corepressor release from thyroid hormone receptor dimers. J Biol Chem 273: 3375–3380, 1998. ONATE SA, TSAI SY, TSAI MJ, AND O’MALLEY BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354 –1357, 1995. ONIGATA K, YAGI H, SAKURAI A, NAGASHIMA T, NOMURA Y, NAGASHIMA K, HASHZUME K, AND MORIKAWA A. A novel point mutation (R243Q) in exon 7 of the c-erbA beta thyroid hormone receptor gene in a family with resistance to thyroid hormone. Thyroid 5: 355–358, 1995. ONO S, SCHWARTZ ID, MUELLER OT, ROOT AW, USALA SJ, AND BERCU BB. Homozygosity for a dominant negative thyroid hormone receptor responsible for generalized thyroid hormone resistance. J Clin Endocrinol Metab 73: 990 –994, 1991. OPPENHEIMER JH, KOERNER D, SCHWARTZ HL, AND SURKS MI. Specific nuclear triiodothyronine binding sites in rat liver and kidney. J Clin Endocrinol Metab 35: 330 –333, 1972. OPPENHEIMER JH AND SCHWARTZ HL. Molecular basis of thyroid hormone-dependent brain development. Endocr Rev 18: 462– 475, 1997. OPPENHEIMER JH, SCHWARTZ HL, LANE JT, AND THOMPSON MP. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 87: 125–132, 1991. OPPENHEIMER JH, SCHWARTZ HL, MARIASH CN, KINLAW WB, WONG NCW, AND FREAKE HC. Advances in our understanding of thyroid hormone action at the cellular level. Endocr Rev 8: 288 –308, 1987. OPPENHEIMER JH, SCHWARTZ HL, AND STRAIT KA. An integrated view of thyroid hormone actions in vivo. In: Molecular Endocrinology: Basic Concepts and Clinical Correlations, edited by Weintraub B. New York: Raven, 1995, p. 249 –268. OPPENHEIMER JH, SCHWARTZ HL, AND SURKS MI. Tissue differences in the concentration of triiodothyronine nuclear binding sites in the rat: liver, kidney, pituitary, heart, brain, spleen, and testis. Endocrinology 95: 897–903, 1974. OSTY J, VALENSI P, SAMSON M, FRANCON J, AND BLONDEAU JP. Transport of thyroid hormones by human erythrocytes: kinetic characterization in adults and newborns. J Clin Endocrinol Metab 71: 1589 –1595, 1990. PACHUCKI J, BURMEISTER LA, AND LARSEN PR. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res 85: 498 –503, 1999. PACKARD CJ, SHEPHERD J, LINDSAY GM, GAW A, AND TASKINEN MR. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab 76: 1209 –1216, 1993.

Volume 81

381. PARMA J, DUPREZ L, VAN SANDE J, HERMANS J, ROCMANS P, VAN VLIET G, COSTAGLIOLA S, RODIEN P, DUMONT JE, AND VASSART G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82: 2695–2701, 1997. 382. PARMENTIER M, LIBERT F, MAENHAUT C, LEFORT A, GERARD C, PERRET J, VAN SANDE J, DUMONT JE, AND VASSART G. Molecular cloning of the thyrotropin receptor. Science 246: 1620 –1622, 1989. 383. PASCHKE R AND LUDGATE M. The thyrotropin receptor in thyroid diseases. N Engl J Med 337: 1675–1681, 1997. 384. PASCUAL AS, CASANOVA J, AND SAMUELS HH. Photoaffinity labeling of thyroid hormone receptors in intact cells. J Biol Chem 257: 9640 – 9647, 1982. 385. PASTOR R, BERNAL J, AND RODRIGUEZ-PENA A. Unliganded c-erbA/ thyroid hormone receptor induces trkB expression in neuroblasoma cells. Oncogene 9: 1081–1089, 1994. 386. PAZOS-MOURA C, ABEL ED, BOERS ME, MOURA E, HAMPTON TG, WANG J, MORGAN JP, AND WONDISFORD FE. Cardiac dysfunction caused by myocardium-specific expression of a mutant thyroid hormone receptor. Circ Res 86: 700 –706, 2000. 387. PELLEQUER JL, WAGER-SMITH KA, KAY SA, AND GETZOFF ED. Photoactive yellow protein: a structural prototype for the three-dimensional fold of the PAS domain superfamily. Proc Natl Acad Sci USA 95: 5884 –5890, 1998. 388. PEREZ P, SCHONTHAL A, AND ARANDA A. Repression of c-fos gene expression by thyroid hormone and retinoic acid receptors. J Biol Chem 268: 23538 –23543, 1993. 389. PEREZ-CASTILLO A, HERNANDEX A, PIPAON C, SANTOS A, AND OBREGON MJ. Multiple regulation of S14 gene expression during brown fat differentiation. Endocrinology 133: 545–552, 1993. 390. PERISSI V, STASZEWSKI LM, MCINERNEY EM, KUROKAWA R, KRONES A, ROSE DW, LAMBERT MH, MILBURN MV, GLASS CK, AND ROSENFELD MG. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13: 3198 –3208, 1999. 391. PERLMANN T, RANGARAJAN PN, UMESONO K, AND EVANS RM. Determinants for selective RAR and TR recognition of direct repeat HREs. Genes Dev 7: 1411–1422, 1993. 392. PERLMANN T, UMESONO K, RANGARAJAN PN, FORMAN BM, AND EVANS RM. Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. Mol Endocrinol 10: 958 –966, 1996. 393. PETRIJ F, GILES RH, DAUWERSE HG, SARIS JJ, HENNEKAM RC, MASUNO M, TOMMERUP N, VAN OMMEN GJ, GOODMAN RH, PETERS DJ, AND BREUNING MH. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348 –351, 1995. 394. PETTY KJ. Tissue- and cell-specific distributions of protein interactions that interact with human b-thyroid hormone receptor. Mol Cell Endocrinol 108: 131–142, 1994. 395. PETTY KJ, DESVERGNE B, MITSUHASHI T, AND NIKODEM VM. Identification of a thyroid hormone response element in the malic enzyme gene. J Biol Chem 265: 7395–7400, 1990. 396. PETTY KJ, KRIMKEVICH YI, AND THOMAS D. A TATA binding proteinassociated factor functions as a coactivator for thyroid hormone receptors. Mol Endcrinol 10: 1632–1645, 1996. 397. PFAFF DW, KOW LM, ZHU YS, SCOTT RE, WU-PENG SX, AND DELLOVADE T. Hypothalamic cellular and molecular mechanisms helping to satisfy axiomatic requirements for reproduction. J Neuroendocrinol 8: 325–336, 1996. 398. PIEDRAFITA FJ, ORTIZ MA, AND PFAHL M. Thyroid hormone receptorbeta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function. Mol Endocrinol 9: 1533–1548, 1995. 399. PINKNEY JH, GOODRICK SJ, KATZ J, JOHNSON AB, LIGHTMAN SL, COPPACK SW, AND MOHAMED-ALI V. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol 49: 583–588, 1998. 400. POHLENZ J, MANDERS L, SADOW PM, KANSAL PC, REFETOFF S, AND WEISS RE. A novel point mutation in cluster 3 of the thyroid hormone receptor beta gene (P247L) causing mild resistance to thyroid hormone. Thyroid 9: 1195–1203, 1999. 401. POHLENZ J, WEISS RE, MACCHIA PE, PANNAIN S, LAU IT, HO H, AND REFETOFF S. Five new families with resistance to thyroid hormone

July 2001

402. 403.

404.

405.

406.

407.

408.

409.

410.

411.

412.

413.

414.

415. 416.

417.

418.

419.

420.

421.

THYROID HORMONE ACTION

not caused by mutations in the thyroid hormone receptor beta gene. J Clin Endocrinol Metab 84: 3919 –3928, 1999. PONTING CP AND ARAVIND L. PAS: a multifunctional domain family comes to light. Curr Biol 7: R674 –R677, 1997. POP VJ, KUIJPENS JL, VAN BAAR AL, VERKERK G, VAN SON MM, DE VIJLDER JJ, VULSMA T, WIERSINGA WM, DREXHAGE HA, AND VADER HL. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol 50: 149 –155, 1999. POU MA AND TORRESANI J. Coordinated stimulation of triiodothyronine of fatty acid synthesis and isoproterenol-sensitive fatty acid release in two preadipocyte cell lines of lean or genetically obese mice. Horm Metab Res 21: 468 – 472, 1989. POWER RF, MAIN S, CODINA J, CONEELY OM, AND O’MALLEY BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636 –1639, 1991. PUIGSERVER P, WU Z, PARK CW, GRAVES R, WRIGHT M, AND SPIEGELMAN BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829 – 839, 1998. QI JS, DESAI-YAJNIK V, GREENE ME, RAAKA BM, AND SAMUELS HH. The ligand-binding domains of the thyroid hormone/retinoic receptor gene subfamily function in vivo to mediate heterodimerizatin, gene silencing, and transactivation. Mol Cell Biol 15: 1817–1825, 1995. RABELO R, SCHIFMAN A, RUBIO A, SHENG X, AND SILVA JE. Delineation of thyroid hormone-responsive sequences within a critical enhancer in the uncoupling protein gene. Endocrinology 136: 1003– 1013, 1995. RABIE A, FAVRE C, CLAVEL MC, AND LEGRAND J. Effects of thyroid dysfunction on the development of the rat cerebellum, with special reference to cell death within the internal granular layer. Brain Res 120: 521–531, 1977. RABIE A AND LEGRAND J. Effects of thyroid hormone and undernourishment on the amount of synaptosomal fraction in the cerebellum of the young rat. Brain Res 61: 267–278, 1973. RACHEZ C, GAMBLE M, CHANG CP, ATKINS GB, LAZAR MA, AND FREEDMAN LP. The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol Cell Biol 20: 2718 –2726, 2000. RACHEZ C, LEMON BD, SULDAN Z, BROMLEIGH V, GAMBLE M, NAAR AM, ERDJUMENT-BROMAGE H, TEMPST P, AND FREEDMAN LP. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398: 824 – 828, 1999. RASTINEJAD F, PERLMANN T, EVANS RM, AND SIGLER PB. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375: 203–211, 1995. REFETOFF S, DEWIND LT, AND DEGROOT LJ. Familial syndrome combining deaf-mutism, stippled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 27: 279 –294, 1967. REFETOFF S, WEISS RA, AND USALA SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 14: 348 –399, 1993. REGINATO MJ, ZHANG J, AND LAZAR MA. DNA-independent and DNAdependent mechanisms regulate the differential heterodimerization of the isoforms of the thyroid hormone receptor with retinoid X receptor. J Biol Chem 271: 28199 –28205, 1996. RENAUD JP, ROCHEL N, RUFF M, VIVAT V, CHAMBON P, GRONEMEYER H, AND MORAS D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378: 681– 689, 1995. RHODES SJ, CHEN R, DIMATTIA GE, SCULLY KM, KALLA KA, LIN SC, YU VC, AND ROSENFELD MG. A tissue-specific enhancer confers pit-1 dependent morphogen inducibility and autoregulation on the pit-1 gene. Genes Dev 7: 913–932, 1993. RIBEIRO RC, APRILETTI JW, WAGNER RL, WEST BL, FENG W, HUBER R, KUSHNER PJ, NILSSON S, SCANLAN T, FLETTERICK RJ, SCHAUFELE F, AND BAXTER JD. Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Rec Prog Horm Res 53: 351–394, 1998. RIBEIRO RC, APRILETTI JW, YEN PM, CHIN WW, AND BAXTER JD. Heterodimerization and deoxyribonucleic acid-binding properties of retinoic X receptor-related factor. J Biol Chem 135: 2076 –2085, 1994. RIBEIRO RCJ, CAVALIERI RR, LOMRI N, RAHAMAOUI CM, BAXTER JD, AND

422.

423.

424.

425. 426.

427.

428.

429.

430. 431.

432.

433.

434.

435.

436.

437.

438.

439.

440.

441.

1137

SCHARSCHMIDT BF. Thyroid hormone export regulates cellular hormone content and response. J Biol Chem 271: 17147–17151, 1996. RIBEIRO RCJ, KUSHMAN PJ, APRILETTI JW, WEST BL, AND BAXTER JD. Thyroid hormone alters in vitro DNA binding of monomers and dimers of thyroid hormone receptors. Mol Endocrinol 6: 1142– 1152, 1992. RIDGWAY ND AND DOLPHIN PJ. Serum activity and hepatic secretion of lecithin:cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia. J Lipid Res 26: 1300 –1313, 1985. RIVKEES SA, BODE HH, AND CRAWFORD JD. Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. N Engl J Med 318: 599 – 602, 1988. RODRIGUEZ-PENA A. Oligodendrocyte development and thyroid hormone. J Neurobiol 40: 497–512, 1999. ROGATSKY I, CRONIN MJ, AND YAMAMOTO KR. Transcriptonal regulatory complexes that confer represion by the gllucocorticoid receptor (Abstract). In: Nuclear Receptors 2000, Keystone Symposium. Steamboat Springs, CO: Keystone, 2000, p. 369. ROHRER DK AND DILLMANN WH. Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2⫹-ATPase in the rat heart. J Biol Chem 263: 6941– 6944, 1988. ROMANI A, MARFELLA C, AND LAKSHMANAN M. Mobilization of Mg2⫹ from rat heart and liver mitochondria following the interaction of thyroid hormone with adenine nucleotide translocase. Thyroid 6: 513–519, 1996. ROSEN ED, O’DONNELL AL, AND KOENIG RJ. Ligand-dependent synergy of thyroid hormone and retinoid X receptors. J Biol Chem 267: 22010 –22013, 1992. ROSS DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 4: 319 –326, 1994. ROWAN BG, WEIGEL NL, AND O’MALLEY BW. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275: 4475– 4483, 2000. RUBIO R, RAASMAJA A, AND SILVA JE. Thyroid hormone and norepinephrine signaling in brown adipose tissue: differential effects of thyroid hormone on beta 3-adrenergic receptors in brown and white adipose tissue. Endocrinology 136: 3277–3284, 1995. SAATCIOGLU F, DENG T, AND KARIN M. A novel cis element mediating ligand-independent activation by c-erbA: implications for hormonal regulation. Cell 75: 1095–1105, 1993. SADOVSKY Y, WEBB P, LOPEZ G, BAXTER JD, FITZPATRICK PM, GIZANGGINSBERG E, CAVAILLES V, PARKER MG, AND KUSHNER PJ. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol Cell Biol 15: 1554 –1563, 1995. SAFER JD, COHEN RN, HOLLENBERG AN, AND WONDISFORD FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem 273: 30175–30182, 1998. SAFER JD, O’CONNOR MG, COLAN SD, SRINIVASAN S, TOLLIN SR, AND WONDISFORD FE. The thyroid hormone receptor-beta gene mutation R383H is associated with isolated central resistance to thyroid hormone. J Clin Endocrinol Metab 84: 3099 –3109, 1999. SAKURAI A, MIYAMOTO T, REFETOFF S, AND DEGROOT LJ. Dominant negative transcriptional regulation by a mutant thyroid hormone receptor b in a family with generalized resistance to thyroid hormone. Mol Endocrinol 4: 1988 –1994, 1990. SAKURAI A, TAKEDA K, AIN K, CECCARELLI P, NAKAI A, SEINO S, BELL GI, REFETOFF S, AND DEGROOT LJ. Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor b. Proc Natl Acad Sci USA 86: 8977– 8981, 1989. SAMSON M, OSTY J, AND BLONDEAU JP. Identification by photoaffinity labeling of a membrane thyroid hormone-binding protein associated with the triiodothyronine transport system in rat erythrocytes. Endocrinology 132: 2470 –2476, 1993. SAMUELS HH, FORMAN BM, HOROWITZ ZD, AND YE S. Regulation of gene expression by thyroid hormone. J Clin Invest 81: 957–967, 1988. SAMUELS HH AND TSAI JS. Thyroid hormone action in cell culture: demonstration of nuclear receptors in intact cells and isolated nuclei. Proc Natl Acad Sci USA 70: 3488 –3492, 1973.

1138

PAUL M. YEN

442. SANDE S AND PRIVALSKY ML. Identification of TRACs, a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol Endocrinol 10: 813– 825, 1996. 443. SANDHOFER C, SCHWARTZ HL, MARIASH CN, FORREST D, AND OPPENHEIMER JH. Beta receptor isoforms are not essential for thyroid hormone-dependent acceleration of PCP-2 and myelin basic protein gene expression in the developing brains of neonatal mice. Mol Cell Endocrinol 137: 109 –115, 1998. 444. SAP J, MUNOZ A, DAMM K, GOLDBERG Y, GHYSDAEL J, LEUTZ A, BEUG H, AND VENNSTROM B. The c-erbA protein is a high affinity receptor for thyroid hormone. Nature 324: 635– 640, 1986. 445. SASAKI S, LESOON-WOOD LA, DEY A, KUWATA T, WEINTRAUB BD, HUMPHREY G, YANG WM, SETO E, YEN PM, HOWARD BH, AND OZATO K. Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene. EMBO J 18: 5389 –5398, 1999. 446. SATOH T, YAMADA M, IWASAKI T, AND MORI M. Negative regulation of the gene for the preprothyrotropin-releasing hormone from the mouse by thyroid hormone requires additional factors in conjunction with thyroid hormone receptors. J Biol Chem 271: 27919 – 27926, 1996. 447. SCARABOTTOLO L, TREZZI E, ROMA P, AND CATAPANO AL. Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis 59: 329 –333, 1986. 448. SCHRADER M, MULLER KM, NAYERI P, KAHLEN S, AND CARLBERG C. Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature 370: 382–386, 1994. 449. SCHUELER PA, SCHWARTZ HL, STRAIT KA, MARIASH CN, AND OPPENHEIMER JH. Binding of 3,5,3⬘-triiodothyronine (T3) and its analogs to the in vitro translation products of c-erbA protooncogenes: differences in the affinity of the a and b forms of the acetic acid analog and failure of the human testis and kidney products to bind T3. Mol Endocrinol 4: 227–234, 1990. 450. SCHULE R AND EVANS RM. Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet 7: 377– 381, 1991. 451. SCHULE R, RANGARAJAN P, KLIEWER S, RANSONE LJ, BOLADO J, YANG N, VERMA IM, AND EVANS RM. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62: 1217–1226, 1990. 452. SEELIG SA, LIAW C, TOWLE HC, AND OPPENHEIMER JH. Thyroid hormone attenuates and augments hepatic gene expression at a pretranslational level. Proc Natl Acad Sci USA 78: 4733– 4737, 1981. 453. SEGAL J AND GORDON A. The effects of actinomycin D, puromycin, cycloheximide, and hydroxyurea on 3⬘5⬘3-triiodo-L-thyronine stimulated 2-deoxy-D-glucose uptake in chick embryo heart cells in vitro. Endocrinology 101: 150 –156, 1977. 454. SEGAL J AND INGBAR SH. Studies on the mechanism by which 3,5,3⬘triiodothyronine stimulates 2-deoxyglucose uptake in rat thymocytes in vitro. Role of calcium and adenosine 3⬘,5⬘-monophosphate. J Clin Invest 68: 103–110, 1981. 455. SEGAL J AND INGBAR SH. 3,5,3⬘-Triiodothyronine increases 3⬘,5⬘monophosphate concentration and sugar uptake in rat thymocytes by stimulating adenylate cyclase activity: studies with the adenylate cyclase inhibitor MDL 12330A. Endocrinology 124: 2166 –2171, 1989. 456. SEGARS JH, MARKS MS, HIRSCHFELD S, DRIGGERS PH, MARTINEZ E, GRIPPO JF, BROWN M, WAHLI W, AND OZATO K. Inhibition of estrogenresponsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Mol Cell Biol 13: 2258 – 2268, 1993. 457. SENSEL MG, LEGRAND-LORANS A, WANG ME, AND BENSADOUN A. Isolation and characterization of clones for the rat hepatic lipase gene upstream regulatory region. Biochim Biophys Acta 1048: 297–302, 1990. 458. SEO H, VASSART G, BROCAS H, AND REFETOFF S. Triiodothyronine stimulates specifically growth hormone mRNA in rat pituitary tumor cells. Proc Natl Acad Sci USA 74: 2054 –2058, 1977. 459. SEOL W, CHOI HS, AND MOORE DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 9: 72– 85, 1995. 460. SEVERNE Y, WIELAND S, SCHAFFNER W, AND RUSCONI S. Metal binding

Volume 81

“finger” structures in the glucocorticoid receptor defined by sitedirected mutagenesis. EMBO J 7: 2503–2508, 1988. 461. SEVERSON DL AND FLETCHER T. Effect of thyroid hormones on acid cholesterol ester hydrolase activity in rat liver, heart and epididymal fat pads. Biochim Biophys Acta 675: 256 –264, 1981. 461a.SHANG Y, HU X, DIRENZO J, LAZAR MA, AND BROWN M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843– 852, 2000. 461b.SHARMA D AND FONDELL JD. Temporal formation of distinct thyroid hormone coactivator complexes in HeLa cells. Mol Endocrinol 14: 2001–2009, 2000. 462. SHERMAN SI, GOPAL J, HAUGEN BR, CHIU AC, WHALEY K, NOWLAKHA P, AND DUVIC M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340: 1075–1079, 1999. 463. SHI YB, WONG J, PUZIANOWSKI-KUZNICKA M, AND STOLOW MA. Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: roles of thyroid hormone and its receptors. Bioessays 18: 391–399, 1996. 464. SHUPNIK MA, CHIN WW, AND RIDGWAY EC. T3 regulation of TSH gene expression. Endocr Res 15: 579 –599, 1989. 465. SHUPNIK MA, GREENSPAN SL, AND RIDGWAY EC. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J Biol Chem 261: 12675–12679, 1986. 466. SHUPNIK MA AND RIDGWAY EC. Thyroid hormone control of thyrotropin gene expression in rat anterior pituitary cells. Endocrinology 121: 619 – 624, 1987. 467. SHUPNIK MA, RIDGWAY EC, AND CHIN WW. Molecular biology of thyrotropin. Endocr Rev 10: 459 – 475, 1989. 468. SIEGRIST-KAISER CA, JUGE-AUBRY C, TRANTER MP, EKENBARGER DM, AND LEONARD JL. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes: a novel extranuclear action of thyroid hormone. J Biol Chem 265: 5296 –5302, 1990. 469. SILVA JE AND LARSEN PR. Adrenergic activation of triiodothyronine production in brown adipose tissue. Nature 305: 712–713, 1983. 470. SILVA JE AND LARSEN PR. Potential of brown adiopse tissue type II thyroxine 5⬘ deiodinase as a local and systemic source of triiodothyronine in rats. J Clin Invest 76: 2296 –2305, 1985. 471. SIMONIDES WS, BRENT GA, THELEN MH, VAN DER LINDEN CG, LARSEN PR, AND VAN HARDEVELD C. Characterization of the promoter of the rat sarcoplasmic endoplasmic reticulum Ca2⫹-ATPase 1 gene and analysis of thyroid hormone responsiveness. J Biol Chem 271: 32048 –32056, 1996. 472. SJOBERG M AND VENNSTROM B. Ligand-dependent and -independent transactivation by thyroid hormone receptor beta 2 is determined by the structure of the hormone response element. Mol Cell Biol 15: 4718 – 4726, 1995. 473. SJOBERG M, VENNSTROM B, AND FORREST D. Thyroid hormone receptors in chick retinal development: differential expression of mRNAs for alpha and N-terminal variant beta receptors. Development 114: 39 – 47, 1992. 475. SMANIK PA, LIU Q, FURMINGER TL, RYU K, XING S, MAZZAFERRI EL, AND JHIANG SM. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226: 339 –345, 1996. 476. SMITH CL, ONATE SA, TSAI MJ, AND O’MALLEY BW. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93: 8884 – 8888, 1996. 477. SPANJAARD RA, NGUYEN VP, AND CHIN WW. Rat Rev-erbA alpha, an orphan receptor related to thyroid hormone receptor, binds to specific thyroid hormone response elements. Mol Endocrinol 8: 286 –295, 1994. 478. SPANJAARD RA, NGUYEN VP, AND CHIN WW. Repression of glucocorticoid receptor-mediated transcriptional activation by unliganded thyroid hormone receptor (TR) is TR isoform-specific. Endocrinology 136: 5084 –5092, 1995. 479. SPENCER TE, JENSTER G, BURCIN MM, ALLIS CD, ZHOU J, MIZZEN CA, MCKENNA NJ, ONATE SA, TSAI SY, TSAI MJ, AND O’MALLEY BW. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194 –1988, 1997. 480. SREENAN S, CARO JF, AND REFETOFF S. Thyroid dysfunction is not associated with alterations in serum leptin levels. Thyroid 7: 407– 409, 1997.

July 2001

THYROID HORMONE ACTION

481. STEINSAPIR J, BIANCO AC, BUETTNER C, HARNEY J, AND LARSEN PR. Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme’s active center. Endocrinology 141: 1127–1135, 2000. 482. STENOIEN DL, MANCINI MG, PATEL K, ALLEGRETTO EA, SMITH CL, AND MANCINI MA. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. Mol Endocrinol 14: 518 –534, 2000. 483. STERLING K AND BRENNER MA. Thyroid hormone action: effect of triiodothyronine on mitochondrial adenine nucleotide translocase in vivo and in vitro. Metabolism 44: 193–199, 1995. 484. STERLING K, BRENNER MA, AND SAKURADA T. Rapid effect of triiodothyronine on the mitochondrial pathway in rat liver in vivo. Science 210: 340 –342, 1980. 485. STERLING K, LAZARUS JH, MILCH PO, SAKURADA T, AND BRENNER MA. Mitochondrial thyroid hormone receptor: localization and physiological significance. Science 201: 1126 –1129, 1978. 486. STRAIT KA, KINLAW WB, MARIASH CN, AND OPPENHEIMER JH. Kinetics of induction by thyroid hormone of the two hepatic mRNAs coding for cytosolic malic enzyme in the hypothyroid and euthyroid states. Evidence against an obligatory role of S14 protein in malic enzyme gene expression. J Biol Chem 264: 19784 –19789, 1989. 487. STRAIT KA, SCHWARTZ HL, PEREZ-CASTILLO A, AND OPPENHEIMER JH. Relationship of c-erbA mRNA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats. J Biol Chem 265: 10514 –10521, 1990. 488. STRAIT KA, SCHWARTZ HL, SEYBOLD VS, LING NC, AND OPPENHEIMER JH. Immunofluorescence localization of thyroid hormone receptor protein beta 1 and variant alpha 2 in selected tissues: cerebellar Purkinje cells as a model for beta 1 receptor-mediated developmental effects of thyroid hormone in brain. Proc Natl Acad Sci USA 88: 3887–3891, 1991. 489. STRAIT KA, ZOU L, AND OPPENHEIMER JH. Beta 1 isoform-specific regulation of a triiodothyronine-induced gene during cerebellar development. Mol Endocrinol 6: 1874 –1880, 1992. 490. SUBRAMANIAN A, GULICK A, NEUMAN J, KNOTTS S, AND ROBBINS J. Transgenic analysis of the thyroid response elements of the acardiac myosin heavy chain gene promoter. J Biol Chem 268: 4331– 4336, 1993. 491. SUEN S AND CHIN WW. Ligand-dependent, Pit-1/GH-1-independent, transcriptional stimulation of rat growth hormone gene expression by thyroid hormone receptors in vitro. Mol Cell Biol 13: 1719 –1727, 1993. 492. SUGAWARA A, YEN PM, APRILETTI JW, RIBEIRO RCJ, SACKS DB, BAXTER JD, AND CHIN WW. Phosphorylation selectively increases triiodothyronine (T3)-receptor homodimer binding to DNA. J Biol Chem 269: 433– 437, 1994. 493. SUGAWARA A, YEN PM, AND CHIN WW. 9-Cis retinoic acid regulation of rat growth hormone gene expression: potential roles of multiple nuclear hormone receptors. Endocrinology 135: 1956 –1962, 1994. 494. SUGAWARA A, YEN PM, DARLING DS, AND CHIN WW. Characterization and tissue expression of multiple triiodothyronine (T3) receptorauxiliary proteins (TRAPs) and their relationship to the retinoid X receptors (RXRs). Endocrinology 133: 965–971, 1993. 495. SUGAWARA A, YEN PM, QI YP, LECHAN RM, AND CHIN WW. Isoformspecific retinoid X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 136: 1766 –1744, 1995. 496. SWIERCZYNSKI J, MITCHELL DA, REINHOLD DS, SALATI LM, STAPLETON SR, KLAUTKY SA, STRUVE AE, AND GOODRIDGE AG. Triiodothyronineinduced accumulations of malic enzyme, fatty acid synthase, acetyl-coenzyme A carboxylase, and their mRNAs are blocked by protein kinase inhibitors. Transcription is the affected step. J Biol Chem 266: 17459 –17466, 1991. 497. SYED MA, THOMPSON MP, PACHUCKI J, AND BURMEISTER LA. The effect of thyroid hormone on size of fat depots accounts for most of the changes in leptin mRNA and serum levels in the rat. Thyroid 9: 503–512, 1999. 498. TAGAMI T, GU WX, PEAIRS PT, WEST BL, AND JAMESON JL. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol 12: 1888 –1902, 1998. 499. TAGAMI T AND JAMESON JL. Nuclear corepressors enhance the dom-

500.

501.

502.

503.

504.

505.

506.

507.

508.

509.

510. 511.

512.

513.

514.

515.

516.

517.

518.

519.

1139

inant negative activity of mutant receptors that cause resistance to thyroid hormone. Endocrinology 139: 640 – 650, 1998. TAGAMI T, MADISON LD, NAGAYA T, AND JAMESON JL. Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 17: 2642–2648, 1997. TAGAMI T, PARK Y, AND JAMESON JL. Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. J Biol Chem 274: 22345–22353, 1999. TAKEDA K, SAKURAI A, DEGROOT LJ, AND REFETOFF S. Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. J Clin Endocrinol Metab 74: 49 –55, 1992. TAKESHITA A, CARDONA GR, KOIBUCHI N, SUEN CS, AND CHIN WW. TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 272: 27629 –27634, 1997. TAKESHITA A, OZAWA Y, AND CHIN WW. Nuclear receptor coactivators facilitate vitamin D receptor homodimer action on direct repeat hormone response elements. Endocrinology 141: 1281–1284, 2000. TAKESHITA A, YEN PM, IKEDA M, CARDONA GR, LIU Y, KOIBUCHI N, NORWITZ ER, AND CHIN WW. Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1. J Biol Chem 273: 21554 –21562, 1998. TAKESHITA A, YEN PM, LIU Y, AND CHIN WW. Functional and in vitro studies of wild-type thyroid hormone receptor and AF-2 mutants display selective effects on basal repression and transcriptional activation. Proc Int Congr Endocrinol San Francisco CA 1996, p. OR1–5. TAKESHITA A, YEN PM, MISITI S, CARDONA GR, LIU Y, AND CHIN WW. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 137: 3594 –3597, 1996. TAN KC, SHIU SW, AND KUNG AW. Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 83: 2921–2924, 1998. TATA JR, ERNSTER L, LINDBERG O, ARRHENIUS ESP, AND HEDMAN R. The action of thyroid hormones at the cell level. Biochem J 86: 408 – 428, 1963. TATA JR AND WIDNELL CC. Ribonucleic acid synthesis during the early action of thyroid hormones. Biochem J 98: 604 – 629, 1966. TAUROG A. Hormone synthesis. In: Werner and Ingbar’s The Thyroid, edited by Braverman L and Utiger R. Philadelphia, PA: Lippincott-Raven, 1996, p. 47– 81. TAYLOR AH, STEPHAN ZF, STEELE RE, AND WONG NC. Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol Pharmacol 52: 542–547, 1997. TAYLOR AH, WISHART P, LAWLESS DE, RAYMOND J, AND WONG NC. Identification of functional positive and negative thyroid hormoneresponsive elements in the rat apolipoprotein AI promoter. Biochemistry 35: 8281– 8288, 1996. TEBOUL M, BISMUTH J, GHIRINGEHELLI O, BONNE J, AND TORRESANI J. Developmental and thyroid regulation of the nuclear T3 receptors/ c-erbA oncogene products in the Ob 17 preadipocyte cell line. J Receptor Res 11: 865– 882, 1991. THOMPSON CC. Thyroid hormone-responsive genes in developing cerebellum include a novel synaptotagmin and a hairless homolog. J Neurosci 16: 7832–7840, 1996. THOMPSON CC AND EVANS RM. Trans-activation by thyroid hormone receptors: functional parallels with steroid hormone receptor competition for DNA sequences in target genes. Proc Natl Acad Sci USA 86: 3494 –3498, 1989. TING YT, BHAT MK, WONG R, AND CHENG S. Tissue-specific stabilization of the thyroid hormone beta1 nuclear receptor by phosphorylation. J Biol Chem 272: 4129 – 4134, 1997. TING YT AND CHENG SY. Hormone-activated phosphorylation of human beta1 thyroid hormone nuclear receptor. Thyroid 7: 463– 469, 1997. TINI M, TSUI LC, AND GIGUERE V. Heterodimeric interaction of the retinoic acid and thyroid hormone receptors in transcriptional

1140

520.

521.

522.

523.

524.

525.

526.

527.

528.

529.

530.

531. 532.

533.

534.

535.

536.

537.

538.

539.

PAUL M. YEN

regulation of the gamma F-crystallin everted retinoic acid response element. Mol Endocrinol 8: 1494 –1506, 1994. TOMURA H, LAZAR J, PHYILLAIER M, AND NIKODEM VM. The N-terminal region (A/B) of rat thyroid hormone receptors alpha 1, beta 1, but not beta 2, contains a strong thyroid hormone-dependent transactivation function. Proc Natl Acad Sci USA 92: 5600 –5604, 1995. TONE Y, COLLINGWOOD TN, ADAMS M, AND CHATTERJEE VK. Functional analysis of a transactivation domain in the thyroid hormone beta receptor. J Biol Chem 269: 31157–31161, 1994. TONG GX, JEYAKUMAR M, TANEN MR, AND BAGCHI MK. Transcriptional silencing by unliganded thyroid hormone receptor beta requires a soluble corepressor that interacts with the ligand-binding domain of the receptor. Mol Cell Biol 16: 1909 –1920, 1996. TONG GX, TANEN MR, AND BAGCHI MK. Ligand modulates the interaction of thyroid hormone receptor beta with the basal transcription machinery. J Biol Chem 270: 10601–10611, 1995. TORA L, GRONEMEYER H, TURCOTTE B, GAUB MP, AND CHAMBON P. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 333: 185–188, 1988. TORA L, WHITE J, BROU C, TASSET D, WEBSTER N, SCHEER E, AND CHAMBON P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477– 487, 1989. TORCHIA J, ROSE DW, INOSTROZA J, KAMEI Y, WESTIN S, GLASS CK, AND ROSENFELD MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387: 677– 684, 1997. TOTONOZ P, HU E, AND SPIEGELMAN BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid activation transcription factor. Cell 79: 1147–1156, 1994. TREMBLAY A, TREMBLAY GB, LABRIE F, AND GIGUERE V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3: 513–519, 1999. TUCA A, GIRALT M, VILLARROYA F, VINAS O, MAMPEL T, AND IGLESIAS R. Ontogeny of thyroid hormone receptors and c-erbA expression during brown adipose tissue development: evidence of fetal acquisition of the mature thyroid status. Endocrinology 132: 1913–1920, 1993. TZAGARAKIS-FOSTER C AND PRIVALSKY ML. Phosphorylation of thyroid hormone receptors by protein kinase A regulates DNA recognition by specific inhibition of receptor monomer binding. J Biol Chem 273: 10926 –10932, 1998. UMESONO K AND EVANS RM. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57: 1139 –1146, 1989. UMESONO K, MURAKAMI K, THOMPSON CC, AND EVANS RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65: 1255–1266, 1991. UNDERWOOD AH, EMMETT JC, ELLIS D, FLYNN SB, LEESON PD, BENSON GM, NOVELLI R, PEARCE NJ, AND SHAH VP. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 324: 425– 429, 1986. UPPALARI R AND TOWLE HC. Genetic dissection of thyroid hormone receptor beta: identification of mutations that separate hormone binding and transcriptonal activation. Mol Cell Biol 15: 1499 –1512, 1995. USALA SJ, BALE AE, GESUNDHEIT N, WEINBERGER C, LASH RW, WONDISFORD FE, MCBRIDE OW, AND WEINTRAUB BD. Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA beta gene. Mol Endocrinol 2: 1217–1220, 1988. USALA SJ, TENNYSON GE, BALE AE, LASH RW, GESUNDHEIT N, WONDISFORD FE, ACCILI D, HAUSER P, AND WEINTRAUB BD. A base mutation of the c-erbAb thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds. J Clin Invest 85: 93–100, 1990. VALCAVI R, DIEGUEZ C, ZINI M, MURUAIS C, CASANUEVA F, AND PORTIOLI I. Influence of hyperthyroidism on growth hormone secretion. Clin Endocrinol 38: 515–522, 1993. VIDAL-PUIG AJ, GRUJIC D, ZHANG CY, HAGEN T, BOSS O, IDO Y, SZCZEPANIK A, WADE J, MOOTHA V, CORTRIGHT R, MUOIO DM, AND LOWELL BB. Energy metabolism in uncoupling protein 3 gene knockout mice. J Biol Chem. In press. VIJLDER JJM DE AND VULSMA T. Hereditary metabolic disorders caus-

540.

541.

542.

543.

544.

545.

546.

547.

548.

549.

550.

551. 552.

553.

554.

555.

556.

557.

558.

559.

560.

Volume 81

ing hypothyroidism. In: Werner and Ingbar’s The Thyroid (7th ed.), edited by Braverman L and Utiger R. Phildadelphia, PA: LipincottRaven, 1996, p. 749 –778. VOEGEL JJ, HEINE MJ, TINI M, VIVAT V, CHAMBON P, AND GRONEMEYER H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17: 507–519, 1998. VOEGEL JJ, HEINE MJS, ZECHEL C, CHAMBON P, AND GRONEMEYER H. TIF2, a 160 kD transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15: 3667– 3675, 1996. VULSMA T, GONS MH, AND DE VIJLDER JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 321: 13–16, 1989. WADE PA, GEGONNE A, JONES PL, BALLESTAR E, AUBRY F, AND WOLFFE AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23: 62– 66, 1999. WAGNER RL, APRILETTI JW, MCGRATH ME, WEST BL, BAXTER JD, AND FLETTERICK RJ. A structural role for hormone in the thyroid hormone receptor. Nature 378: 690 – 697, 1995. WEINBERGER C, THOMPSON CC, ONG ES, LEBO R, GRUOL DJ, AND EVANS RM. The c-erbA gene encodes a thyroid hormone receptor. Nature 324: 641– 646, 1986. WEIS KE, EKENA K, THOMAS JA, LAZENNEC G, AND KATZENELLENBOGEN BS. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10: 1388 –1398, 1996. WEISS RE, FORREST D, POHLENZ J, CUA K, CURRAN T, AND REFETOFF S. Thyrotropin regulation by thyroid hormone in thyroid hormone receptor beta-deficient mice. Endocrinology 138: 3624 –3629, 1997. WEISS RE, HAYASHI Y, NAGAYA T, PETTY KJ, MURATA Y, TUNCA H, SEO H, AND REFETOFF S. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective co-activator. J Clin Endocrinol Metab 81: 4196 – 4203, 1996. WEISS RE, TUMCA H, GERSTEIN HC, AND REFETOFF S. A new mutation in the thyroid hormone receptor (TR) b gene (V458A) in a family with resistance to thyroid hormone (RTH). Thyroid 6: 311–312, 1996. WEISS RE, XU J, NING G, POHLENZ J, O’MALLEY BW, AND REFETOFF S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18: 1900 –1904, 1999. WERNER SC. A History of the Thyroid. Philadelphia, PA: Lippincott, 1991. WIKSTROM L, JOHANSSON C, SALTO C, BARLOW C, CAMPOS BARROS A, BAAS F, FORREST D, THOREN P, AND VENNSTROM B. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 17: 455– 461, 1998. WILLIAMS G. Tissue specific expression of two novel thyroid hormone receptor (beta) variants (Abstract). Proc Annu Meet Am Thyroid Assoc 71d Palm Beach FL 1999, p. 232. WILLIAMS GR, BLAND R, AND SHEPPARD M. Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotypes: interactions among T3, vitamin D3, and retinoid signaling. Endocrinology 1335: 2375–2385, 1994. WILLIAMS GR AND BRENT GA. Thyroid hormone response elements. In: Molecular Endocrinology: Basic Concepts and Clinical Correlations, edited by Weintraub B. New York: Raven, 1995, p. 217–239. WILLIAMS GR, FRANKLYN JA, NEUBERGER JM, AND SHEPPARD MC. Thyroid hormone receptor expression in the “sick euthyroid” syndrome. Lancet 2: 1477–1481, 1989. WILLIAMS GR, HARNEY JW, MOORE DD, LARSEN PR, AND BRENT GA. Differential capacity of wild type promoter elements for binding and trans-activation by retinoic acid and thyroid hormone receptors. Mol Endocrinol 6: 1527–1537, 1992. WILLIAMS LT, LEFKOWITZ RJ, WATANABE AM, HATHAWAY DR, AND BESCH HR JR. Thyroid hormone regulation of beta-adrenergic receptor number. J Biol Chem 252: 2787–2789, 1977. WISEMAN SA, POWELL JT, HUMPHRIES SE, AND PRESS M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab 77: 108 –112, 1993. WONDISFORD FE, STEINFELDER HJ, NATIONS M, AND RADOVICK S. AP-1

July 2001

561.

562.

563.

564.

565.

566.

567.

568.

569.

570.

571.

572.

573.

574.

575.

576.

577.

578.

THYROID HORMONE ACTION

antagonizes thyroid hormone receptor action on thyrotropin bsubunit gene. J Biol Chem 268: 2749 –2754, 1993. WONG J, SHI YB, AND WOLFFE AP. Determinants of chromatin disruption and transcriptional regulation instigated by the thyroid hormone receptor: hormone-regulated chromatin disruption is not sufficient for transcriptional activation. EMBO J 16: 3158 –3171, 1997. WONG J, SHI YB, AND WOLFFE AP. A role for nucleosome assembly in both silencing and activation of the Xenopus TR beta A gene by the thyroid hormone receptor. Genes Dev 9: 2696 –2711, 1996. WONG R, VASILYEV VV, KUTLER DI, TING YT, WILLINGHAM M, CHENG SY, AND WEINTRAUB BD. A transgenic model of resistance to thyroid hormone (RTH): correlation of mutant thyroid hormone b1 receptor (TRb1) levels with the phenotype of fat loss and hyperactivity (Abstract). J Invest Med 43 Suppl 2: 223A, 1995. WONG R, VASILYEV VV, TING YT, KUTLER DI, WILLINGHAM MC, WEINTRAUB BD, AND CHENG S. Transgenic mice bearing a human mutant thyroid hormone beta 1 receptor manifest thyroid function anomalies, weight reduction, and hyperactivity. Mol Med 3: 303–314, 1997. WOOD DF, DOCHERTY K, RAMSDEN DB, SHENNAN KI, AND SHEPPARD MC. Thyroid status affects the regulation of prolactin mRNA accumulation by tri-iodothyronine and thyrotrophin-releasing hormone in cultured rat anterior pituitary cells. J Endocrinol 115: 497–503, 1987. WOOD WM, DOWDING JM, BRIGHT TM, MCDERMOTT MT, HAUGEN BR, GORDON DF, AND RIDGWAY EC. Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1. J Biol Chem 271: 24213–24220, 1996. WRUTNIAK C, CASSAR-MALEK I, MARCHAL S, RASCLE A, HEUSSER S, KELLER J, FLECHON J, DAUSCA M, SAMARUT J, AND GHYSDAEL J. A 43 kD protein related to c-erb A alpha 1 is located in the mitochondrial matrix of rat liver. J Biol Chem 270: 16347–16354, 1995. WU Y, YANG YZ, AND KOENIG RJ. Protein-protein interaction domains and the heterodimerization of thyroid hormone receptor variant alpha2 with retinoid X receptors. Mol Endocrinol 12: 1542–1550, 1998. XU J, LIAO L, NING G, YOSHIDA-KOMIYA H, DENG C, AND O’MALLEY BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/ TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 23: 23, 2000. XU J, QIU Y, DEMAYO FJ, TSAI SY, TSAI MJ, AND O’MALLEY BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279: 1922–1925, 1998. YAGI H, POHLENZ J, HAYASHI Y, SAKURAI A, AND REFETOFF S. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3⬘-triiodothyroinine binding affinity. J Clin Endocrinol Metab 82: 1608 –1614, 1997. YALCIN Y, CARMAN D, SHAO Y, ISMAIL-BEIGI F, KLEIN I, AND OJAMAA K. Regulation of Na/K-ATPase gene expression by thyroid hormone and hyperkalemia in the heart. Thyroid 9: 53–59, 1999. YAMADA M, ROGERS D, AND WILBER JF. Exogenous triiodothyronine lowers thyrotropin-releasing hormone concentrations in the specific hypothalamic nucleus (paraventricular) involved in thyrotropin regulation and also in posterior nucleus. Neuroendocrinology 50: 560 –563, 1989. YANG XJ, OGRYZKO VV, NISHIKAWA J, HOWARD BH, AND NAKATANI Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319 –324, 1996. YANG Z, HONG SH, AND PRIVALSKY ML. Transcriptional anti-repression. Thyroid hormone receptor beta-2 recruits SMRT corepressor but interferes with subsequent assembly of a functional corepressor complex. J Biol Chem 274: 37131–37138, 1999. YANG-YEN HF, CHAMBARD JC, SUN YL, SMEAL T, SCHMIDT TJ, DROUIN J, AND KARIN M. Transcriptional interference between c-jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62: 1205–1215, 1990. YAO P, KU G, ZHOU N, SCULLY R, AND LIVINGSTON DM. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 93: 10626 –10631, 1996. YAO TP, OH SP, FUCHS M, ZHOU ND, CH’NG LE, NEWSOME D, BRONSON

579.

580.

581.

582.

583.

584.

585.

586.

587.

588.

589.

590.

591.

592.

593.

594.

595.

596.

1141

RT, LI E, LIVINGSTON DM, AND ECKNER R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361–372, 1998. YARWOOD NJ, GURR JA, SHEPPARD MC, AND FRANKLYN JA. Estradiol modulates thyroid hormone regulation of the human glycoprotein hormone alpha subunit gene. J Biol Chem 268: 21984 –21989, 1993. YE ZS, FORMAN BM, ARANDA A, PASCUAL A, PARK HY, CASANOVA J, AND SAMUELS HH. Rat growth hormone gene expression. Both cellspecific and thyroid hormone response elements are required for thyroid hormone regulation. J Biol Chem 263: 7821–7829, 1988. YEN PM, BRUBAKER JH, APRILETTI JW, BAXTER JD, AND CHIN WW. Roles of T3 and DNA-binding on thyroid hormone receptor complex formation. Endocrinology 134: 1075–1081, 1994. YEN PM AND CHIN WW. Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol Endocrinol 8: 1450 – 1454, 1994. YEN PM AND CHIN WW. New advances in understanding the molecular mechanisms of thyroid hormone action. Trends Endocrinol Metab 5: 65–72, 1994. YEN PM, DARLING DS, CARTER RL, FORGIONE M, UMEDA PK, AND CHIN WW. Triiodothyronine (T3) decreases DNA-binding of receptor homodimers but not receptor-auxiliary protein heterodimers. J Biol Chem 267: 3565–3568, 1992. YEN PM, DARLING DS, AND CHIN WW. Basal and thyroid hormone receptor auxiliary protein-enhanced binding of thyroid hormone receptor isoforms to native thyroid hormone response elements. Endocrinology 129: 3331–3336, 1991. YEN PM, IKEDA M, WILCOX EC, BRUBAKER JH, SPANJAARD RA, SUGAWARA A, AND CHIN WW. Half-site arrangement of hybrid glucocorticoid and thyroid hormone response elements specifies thyroid hormone receptor complex binding to DNA and transcriptional activity. J Biol Chem 269: 12704 –12709, 1994. YEN PM, LIU Y, SUGAWARA A, AND CHIN WW. Vitamin D receptors (VDRs) repress basal transcription and have dominant negative activity on T3-mediated transcription. J Biol Chem 271: 10910 – 10916, 1996. YEN PM, SPANJAARD RA, SUGAWARA A, DARLING DS, NGUYEN VP, AND CHIN WW. Orientation and spacing of half-sites differentially affect T3-receptor (TR) monomer, homodimer, and heterodimer binding to thyroid hormone response elements (TREs). Endocr J 1: 461– 466, 1993. YEN PM, SUGAWARA A, AND CHIN WW. Triiodothyronine (T3) differentially affects T3-receptor/retinoic acid receptor and T3-receptor/ retinoid X receptor heterodimer binding to DNA. J Biol Chem 267: 23248 –23252, 1992. YEN PM, SUNDAY ME, DARLING DS, AND CHIN WW. Isoform-specific thyroid hormone receptor antibodies detect multiple thyroid hormone receptors in rat and human pituitaries. Endocrinology 130: 1539 –1546, 1992. YEN PM, WILCOX EC, AND CHIN WW. Steroid hormone receptors selectively affect transcriptional activation but not basal repression by thyroid hormone receptors. Endocrinology 136: 440 – 445, 1995. YEN PM, WILCOX EC, HAYASHI Y, REFETOFF S, AND CHIN WW. Studies on the repression of basal transcription (silencing) by artificial and natural thyroid hormone receptor-b mutants. Endocrinology 136: 2845–2851, 1995. YOH SM, CHATTERJEE VK, AND PRIVALSKY ML. Thyroid hormone resistance manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 11: 470 – 480, 1997. YU VC, DELSERT C, ANDERSEN B, HOLLOWAY JH, DEVARY OV, NAESER AM, KIM-J BOUTIN SY, GLASS CK, AND ROSENFELD MG. RXR beta: a co-regulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67: 1251–1266, 1991. YUAN CX, ITO M, FONDELL JD, FU ZY, AND ROEDER RG. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci USA 95: 7939 –7944, 1998. ZAMIR I, DAWSON J, LAVINSKY RM, GLASS CK, ROSENFELD MG, AND LAZAR MA. Cloning and characterization of a corepressor and po-

1142

597.

598.

599.

600.

601.

602.

603.

PAUL M. YEN

tential component of the nuclear hormone receptor repression complex. Proc Natl Acad Sci USA 94: 14400 –14405, 1997. ZAMIR I, HARDING HP, ADKINS GB, HORLEIN A, GLASS CK, ROSENFELD MG, AND LAZAR MA. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol 16: 5458 –5465, 1996. ZARAIN-HERZBERG A, MARQUES J, AND SUKOVICH D. Thyroid hormone receptor modulates the expression of the rabbit cardiac sarco(endo)plasmic reticulum Ca(2⫹)-ATPase gene. J Biol Chem 269: 1460 –1467, 1994. ZHANG J, HU X, AND LAZAR MA. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol Cell Biol 19: 6448 – 6457, 1999. ZHANG W, BROOKS RL, SILVERSIDES DW, WEST BL, LEIDIG F, BAXTER JD, AND EBERHARDT ML. Negative thyroid hormone control of human growth hormone gene expression is mediated by 3⬘-untranslated/3⬘flanking DNA. J Biol Chem 267: 15056 –15063, 1992. ZHANG X, JEYAKUMAR M, AND BAGCHI MK. Ligand-dependent crosstalk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s). J Biol Chem 271: 14825– 14833, 1996. ZHANG XK, HOFFMAN V, TRAN B, GRAUPNER G, AND PFAHL M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355: 441– 446, 1992. ZHANG XK, WILLS KN, GRAUPNER G, TZUKERMAN M, HERMANN T, AND PFAHL M. Ligand-binding domain of thyroid hormone receptors modulates DNA binding and determines their bifunctional roles. New Biologist 3: 169 –181, 1991.

Volume 81

604. ZHANG K, WILLS KN, HUSMANN M, HERMANN T, AND PFAHL M. Novel pathway for thyroid hormone receptor action through interaction with jun and fos oncogene activities. Mol Cell Biol 11: 6016 – 6025, 1991. 605. ZHU XG, HANOVER JA, HAGER GL, AND CHENG SY. Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera. J Biol Chem 273: 27058 –27063, 1998. 606. ZHU XG, KANESHIGE M, PARLOW AF, CHEN E, HUNZIKER RD, MCDONALD MP, AND CHENG SY. Expression of the mutant thyroid hormone receptor PV in the pituitary of transgenic mice leads to weight reduction. Thyroid 9: 1137–1145, 1999. 607. ZHU XG, MCPHIE P, LIN KH, AND CHENG SY. The differential hormone-dependent transcriptional activation of thyroid hormone receptor isoforms is mediated by interplay of their domains. J Biol Chem 272: 9048 –9054, 1997. 608. ZHU S, PFAFF DW, DELLAVERDE TL, YEN PM, AND CHIN WW. Interaction of estrogen and thyroid hormone on regulation of proenkephalin gene expression in hypothalamus and striatum of female rats. Proc Neurosci Meet San Diego CA 1995, p. 180 –186. 609. ZHU S, YEN PM, CHIN WW, AND PFAFF DW. Estrogen and thyroid hormone interaction in regulation of gene expression. Proc Natl Acad Sci USA 93: 12587–12392, 1996. 610. ZIMMERMANN-BELSING T, DREYER M, HOLST JJ, AND FELDT-RASMUSSEN U. The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clin Endocrinol 49: 589 –595, 1998.